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ABSTRACT 
Alzheimer's disease (AD) is the leading cause of senile dementia and the current lack of 
effective treatments provides a strong incentive for an improved therapeutic strategy. In 
particular, non-pharmacological treatments, such as calorie restriction (CR), were shown to 
be useful in delaying or preventing AD onset. This has given insight into the molecular 
pathways involved. 
Sirtuins (SIRTI-7) are evolutionary conserved enzymes that modulate life expectancy in 
simple organisms. In mammals, sirtuins are involved in pathways linked to age-related 
diseases, such as AD. In particular, they seem to be the molecular effectors of some 
beneficial effects mediated by external stimuli such as CR and physical activity. 
This thesis aims at investigating, for the first time, the involvement of all 7 sirtuins in AD. 
The relevance of sirtuin gene variation to AD risk was assessed by a combined mutation 
screening and case-control genetic study design. Sirtuin expression levels were also 
assessed in a transgenic mouse model of AD (APP23 mice) and within the application of a 
non-pharmacological approach (environmental enrichment-EE). Finally, the possible role 
of SIRT1 in AD pathogenesis was better elucidated through in vitro studies. 
Overall, in vitro studies confirmed the neuroprotective role of SIRTI activator resveratrol 
in etiopathological contexts related to AD. Moreover, genetic studies have highlighted 
SIRT2 could be involved in modulating AD etiology. In particular, a common 
polymorphism in SIRT2 could be a weak genetic risk factor for AD. Finally, in vivo studies 
confirmed the beneficial effects of an EE protocol in delaying AD onset. However, despite 
sirtuin involvement in other environmental paradigms, no apparent modulation was 
registered under EE. 
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CHAPTER 1: 
GENERAL INTRODUCTION 
1.1. ALZHEIMER'S DISEASE 
Alzheimer's disease (AD) is the most common cause of senile dementia accounting for 60- 
70% of all dementia cases (Barker et al., 2002). AD bears the name of the Bavarian 
psychiatrist Alois Alzheimer who reported the first description of this dementing illness in 
1906. He documented a case of a woman in her fifties who had shown progressive 
cognitive impairment pertaining to memory, language, and social interaction. After her 
death, Alzheimer stained sections from the autopsied brain and discovered the presence of 
"miliar foci, which are caused by deposition of a peculiar substance in the cortex" (now 
recognized as neuritic or senile plaques) and "very peculiar changes in the neurofibrils" 
(now recognized as neurofibrillary tangles) (Möller and Graeber, 1998). These two brain 
features are now core determinants of the gold standard of post mortem AD diagnosis. 
Although dr. Alzheimer's discovery, it was not until the 1970's, when neurological studies 
became more widespread and common, that AD became more formally accepted as a 
major disease in its own right and not just a general part of ageing as had been originally 
thought. 
Global dementia prevalence 
The last estimate of global dementia prevalence published in the World Alzheimer Report 
released in 2009 (Alzheimer's Disease International, 2009), assessed that 35.6 million 
people worldwide would have been living with dementia in 2010 and that this number will 
almost double every 20 years, rising to 65.7 million in 2030 and 115.4 million in 2050. 
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According to the report, much of the expected increase in the number of demented people 
will be attributed to low and middle income countries (LAMIC - parts of Asia, Africa and 
South America). In 2010,57.7% of all people with dementia lived in LAMIC, rising to 
63.4% in 2030 and 70.5% in 2050. This expected increase can be explained by a longer life 
expectancy in these regions as a result of better healthcare. Also developed countries (HIC- 
high income countries) will continue to experience increases in the number of people with 
dementia. Over the next 20 years, it is forecast a 40% increase in demented people in 
Europe, 63% in North America, 77% in the southern Latin America, 89% in the developed 
Asia Pacific countries. This predicted growth compares with 117% growth in east Asia, 
107% in south Asia, 134-146% in the rest of Latin America, and 125% in North Africa and 
the Middle East (Alzheimer's Disease International, 2009). 
Alongside the anticipated rises in the number of patients, there is and will continue to be a 
natural escalation in the cost of caring for this increasing number of demented people. As 
such dementia will be declared a global health priority. A World Health Organization 
(WHO) report estimated that dementia contributed 11.2% of years spent living with a 
disability in people over 60 years old, more than stroke, cardiovascular disease, and cancer 
(World Health Organization, 2003). Due to the prevalence of AD amongst other forms of 
dementia, AD in its own right is likely to become one of the most important global public 
health issues for the foreseeable future. 
1.1.1. CLINICAL FEATURES OF ALZHEIMER'S DISEASE 
1.1.1.1. Symptomatoloýy 
Although AD is recognised to have a number of pathological facets including the 
involvement of numerous biochemical pathways, common clinical features are recognised 
during the progress of the disease. AD typically begins with deterioration of episodic 
memory. At this stage the patients suffer from forgetfulness or confusion and have 
difficulties to remember recently learned tasks. Apathy and depression are also common 
early symptoms of the disease. Normally these symptoms are very mild and the presence 
of the disease may neither be apparent to the person experiencing the symptoms nor to his 
relatives or the difficulties experienced are thought to be the result of some other causes. 
Later symptoms include impaired judgment, disorientation, behaviour changes and 
difficulty in speaking, swallowing and walking (Isik, 2010). In the latest stages of the 
disease, people become bed-bound and wholly reliant on caregivers. On average, people 
with AD generally live for 8 to 10 years after diagnosis, and in some cases AD can last as 
long as 20 years or more. Death is usually caused by secondary pathologies; in fact AD 
makes people more vulnerable to infections such as pneumonia. 
1.1.1.2. Diagnosis 
There are two stages to the diagnosis of AD: what is often termed the clinical diagnosis, 
usually referring to while people are still alive, and the post mortem diagnosis which does 
not always occur but is the only means to definitely confirm the presence of AD for the 
dementia in question. The clinical diagnosis is often based on international criteria such as 
the NINCDS-ADRDA criteria (National Institute of Neurological and Communicative 
Disorders and Stroke and Alzheimer 's disease and Related Disorders Association) 
(McKhann et al., 1984). These criteria are actually research-based criteria and link clinical 
features to neuropathology and provide a diagnosis that distinguishes patients who have 
possible, probable and eventually definite AD (McKhann et al., 1984). As mentioned, 
definite AD diagnosis is only attributable post mortem requiring also neuropathological 
evidence. 
A diagnosis of probable AD is made by clinical examination and confirmed by 
neuropsychological tests. A detailed history of the type and course of symptoms is taken 
from the patient or another source (e. g. care giver) to assess whether there is cognitive 
impairment. Supportive features of AD include progressive deterioration of language, 
praxis and visual recognition, with impaired activities of daily living (social, occupational, 
or other instrumental functions) or a positive family history of AD. Neuropsychological 
testing can help to highlight objective signs of memory disturbance in early cases. 
NINCDS-ADRDA criteria, written 27 years ago, have been revised over time. In 
particular, there are ongoing efforts to address two crucial shortcomings in AD diagnosis: 
1) to improve sensitivity and specificity in distinguishing between AD and other forms of 
dementia, 2) to detect AD in a presymptomatic stage. 
Diagnosis of AD at the preclinical stage will be vital towards the successful discovery of 
disease-modifying treatments. Currently there is a large effort to discover biomarkers that 
can, be measured in 
for example, blood or cerebrospinal fluid that will allow the detection 
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of early stages of the disease. Such biomarkers could also offer valuable tools in clinical 
trials and potentially in clinical practice as they could allow better monitoring of disease 
progression and the effectiveness of therapeutic intervention and reduce the likelihood of 
misdiagnosis of the disease (Aluise et al., 2008). New criteria for earlier diagnosis of AD, 
developed in 2007 which are now being validated, retain the requirement for the presence 
of objective memory deficits but do not include a requirement that disability must already 
be present (Dubois et al., 2007). These new criteria also require evidence of at least one 
biomarker consistent with an AD diagnosis [e. g. brain atrophy detected by high-resolution 
magnetic resonance imaging (MRI), functional alterations such as temporoparietal cortical 
hypometabolism detected by positron emission tomography (PET) and/or abnormality of 
cerebrospinal fluid markers] to support the clinical diagnosis of preclinical AD (Dubois et 
al., 2007). 
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In addition to the attempts to identify preclinical forms of AD, newly proposed criteria also 
suggest a revision to the possible diagnostic categories of AD from the possible, probable 
and definite categories proposed through the NINCDS-ADRDA criteria. Furthermore, 
these new proposed guidelines for AD diagnosis also involved three stages of AD but in 
this case they are preclinical, mild cognitive impairment (MCI), and clinical AD (Dubois et 
al., 2007). 
The term MCI was introduced in the 1990s and is used to refer to patients with early 
clinical signs of AD who did not yet fulfil the criteria of dementia. MCI is often subdivided 
into different subtypes: the amnestic variant, characterized by dysfunction in memory with 
retention of normal cognitive abilities in judgment, reasoning, and perception; the non- 
amnestic MCI, which involves impairment in cognitive functions related to attention, 
perception, and language, predominates over deficits in memory. Amnestie MCI has been 
suggested to constitute a transitional stage between normal ageing and AD (Petersen, 
2004). About two-third of all patients with amnestic MCI harbour the pathological features 
of AD and develop the clinical syndrome of AD within 5 years, whereas the remaining 
one-third have non-progressive or very slowly progressive causes of cognitive impairment 
(e. g. depression, age-related cognitive impairment) (Petersen, 2004; Visser et al., 2005). 
Current thinking is that the earliest manifestations of AD-related changes in the brain begin 
years, perhaps decades, before any obvious symptoms occur. It is hoped that these earliest 
changes and this long preclinical stage could be identified and characterized by measurable 
changes in biomarkers before any observable disruptions in memory, thinking or 
behaviour. However, as yet no biomarkers fulfil the necessary requirements in such a 
context and as such the proposed diagnostic criteria have yet to be validated. 
Until this is resolved, the use of NINCDS-ADRDA criteria is likely to continue for many 
specialist memory centres; however, in primary care, where there is arguably less specialist 
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knowledge, diagnosis of AD is also done using standard criteria for the classification of 
mental disorders such as DSM-IV and the international classification of diseases (ICD-10) 
diagnostic criteria. 
1.1.2. NEUROPATHOLOGY 
The neuropathology of AD is characterized by a number of features; however, the two 
main hallmarks, which figure heavily in the post mortem diagnosis of AD, are: senile 
plaques (SPs) and neurofibrillary tangles (NFTs). 
1.1.2.1. Senile plaques 
SPs are spherical lesions found in the neocortex, hippocampus and other subcortical 
regions, measuring up to 100 µm. SPs, also known as neuritic plaques (NPs), have a 
central core of extracellular amyloid surrounded by a halo of dystrophic neuronal processes 
with neurofibrillary degeneration. The amyloid core of these plaques has a fibrillary fine 
structure with a ß-sheet conformation as identified by electron microscopy. NPs can also 
be recognized by light microscopy with stains such as Congo Red and Thioflavin-S, like 
other amyloids. Furthermore, in areas surrounding NPs, there is also gliosis with 
hypertrophy and alteration of the morphology, as well the proliferation of astrocytes and 
microglia (Heneka and O'Banion, 2007). 
In mid-1980s researchers succeeded in purifying plaque cores and identified a small 
peptide called ß-amyloid peptide (Aß), the major amyloid component of SPs (Masters et 
al., 1985). This peptide was later found to be derived from a larger protein called amyloid 
precursor protein (APP), which is a normal component of neurons (McKenzie et al., 1996). 
Besides NPs, Aß can be deposited and aggregated in a non-ß-sheet (non fibrillar) 
conformation, in diffuse non-fibrillar deposits (i. e. diffuse plaques). Moreover, Aß 
aggregates are found in blood vessels walls independently of deposition in the neuropil 
(which occurs in many cases of AD) in what are called cerebrovascular plaques or cerebral 
amyloid angiopathy (CAA) (Smith and Greenberg, 2009). 
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FIGURE 1.2. Senile plaques. 
Taken from (Holtzman et al., 2011). 
Anti-Aß antibody immunohislochemical staining of sections of brain tissue taken from an 
AD brain shows diffuse plaques containing Aß (large arrow), compact plaques (medium 
size arrow), and CAA (smallest arrow) 0 OOX magnification). 
1.1.2.2. Neurofibrillary tangles 
NFTs are deposits of protein filaments in the neuronal cell body. Similar deposits are 
present in the dystrophic processes that surround the amyloid core of SPs and in dendrites 
(i. e. neuropil threads). These aggregates have a high ß-sheet content and ultrastructurally 
appear as paired helical filaments (PHFs) (Lee et al., 1991). 
The discovery that the protein component of NFTs and neuropil threads was a 
hyperphosphorylated, aggregated form of the microtubule-binding protein tau was made 
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during the 1980s (Kosik et al., 1986; Grundke-Igbal et al., 1986). NFTs appear first in the 
entorhinal cortex and hippocampus and then spread to the neocortex. 
Most cases of AD show a combination of SPs and NFTs, but there are rarer collections of 
cases where there have been reports of a predominance of one or the other marker. NFTs 
are also found in other neurodegenerative diseases 
frontotemporal dementia (FTD). 
FIGURE 1.3. Neurofibrillary tangles. 
Taken from (Holtzman et al., 2011). 
Anti phospho-tau 
tau accumulation 
besides AD, particularly in 
antibody immunohistochemical staining reveals hyperphosphorylated 
in neuronal cell bodies (large arrow) and throughout the neuropil in 
neuronal processes called neuropil threads (smaller arrow; 20OX magnification). 
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1.1.2.3. Other neuropathological hallmarks 
In addition to SPs and NFTs, other neuropathological hallmarks of AD include loss of 
synapses and selective neuronal cell death. 
Neurons that are particularly vulnerable in AD include those in layer II of the entorhinal 
cortex, the pyramidal layers of the hippocampus, and certain areas of the temporal, 
parietal, and frontal neocortex (Geula, 1998). AD brain tissue from patients with an 
advanced form of the disease display high levels of atrophy of both neocortex and 
subcortical regions (in particular atrophy of the hippocampus), as well as enlargement of 
the ventricles. 
FIGURE 1.4. Brain atrophy. 
't'aken. from (Holtzman et al., 2011). 
Coronal slices of a post mortem brain taken from an AD case (left) compared with that of 
cognitively normal individual (right) reveal severe brain atrophy in AD. 
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Inflammation is another pathological feature of AD. Indeed, in AD there is evidence of a 
chronic neuroinflammatory process and the inflammatory mediators IL-1, IL-6, IL-10 and 
TNFa have all been implicated (Glass et al., 2010; McGeer and McGeer, 1996). 
Another important but often-overlooked facet of AD is the occurrence of cerebrovascular 
diseases (CVDs), some of which are thought to occur as some of the earliest pathologies of 
AD (Murray et al., 2011). Indeed, high levels of co-morbidity of CVD often produce other 
symptoms which are more typically seen in forms of vascular dementia (VaD). As such 
these co-morbidities complicate the diagnosis of AD and commonly result in a diagnosis of 
a mixed dementia (Jellinger, 2008). 
1.1.3. EPIDEMIOLOGY 
Most often, AD is diagnosed amongst people over 65 years of age and thus it is commonly 
known as late onset AD (LOAD). LOAD is also referred as "sporadic" (SAD) because 
there is no evidence of a genetic underpinning or of a known family history of the disease. 
For LOAD no causal factors have still been found but a number of factors that can increase 
the risk of developing the disease (i. e. risk factors) have now been identified. In addition to 
LOAD, a small percentage of AD cases (less than 5%) occurs within families (FAD) and is 
inherited in an autosomal dominant fashion. In these families, dementia onset is usually 
between the ages of 30 and 60 years (early onset AD, EOAD) and can occur in multiple 
members of the same family and across numerous generations. Despite the different 
clinical presentations and the often more rapid form of progression seen in FAD (Lippa et 
al., 1996), brain tissue from both FAD and SAD are almost indistinguishable when 
examined post mortem for distributions of the various pathologic features of AD (e. g. SPs, 
NFTs, neuronal loss). The similarity in end-stage neuropathology provides evidence for a 
final common pathophysiologic pathway in AD. 
1.1.3.1. Non, aenetic risk factors 
Although the etiology of SAD is still uncertain, several risk factors have been proposed. 
" Age - ageing is the well-accepted risk factor for AD. Indeed, AD prevalence 
increase almost exponentially in elderly people, being below 1% in individuals 
aged 60-64 years and between 24% and 33% in people older than 85 years, in the 
Western world (Ferri et al., 2006). As we age, repair mechanisms that counteract 
insults are less efficient and clinical conditions that are risk factors for the disease 
tend to increase (such as diabetes, elevated cholesterol and being overweight); 
" Vascular risk factors - midlife hypertension (Qiu et at., 2005), hypercholesterolemia 
(Anstey et al., 2008), obesity (Beydoun et al., 2008) and smoking (Lee et al., 2010) 
have been reported to increase the risk of AD. Moreover, strokes and small 
haemorrhages in the brain (Pendlebury and Rothwell, 2009) are also well-accepted 
risk factor for AD and for VaD. 
" Traumatic brain injury (TBI) (Sundström et al., 2007) - TBI at any age, and 
especially repeated concussions, is a risk factor for AD. Interestingly, both in stroke 
and TBI, increased Aß production and deposition have been shown (Loane et al., 
2009). 
" Type 2 Diabetes (T2D) (Lu et at., 2009) - T2D is another risk factor for AD. 
Recent experimental evidence have shown that impaired insulin signal may be 
implicated in AD suggesting that the AD brain has a diabetes-like condition that 
some are calling type 3 diabetes (de la Monte and Wands, 2008). 
" Down's syndrome - most of the individuals with Down's syndrome who live into 
their forties and beyond develop neuropathological changes characteristic of AD 
(SPs and NTFs) and eventually dementia (Menendez, 2005). 
" Others - in addition to the risk factors described above, all of the following have 
been documented as risk factors for AD: chronic inflammatory conditions such as 
certain forms of arthritis, a history of episodes of clinical depression, stress and the 
post-menopausal state in women because of the decline in the hormone estrogen. 
1.1.3.2. Genetic risk factors 
Genetics of FAD 
The etiology of EOAD, which has an onset before 65 years, has a strong genetic 
component. As already mentioned there are autosomal dominant mutations causing FAD. 
These mutations have been identified in three genes: APP on chromosome 21, presenilin 1 
(PSENI) on chromosome 14 and presenilin 2 (PSEN2) on chromosome 1. Currently 32 
mutations in APP, 182 in PSENI, and 14 in PSEN2 are reported, which have been 
identified in 86,401, and 23 families, respectively (Alzheimer Disease & Frontotemporal 
Dementia Mutation Database, http: //www. molgen. ua. ac. be/ADMutations/). AD-linked 
mutations in these three genes exhibit high penetrance (>85%) and in most of the cases 
show autosomal dominant inheritance. These mutations are thought to be the direct cause 
of the disease in FAD patients hence they can be used as `diagnostic biomarkers' of the 
disease. However, these mutations only account for <5% of all AD cases. 
Genetics of SAD 
Although there are no reported genes that cause SAD, a genetic contribution exists also for 
this disease. First-degree relatives of patients with LOAD have twice the expected lifetime 
risk of developing the disease in comparison with people who do not have an AD-affected 
first-degree relative (Green et al., 2002). Moreover, twin studies have demonstrated a 
heritability of 58%-79% for LOAD (Gatz et al., 2006), which is consistent with a genetic 
contribution. In the last two decades, numerous genetic factors have been proposed for 
SAD. 
APOE, which is the gene that encodes for apolipoprotein E (APOE), is the only established 
susceptibility gene for LOAD. APOE is a lipid-binding protein that is expressed in humans 
as one of three common isoforms (APOE E2, E3, and E4), which are encoded by three 
different alleles (i. e. APOE P-2, APOE s3, APOE s4), and that only differ in sequence by 
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one amino acid at either position 112 or 158. Having at least one copy of APOE E4 
increases risk of AD by - 3-fold whereas two copies ,,, 12-fold. Moreover each inherited 
APOE c4 allele lowers the age of AD onset by - 5-6 years (Corder et al., 1993; Kurz et al., 
1996; Poirier et al., 1993). The APOE E4 allele has also been shown to be associated with 
memory impairment, MCI and progression from MCI to dementia (Farlow et al., 2004). 
APOE E4 has been suggested to account for 50% of the genetic risk of SAD (Saunders et 
al., 1993). Hence other genetic factors could explain the remaining genetic contribution in 
SAD. However, despite hundreds of genetic association studies during the last 15 years, 
few reported genetic associations have been replicated across studies (see 
http: //www. alzgene. org) (Bertram et al., 2010). More recent Genome Wide Association 
studies (GWAs), evaluating millions of single nucleotide polymorphisms (SNPs) in 
thousands of samples have resulted in evidence for a number of new genetic risk factors 
including bridging integrator protein I (BIN]), clusterin (CLO, ATP-binding cassette sub- 
family A member 7 (ABCA 7), complement receptor I (CR1), phosphatidylinositol-binding 
clathrin assembly protein (PICALM) and others (Hollingworth et al., 2011; Naj et al., 
2011). However, the common SNPs identified in these GWAs have low odds ratios. It still 
seems that APOE E4 remains the most important genetic risk factor in modulating AD risk. 
Nevertheless, these new gene discoveries provide new impetus for focused studies aimed 
at improved understanding of the pathogenesis of AD. Indeed, some of these new genes 
appear to be involved in Aß metabolism (for example, CLU, whilst several others may 
highlight new pathological pathways involving inflammation, endocytosis, and lipid 
biology. 
1.1.3.3. Protective factors 
Over the last decade or so, research has also uncovered factors that may offer some 
protection against this currently uncurable disease. A lifestyle including healthy eating, 
maintaining a healthy weight, taking part in regular physical activity, maintaining normal 
blood pressure and cholesterol levels and participating in activities that involve socializing 
and stimulating brain have all been suggested to reduce the personal overall risk of 
developing AD. 
Diet 
Mediterranean diet, a diet characterized by a high intake of plant foods, high consumption 
of olive oil and fish, a moderate intake of wine and a low intake of red meat and poultry 
reduces the incidence of AD and slows Mini Mental State Examination (MMSE) cognitive 
decline (Feart et al., 2009; Scarmeas et al., 2006). Omega 3-fatty acids, present in high 
amounts in fish, were shown to limit AD pathology by reducing Aß deposition by 
increasing its clearance (Cole et al., 2005; Fotuhi et al., 2009). Furthermore, a moderate 
intake of red wine was associated with a reduction in the risk of AD and dementia in a 
meta-analysis of 15 prospective studies exploring the effect of alcohol on dementia risk 
(Anstey et al., 2009) and this might be attributed to some extent to alcohol-induced 
elevations in high density lipoprotein cholesterol and reduction in thrombotic factors 
(Rimm et al., 1999). In addition, the Mediterranean diet includes foods that are rich in 
antioxidants and vitamins, like berries and dark green leafy vegetables. Moreover, other 
beneficial effects of fruit and vegetable juice was reported (at least three glasses weekly); 
this effect appears to be more related to the presence of antioxidants called polyphenols, 
rather than vitamins such as E or C (Dai et al., 2006). However it is of note that there is 
also evidence that reduced blood levels of folate (which can be supplemented through diet) 
and increased levels of homocysteine have been associated with increased incidence of 
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dementia (Kim et al., 2008). As it remains unclear if supplementation with folate and other 
associated vitamins can offer some levels of protection against AD. 
Physical exercise 
Epidemiological and experimental data suggest that physical activity (PA) may promote 
brain health. A recent meta-analysis that included 13 prospective studies focused on AD, 
dementia or both, capturing data from at least 150 000 participants found that PA produced 
beneficial effects both in dementia and AD patients (Hamer and Chida, 2009). Several 
molecular mechanisms have been proposed to explain these beneficial effects including 
alterations of neurotrophins, oxidative stress, inflammation, Aß degrading enzymes, blood 
flow, and metabolism (Radak et al., 2010). Several studies have shown that PA results in 
increased levels of brain derived neurotrophic factor (BDNF) (Macias et al., 2007), glial 
cell derived neurotrophic factor (Kleim et al., 2003), and nerve growth factor (Neeper et 
al., 1996), three neurotrophic factors that play an important role in cell survival and brain 
plasticity-enhancing properties of neurons, thus resulting in enhanced cognitive functions. 
Moreover PA is widely recognised for reducing reactive oxygen species (ROS) production 
and increase the level/activity of antioxidant enzymes in rat brain (Radäk et al., 2001). It is 
also documented that a regular exercise decreases the level of lipid peroxidation and 
protein oxidation (Radäk et al., 2001). Perhaps of more interest is the experimental 
evidence that PA decreases cortical Aß accumulation in a transgenic mouse model of AD 
(Adlard et al., 2005). In addition, PA significantly increases both the cerebral blood flow 
(Ogoh and Ainslie, 2009) and cerebral metabolism in humans (Quistorff et al., 2008), both 
of which are compromised in AD patients. Increased oxygen supply to the brain resulting 
from PA is also important because hypoxia, which results from a reduced oxygen supply, 
promotes the production of Aß (Li et al., 2009). 
Cognitive activity 
Epidemiological studies have demonstrated that higher levels of education or a lifetime of 
mental activity, which can increase brain reserve, reduced AD incidence (Stern et al., 
1994). Similarly, higher levels of cognitive activity decrease the risk of cognitive decline 
(Fratiglioni and Wang, 2007). Several prospective studies have found that both young 
(Carlson et al., 2008) and old (Fratiglioni and Wang, 2007) people who were engaged in 
cognitive activity, such as learning, reading or playing games, were less likely to develop 
dementia than individuals who did not engage in these activities. Another study, on 107 
same-gender twin pairs, have shed light on gender-specificity in taking advantage from 
stimulating activities; indeed, greater participation in intellectual activities was associated 
with lower risk of AD for women, but not for men (Crowe et al., 2003). Overall, the effect 
of cognitive activity on the risk of dementia is unclear. 
Social interaction 
Data from several independent time points from a large Swedish epidemiological study 
have suggested that better social networks and social activities might be associated with 
reduced incidence of AD (Fratiglioni et al., 2004), but this has not been examined 
systematically in large epidemiological cohorts. Whilst interesting, studies to properly 
explore this, particularly in the context of gold standard controlled trials, would be very 
problematic to design and so widespread study of this potential protective factor is 
unlikely. 
1.1.4. PATHOGENESIS 
1.1.4.1. Biology of AD 
13-am loid 
ß-amyloid (Aß) is the major constituent of amyloid plaques. Aß peptides (consisting of 36 
to 43 amino acids) are cleavage products of APP following the sequential enzymatic 
actions of ß-secretase and y-secretase (figure 1.5). 
The physiological function of APP is still undetermined. A role for APP has been 
suggested in neurite outgrowth and synaptogenesis, neuronal protein trafficking along the 
axon, transmembrane signal transduction, cell adhesion, calcium metabolism, and others, 
all requiring additional in vivo evidence (Zheng and Koo, 2006). 
The most abundant Aß species produced in the brain and found in the cerebrospinal fluid 
(CSF) is Aß40 (where 40 denotes the number of amino acids). Aß42 is generally present in 
tissues and body fluids at levels from 5 to 10% of those of Aß40, and it appears to be 
central to initiating Aß aggregation because it is more hydrophobic and prone to aggregate 
(Kim and Hecht, 2005). An imbalance between production, clearance and aggregation of 
Aß peptides, has been proposed as the initiating event in AD (cfr. "amyloid cascade 
hypothesis"). Aß spontaneously self-aggregates in multiple coexisting physical forms; one 
of these consists of oligomers (2-6 peptides) that are currently considered the most 
neurotoxic form (Lambert et al., 1998). 
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FIGURE 1.5. Schematic diagram of APP processing. 
mJAICD 
Revised from (Zhang et al., 2011). 
Abbreviations: sAPP, soluble APP; CTF, C-terminal fragment; AICD, APP intracellular 
domain. 
APP is a transmembrane protein with a large N-terminal extracellular tail and a domain 
termed "Aß" which is partly embedded in the plasma membrane. APP can be processed 
along two main pathways. In the a-secretase pathway, a-secretase cleaves APP within the 
Aß domain, releasing sAPPa. The remaining a-CTF, or C83, is cleaved by the y-secretase 
complex releasing the p3. The remaining AICD is metabolised in the cytoplasm. Since APP 
cleavage by a-secretase is within the Aß domain this precludes Aß generation. In the ß- 
secretase pathway, ß-secretase cleaves APP just before the Aß domain, releasing soluble 
sAPPß. The remaining ß-CTF, or C99 is cleaved by the y-secretase complex releasing the 
40 or 42 aminoacid Aß peptide. The remaining AICD is metabolised in the cytoplasm. 
Familial missense mutations in APP and PSEN genes 
As mentioned, missense mutations occur in APP and these are thought to cause the disease 
because they lead to amino acid changes which are located at or near the sites of APP 
endoproteolysis by ß-secretase and y-secretase (Goate et al., 1991) or a rare familial 
disease with CAA and cerebral haemorrhage (Levy et al., 1990). Mutations adjacent to the 
y-secretase site, lead to an increase in the ratio of Aß42 to Aß40 being produced without 
having a significant effect on total Aß levels (Haass et al., 1994) however over time this 
increased Aß42 is likely to be central to AD pathogenesis. In contrast, another mutation, 
the APP Swedish FAD mutation (identified in a Swedish family with FAD), occurs near 
the (3-secretase cleavage site (Mullan et al., 1992). This mutation leads to increased 
production of all species of Aß and is associated with both AD and CAA (Citron et al., 
1992). Some of the APP mutations that lead to FAD and CAA do not increase Aß 
production and are located within the Aß peptide itself. These mutations are C-terminal to 
the a-secretase cleavage site in APP and change the sequence of Aß such that it increases 
the propensity of Aß to oligomerize, fibrillize, or be cleared less effectively (Nilsberth et 
al., 2001). Another recently described APP mutation exhibits autosomal recessive 
inheritance of AD and results in the deletion of one amino acid at position 22 in Aß 
producing a peptide that is markedly fibrillogenic (Tomiyama et al., 2008). 
In addition to the APP mutations, those that have also been described to occur in PSENI 
(Sherrington et al., 1995; Levy-Lahad et al., 1995) and PSEN2 (Sherrington et al., 1995) 
also contribute to Aß production. The presenilin genes encode for constituent parts of the 
1-secretase complex which also involve three other proteins: APH-1, PEN2, and nicastrin 
(Takasugi et al., 2003). Similar to what is observed with many APP mutations, a selective 
and significant increase in the total level of Aß42 or the ratio of Aß42 to Aß40 is found in 
the plasma, and in the media of cultured fibroblasts, from patients with PSEN mutations 
(Scheuner et al., 1996). 
Tau 
Besides amyloid plaques, the major component of NFTs is the abnormally 
hyperphosphorylated and aggregated form of tau. Tau is the major neuronal microtubule- 
associated protein, prevalently localized in the axons, which promotes assembly and 
stability of microtubules (Weingarten et al., 1975). Tau is actively phosphorylated in 
normal individuals regulated by the balance between multiple kinases [glycogen synthase 
kinase-3 (GSK-3), cyclin dependent protein kinase-5 (CDK5), protein kinase A (PKA), 
calcium and calmodulin-dependent protein kinase-II (CaMKII), casein kinase-1 (CK-1), 
mitogen-activated protein (MAP) kinase ERK 1/2, and stress-activated protein kinases 
(SAPKs)] and phosphatases (protein phosphatase PP-2A and PP-1) (Iqbal et al., 2009). In 
AD brain, tau is at least three- to four-fold more hyperphosphorylated (Iqbal et al., 1986; 
Köpke et al., 1993). Hyperphosphorylated tau is insoluble, lacks affinity for microtubules, 
self-associates into PHFs and accumulates in the somato-dendritic compartment (Alonso et 
al., 2001; Iqbal et al., 2010). 
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1.1.4.2. Pathojienic hypothesis 
Amyloid hypothesis 
A major advance in the study of AD came with the sequencing of the main constituent of 
SPs (i. e. the Aß peptide) (Glenner and Wong, 1984; Masters et al., 1985). This led in rapid 
sequence to four key discoveries: 
" Aß peptide is a part of the large type I membrane protein APP (Kang et al., 1987); 
" APP is mutated in a significant fraction of the cases of FAD (Goate et al., 1991); 
" Individuals with Down's syndrome, who have three copies of chromosome 21 and 
hence three copies of APP, develop clinical and pathological signs of early-onset 
AD (Delabar et al., 1987; Olson and Shaw, 1969); 
" Mutations in PSENI and PSEN2, encoding the catalytic subunit of the y-secretase 
activity that liberates the Aß peptide from the C-terminus of APP, can behave as 
dominant familial AD genes (Scheuner et al., 1996). 
Collectively these findings formed the cornerstones of the "amyloid cascade hypothesis". 
This hypothesis suggests that Aß deposition, due to an imbalance between the production 
and clearance of Aß in the brain is the initiating event of a number of downstream 
consequences ranging from synapse loss to inflammation, triggering of tau 
hyperphosphorylation, and the death of susceptible neurons (Hardy and Selkoe, 2002). 
The amyloid hypothesis has prevailed for over two decades. Initially, it was thought that 
Aß deposited in SPs was the primary source of neurotoxicity. However, more recent 
findings have pointed to unpleated Aß oligomers being responsible for inhibiting 
hippocampal long-term potentiation and disrupting synaptic plasticity well before the 
accumulation of fibrillary Aß (Ferreira et al., 2007). In particular, Aß* 56, a specific form 
of Aß oligomer (56 kDa), was demonstrated to be associated with cognitive decline 
(Morris and Mucke, 2006). 
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FIGURE 1.6. The amyloid cascade hypothesis. 
Taken from (Hardy and Selkoe, 2002). 
The violet arrows indicate the proposed sequential events that lead to dementia in FAD 
patients. Noteworthy, Aß oligomers may directly injure the synapses and neurites of brain 
neurons (curved arrow), or indirectly through the activation of microglia and astrocyles. 
Tau hypothesis 
The tau hypothesis is supported by several observations: 
" AD severity correlates well with the increasing accumulation of NFTs in the brain 
(Ghoshal et al., 2002); 
" Phosphorylated forms of tau, in the CSF from AD brain, are highly correlated with 
the extent of cognitive impairment (Maccioni et al., 2006); 
" Drugs that decrease tau filaments alleviate cognitive impairment (Duff et al., 2010). 
The tau hypothesis states that in AD tau hyperphosphorylation starts intracellularly, and 
leads to sequestration of normal tau and other microtubule-associated proteins, which 
causes disassembly of microtubules and thus impaired axonal transport, compromising 
neuronal and synaptic functions (Igbal et al., 2005). Recently it has been proposed that as 
much as 40% of the abnormally hyperphosphorylated tau in AD brain is present in the 
cytosol and not polymerized into PHFs/NFTs. The AD cytosolic abnormally 
phosphorylated tau (p-tau) does not bind to tubulin to promote microtubule assembly, but it 
inhibits microtubule assembly and sequesters normal tau generating oligomeric species that 
self-assemble into PHFs and straight filament (SFs) and then form NFTs. The current idea 
is that, like Aß oligomers, intermediate aggregates of abnormal tau molecules are cytotoxic 
and are reported to impair cognitions (Igbal et al., 2010). As a result of neuronal death, 
oligomeric forms and tau filaments are released to the extracellular environment, 
contributing to activation of microglial cells and stimulating the deleterious cycle leading 
to progressive neuronal degeneration (Herrup, 2010). 
According to the updated tau hypothesis, tau hyperphosphorylation constitutes a final 
common pathway in AD pathogenesis, upon which a host of signalling mechanisms 
converge, and this phenomenon precedes widespread neuronal degeneration (Fernandez et 
al., 2008). 
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In AD brain a phosphorylation/dephosphorylation imbalance leads to abnormal 
hyperphosphorylation of tau. This AD p-tau on one hand sequesters normal MAPs from 
microtubules and causes inhibition and disruption of microtubules. On the other hand, 
while the binding of AD p-tau to MAP] or MAP2 results in amorphous aggregates, the 
binding to normal tau forms oligomers. Unlike normal tau, which is highly soluble, the tau 
oligomers formed with AD p-tau self-assemble into PHFs/SFs in the, form of NFTs. 
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Other hypotheses 
Several other hypotheses of disease mechanisms have been proposed to explain specific 
features of AD pathogenesis, including inflammatory mechanisms, oxidative stress, altered 
vasoactive pathways (Kehoe et al., 2009) and mitochondrial dysfunction with disruption in 
neuronal energy metabolism. 
Mitochondrial dysfunction has an established role in age-related neurodegenerative 
diseases, such as AD (Beal, 1998). Mitochondria sustain the activity of neurons by 
producing ATP via the electron transport system by coupling electron transfer to the 
pumping of protons across the inner mitochondrial membrane. However, electrons can 
escape the electron transport chain and reduce ROS. Oxidative damage results from a 
disturbance in the ROS-antioxidant balance that promotes oxidation. Oxidative damage to 
mitochondria may be especially relevant in neurodegenerative diseases since mitochondria 
are regulators of both cellular metabolism and apoptosis (Sullivan et al. 2005). 
Mitochondria also maintain intracellular Ca 2+ homeostasis and alterations in Ca 2+ 
homeostasis in SAD patients was firstly reported in the middle of the 1980s (Peterson et 
al., 1986). Increased mitochondrial Ca2+ overload as a result of excitotoxicity has been 
associated with the generation of superoxide and may induce the release of pro-apoptotic 
mitochondrial proteins, proceeding through DNA fragmentation/condensation and 
culminating in cell demise by apoptosis and/or necrosis (Rego and Oliveira, 2003). 
To date, an unifying hypothesis takes into account previously formulated hypotheses 
(Herrup, 2010). Three main stages can be identified: 
1) A precipitating injury begins the pathogenic process (e. g. Aß oligomers, oxygen free 
radicals, iron overload, disorders of lipid metabolism, hyperglycaemia, deregulation of 
insulin levels, chronic infections, head trauma, and others), 
2) The injury triggers a chronic inflammatory process that adds additional relentless stress 
to brain cells already weakened by age [i. e. activated glial cells respond by releasing 
Nuclear Factor Kappa P (NF-KB) and overproduce proinflammatory cytokines which 
contribute to brain inflammation and alterations in neuron-glia interaction pattern], 
3) Eventually there is a major shift in the cellular physiology of brain cells (e. g. synaptic 
dysfunction and neuronal death). 
1.1.5. TREATMENTS 
1.1.5.1. Symptomatic drugs 
Currently, there are only 5 drugs approved by the Food and Drug Administration (FDA) to 
treat AD. These are all symptomatic treatments, addressing the cognitive impairments of 
the AD patients, but do not target the underlying pathology. 
Acetylcholinesterase inhibitors 
Although most of the vulnerable neurons in AD use glutamate, the major neurotransmitter 
in the brain, there is also loss/dysfunction of certain subcortical projection neurons such as 
basal forebrain cholinergic neurons and noradrenergic neurons in the locus coeruleus 
(Coyle et al., 1983). The cholinergic hypothesis in AD states that cholinergic system in the 
basal forebrain nuclei is affected early in the disease process causing disturbances in 
presynaptic cholinergic terminals in the hippocampus and neocortex, resulting in memory 
disturbances as well as deterioration of other cognitive and non-cognitive functions such as 
neuropsychiatric symptoms (Terry and Buccafusco, 2003; Bartus et al., 1982). Drugs 
inhibiting acetylcholinesterase, increase the availability of acetylcholine (ACh) and 
enhance cholinergic neurotransmission. Four Acetylcholinesterase inhibitors were 
originally approved by FDA for clinical use in AD: tacrine (1993), donepezil (1996), 
rivastigmine (2000) and galantamine (2001). Persistent treatment with cholinesterase 
inhibitors slows clinical progression of AD in early to moderate AD patients (Rountree et 
al., 2009). However, in most of the cases the therapeutic efficacy of these drugs is 
moderate and sometimes wears off after a short treatment period (- 6 months) although 
other patients can benefit for a number of years. Tacrine is no longer used because of its 
high prevalence of hepatotoxicity (Ames et al., 1988). 
Memantine 
A dysfunction of glutamatergic neurotransmission, causing neuronal excitotoxicity, is also 
known to be involved in the etiology of AD (Areosa et al., 2005). Targeting the 
glutamatergic system, specifically N-Methyl-D-aspartate (NMDA) receptors, has served as 
one current important therapeutic strategy. Indeed, NMDA receptors control synaptic 
plasticity and memory function in the brain (Li and Tsien, 2009) while Aß disturb the 
function of postsynaptic NMDA receptors causing excessive Ca2+ influx into neurons and 
activation of NMDA-dependent downstream pathways. The cytosolic and mitochondrial 
Ca 2+ overload that in turn initiates a cascade of oxidative citotoxicity and apoptosis (Hynd 
et al., 2004). 
Memantine is a non-competitive NMDA-receptor antagonist that is believed to protect 
neurons from excitotoxicity without preventing the physiological NMDA-receptor 
activation needed for cognitive functioning (Wilcock, 2003). It was approved by FDA in 
2003 for the treatment of patients with moderate to severe AD. Combination use of 
memantine and donepezil have proved a significant benefit in cognitive function compared 
to treatment with memantine alone in patients with moderate to severe AD (Tariot et al., 
2004). 
1.1.5.2. Disease-modifying drugs 
Unlike treatments that target symptoms of cognitive dysfunction, disease-modifying 
therapies could slow or arrest AD progression by interrupting underlying pathophysiologic 
processes (Mangialasche et al., 2010). For example drugs targeting Aß production (e. g. ? - 
secretase inhibitors), clearance (e. g. immunotherapy) or aggregation to avoid the 
generation of toxic Aß oligomers may show potential benefit for AD treatment in mild to 
moderate AD (Mangialasche et al., 2010). Besides drugs aimed to interfere with Aß 
metabolism, treatments that could target abnormal tau protein are also being investigated 
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(e. g. inhibitors of tau-phosphorylating kinases and compounds that inhibit tau aggregation 
and/or promote aggregate disassembly) (Gong and Iqbal, 2008). Other promising strategies 
target mitochondrial dysfunction or increase neurotrophic agents to rescue cholinergic cell 
death. To this concern, Cerebrolysin, a peptidergic drug that exerts nerve growth factor like 
activities on neurons is currently approved and marketed in several countries worldwide 
for the treatment of AD. 
1.2. SIRTUINS IN AGEING AND AGE-RELATED DISEASES 
1.2.1. GENERAL INTRODUCTION ON SIRTUINS 
1.2.1.1. The sirtuin protein family 
The Sir2-related proteins (HST - homologues of SIR2), also known as sirtuins, are 
evolutionary conserved enzymes found in all domains of life (Brachmann et al., 1995). In 
the last decade, a growing interest in resolving the function of mammalian sirtuins has 
arisen after the discovery that this protein family regulates ageing and longevity in lower 
organisms such as yeast, worms and flies (Fontana et al., 2010). 
Sir2p (silent mating type information regulation 2), of the budding yeast 
Saccharomyces cerevisiae (S. c. ), was the first member of this family to be discovered by 
Klar and colleagues in the late 1970s (Klar et al., 1979). Sir2p was later shown to be 
essential for genome integrity by regulating gene silencing at three genetic loci: mating- 
type loci, ribosomal DNA (rDNA), and telomeres (Bryk et al., 1997; Gottschling et al., 
1990; Rine and Herskowitz, 1987; Smith and Boeke, 1997). In particular, silencing at the 
rDNA seems to be the mechanism through which Sir2p promotes longevity in yeast, by 
preventing accumulation of extrachromosomal rDNA circles, a yeast specific cause of 
ageing. The first identified protein substrates of yeast Sir2p were histones (Blander and 
Guarente, 2004), indeed it was shown that Sir2 exerted its function through deacetylation 
of specific lysine residues in the amino-terminal tail of histones H3 and H4. 
The alignment between sirtuin protein sequences, ranging from bacteria to humans, 
revealed that these proteins are -30-65% identical to yeast Sir2p overall (Sherman et al., 
1999). In particular sirtuins all contain a characteristic core domain (- 260 amino acid 
long), highly conserved (up to 84% identical to Sir2p), relevant for sirtuin catalytic activity 
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(Sherman et al., 1999). Based on sequence similarity in this conserved domain, the 
eukaryotic HST proteins were grouped into four main classes (class I-IV). Yeast Sir2p 
belongs to class 1, while the 7 human sirtuins are represented across all four classes: 
SIRT1, SIRT2, and SIRT3 (class I); SIRT4 (class 11) SIRT5 (class III); and SIRT6 and 
SIRT7 (class IV). A fifth class also exists (class U) found only in Gram-positive bacteria 
(Frye, 2000). 
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Taken from (North and Verdin, 2004). 
Abbreviations: A. act, Actinohacillus actinomycelemcomilans; A. aeo, Aquifex aeolicus; A. ful, 
Archaeoglohus fulgidus; A. per, Aeropyrum pernix; A. tha, Arabidopsis thaliana; B. per, 
Bordetella pertussis; B. sub, Bacillus subtilis; C. ace, Clostridium acetahutylicum; C. alb, Candida 
albicans; C. dif, Clostridium difficile; C. ele, Caenorhabditis elegans; C. jej, Campylohacter 
jejuni; D. mel, Drosophila melanogaster; D. rad, Deinococcus radiodurans; E. col, Escherichia 
coli; E. fae, Enlerococcus faecalis; H. sap, Homo sapiens; H. pyl, Helicohacter pylori; L. maj, 
Leishmania major: M. avi, Mycobacterium avium; M. tub, Mycobacterium tuberculosis; O. sat, 
Oryza saliva; P. aby, Pyrococcus abyssi; P. fal, Plasmodium falciparum; P. hor, Pyrococcus 
horikoshii; S. aur, Staphylococcus aureus; S. coe, Sireplonryces coelicolor; S. pom, 
Schizosaccharomyces pombe, S. typ, Salmonella typhimurium; S. cer, Saccharomyces cerevisiae; 
T. hru, Trypanosoma brucei; T. mar, Thermotoga marilima; Y. pes, Yersinia peslis. 
1.2.1.2. Sirtuin mechanism of action 
The first reaction characterized for sirtuins was a ribosyltransfer reaction catalysed by the 
Sir2 homolog CobB in Salmonella typhimurium (Tsang and Escalante-Semerena, 1998). 
More recently, sirtuins were discovered to act as deacetylases and/or mono-ADP- 
ribosyltransferases a function found to be dependent on oxidized nicotinamide adenine 
dinucleotide (NAD+). Sirtuins are histone deacetylase enzymes (HDACs). HDACs occur 
in four groups (HDAC I-IV) based on function and DNA sequence similarity. Sirtuins are 
unconventional HDACs and alone constitute Class III due to their unique enzymatic 
mechanism. Their main peculiarities are the use of NAD+ instead of zinc as a co-factor and 
the lack of production of acetate (Hernick and Fierke, 2005). Moreover sirtuins are not 
affected by Trichostatin A (TSA) and sodium butyrate (SB), two inhibitors of `'classical" 
HDACs. 
Landry et al. in 1999 elucidated the mechanism of Sir2p-mediated deacetylation showing 
that the deacetylase reaction is tightly coupled to the formation of a novel product (0- 
acetyl-ADP ribose, OAADPr). One molecule of NAD+ and one molecule of acetyl-lysine 
of the target protein are readily catalysed to one molecule of deacetylated lysine, 
nicotinamide (NAM), and OAADPr (Tanner et al., 2000) as shown in figure 1.9. The 
unique product OAADPr was proposed to have an important signalling role as a cofactor 
for SIR2 catalytic activity (Tanner et at., 2000). 
Besides deacetylation, some sirtuins possess mono-ribosyltransferase activity. Sirtuin- 
mediated mono-ribosyltransferase reaction transfers the ADP-ribose group from NAD+ to 
acceptor proteins in a post-translational modification called ADP-ribosylation. This 
reaction produces mono-ADP-ribosylated proteins and, similiar to the deacetylation 
reactions, also yields NAM (Sauve, 2010). The requirement of NAD+ for sirtuin catalyses, 
which is different to HDAC 1/1I mediated reactions that simply hydrolyse acetyl-lysine, 
suggests that sirtuins may have evolved as sensors of cellular energy and redox state 
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coupled to the metabolic status of the cell (Sinclair and Guarente, 2006). Indeed, sirtuins 
respond to changes in the concentrations of NAD+, NADH and NAM (NADH and NAM 
are inhibitors of sirtuins) (Sauve, 2010). 
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Sirtuins catalyse two reactions that are NAD+-dependent: A. DEACETYLATION. The 
amide cleavage of NAD+ is the driving force that cleaves an acetyl group from an acetyl- 
lysine residue of a target protein generating OAADPr and NAM; B. ADP-RIBOSYL 
TRANSFER. An ADP-ribose from one NAD+ molecule is transferred to an uncoupled 
protein generating NAM 
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1.2.1.3. Mammalian sirtuins 
As mentioned, the mammalian sirtuin family so far consists of 7 sirtuins (SIRTI-7) 
discovered in humans (Michishita et al., 2005). These proteins are involved in a variety of 
cellular functions such as stress resistance and apoptosis, genomic integrity and cellular 
metabolism (Michan and Sinclair, 2007). 
Mammalian sirtuins share, as well as all the other HST proteins, the sirtuin core domain. 
Although mammalian sirtuins are well conserved in their core domain, they vary in length 
in the N- and C-terminal flanking sequences. Moreover, they have different patterns of 
subcellular localization and expression, unique binding partners and substrates and display 
different enzymatic activities. Indeed, sirtuins act preferentially as deacetylases and/or 
mono-ADP-ribosyl transferases. For example in terms of activity, S1RT1 has a robust 
deacetylase activity, SIRT4, only shows a mono-ADP-ribosyl transferase activity, while 
SIRT3 performs both deacetylase as well as mono-ADP-ribosyl transferase activities 
(Michan and Sinclair, 2007). In terms of subcellular localization differences SIRT2 is 
predominantly localized in the cytoplasm; SIRT3, SIRT4 and SIRT5 in the mitochondria 
and SIRTI, SIRT6 and SIRT7 are predominantly nuclear (Michishita et al., 2005). 
Although this classification is still valid, more recent studies have shown that sirtuins are 
distributed among multiple compartments of the cell and their localization may be 
dynamic, depending on tissue/cell type and physiologic condition. For example SIRTI and 
SIRT2 were found to localize in both the nucleus and the cytoplasm and to interact with 
both nuclear and cytosolic proteins (North and Verdin, 2007; Tanno et al., 2007). 
Consistently, SIRTI was shown to possess two nuclear import signals and two nuclear 
export signals in its sequence (Tanno et al., 2007). Also SIRT2 was shown to possess a 
nuclear localization signal (North and Verdin, 2007). 
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Mammals have 7 sirluins, SIRTI-7. All have a NAD+-dependent catalytic core domain 
that may act preferentially as a mono-ADP-ribosyl transferase (ART) and/or NAD+- 
dependent deacetylase (DAC). Additional N-terminal and/or C-terminal sequences of 
variable length may flank this core domain. The 7 sirtuins show different cellular 
localizations. 
Besides cellular localization, post-translational modifications regulate sirtuin function. For 
example SIRT2 activity was shown to be regulated by phosphorylation at multiple sites. 
Phosphorylation at Ser 331 mediated by CDK2 and CDK5 is predicted to inhibit the 
deacetylase activity of SIRT2 (Pandithage et al., 2008) while phosphorylation at Ser 368 
by CDKI. inhibited SIRT2 degradation through the 26S proteasome (Dryden et al., 2003). 
SIRTI was shown to be positively regulated by phosphorylation by different kinases 
among which JNKI and CDKI (Sasaki et al., 2008; Nasrin et al., 2009) and its deacetylase 
activity was also reported to be positively regulated by sumoylation at Lys 734 (Yang et 
al., 2007b). 
Recent reports showed that SIRTI function is also regulated by other proteins including 
the activators AROS, necdin and DBC I. Both DBC I and AROS bind to the N-terminus of 
SIRTI, the same region to which SIRTI small-molecule activators hind, raising the 
possibility of a common mechanism of control (Haigis and Sinclair, 2010). Moreover, 
despite their different targets and cellular localization, perturbation of the activity of one 
sirtuin has been shown to impact the activities of other sirtuin members. For example 
SIRTI can regulate SIRT6 expression (Kim et al., 2010). Intensive crosstalk between 
nuclear and mitochondrial sirtuins have also been implied in the literature (Kong et al., 
2010; Nasrin et al., 2010). 
1.2.1.4. Pharmacological activators and inhibitors of sirtuins 
Activators 
In an initial screening of chemical libraries, a series of naturally occurring plant 
polyphenols were identified as SIRTI activators, in particular quercitin and resveratrol 
(RES) (Howitz et al., 2003). More recently, several isoflavones were observed either to 
activate SIRTI or increase its expression or do both (Rasbach and Schnellmann, 2008). 
These compounds are collectively called Sirtuin Activating Compounds (STACs). 
RES was reported to be the most potent naturally available SIRTI activator, and numerous 
studies showed that RES treatment in vivo and in vitro recapitulates biochemical effects 
exerted by SIRTI genetic overexpression. However, controversial data about SIRT 1 
activation still exist and some authors have suggested that RES may activate sirtuins 
indirectly or even not activate it (Hu et al., 2011). Despite the SIRTI ambiguities RES was 
also shown to activate other sirtuins in vitro; for example exposure of cardiornyocyte cells 
to RES caused rapid activation of SIRTI\3\4 and 7 (Yu et al., 2009). 
Other SIRTI activators also exist but to date there are currently few published examples of 
compounds that have a higher specificity for SIRT2-SIRT7. In 2007 Sirtris 
Pharmaceuticals identified three compounds to serve as novel SIRTI activators containing 
an imidazothiazole scaffold and which did not resemble RES structure. They named these 
compounts SRTs (Milne et al., 2007). Among these SRT 1720 and SRT2183 were reported 
to be the most potent activators of SIRTI. Like RES, no clear data are yet available about 
SIRTI effective activation by SRTs. Although the exact mechanisms of activation are not 
yet clear, some authors have proposed that sirtuin activators bind to the N-terminus of 
SIRTI, lower the Km for the substrate and for NAD+ and in a lesser extent, increase the 
maximum enzyme velocity (Vmax). 
Inhibitors 
The first step in sirtuin catalysis is the formation of a ternary complex of the enzyme, 
NAD+, and acetylated peptide, followed by the expulsion of NAM to form an AD-ribose- 
peptidyl imidate intermediate. This intermediate can proceed in the forward reaction steps 
leading to production of deacetylated peptide and OAADP and reverse reaction steps with 
reincorporation of NAM and synthesis of substrates. NAM, produced by sirtuin catalysis, 
is a naturally occurring potent inhibitor of sirtuins' activity (particularly Sir2p, SIRT1 and 
SIRT2). In fact, excess NAM is thought to promote the reverse reaction (Blum et al., 
2010). 
Although NAM is not specific for any particular sirtuin, its analogue 2-anilinobenzamine 
was identified to be a potent SIRTI inhibitor (Suzuki et al., 2009). Also NAD+ analogues, 
such as carbamido-NAD, were shown to inhibit sirtuins. While NAM is a non-competitive 
allosteric inhibitor, carbamido-NAD acts by competing for the NAD+ binding site within 
the active site. 
In a high-throughput screening, indole-based compounds were identified as sirtuin 
inhibitors (Napper et al., 2005). These compounds were hypothesized to bind close to or in 
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conjunction with the NAM binding site. Among these, EX527 was reported to be the 
highest specific inhibitor of SIRT1, approximately 1000 fold more potent than NAM. 
One of the first commercially available sirtuin inhibitors was sirtinol. This compound, 
shown to inhibit SIRTI, SIRT2 and Sir2p, was widely employed and a number of more 
potent analogues were developed rationally designed to improve SIRTI activation, such as 
salermide. 
A specific reversible inhibitor for SIRT2 is also available, named AGK2. 
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FIGURE 1.11. Chemical structure of sirtuin activators and inhibitors. 
1.2.1.5. Function of the mammalian sirtuins 
SIRTI 
SIRTI is the most extensively studied mammalian sirtuin and it is implicated in the 
regulation of multiple biological phenomena including DNA damage repair, mitochondrial 
biogenesis, insulin secretion, stress response, apoptosis as well as genome stability. SIRTI 
is highly expressed in several brain regions including the hypothalamus, and has been 
found in the heart, kidney, liver, pancreas, skeletal muscle, spleen, and white adipose 
(Michishita et al., 2005). 
SIRTI, similar to yeast Sir2p, induces heterochromatin formation, which generally is 
associated with hypoacetylation and gene repression by deacetylating various histones (e. g. 
histone HI) (Vaquero et al., 2004). However, although sirtuins were initially thought to be 
exclusively histone deacetylases, more recently a variety of non-histone targets have been 
identified. 
SIRTI and energy metabolism 
SIRT I plays a critical role in the regulation of metabolic responses to changes in nutrient 
availability in multiple tissues. Calorie restriction upregulates SIRTI in different tissues 
including liver, skeletal muscle and white adipose tissue (Haigis et al., 2006). In these 
tissues, through different targets, SIRT1 exerts important metabolic functions. In skeletal 
muscle, SIRT1 deacetylates PGC-la thus upregulating the transcription of genes involved 
in mitochondrial biogenesis, muscle oxidative capacity, fatty acid oxidation and energy 
expenditure (Gerhart-Hines et al., 2007). 
In liver, during short-term fasting, SIRT1 inhibits TORC2, a key mediator of early phase 
gluconeogenesis, and prolonged fasting leads to increased SIRT1 deacetylation and 
activation of PGC-la, an essential co-activator for a number of transcription factors, 
resulting in increased fatty acid oxidation and 
, 
improved glucose homeostasis 
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(Purushotham et at., 2009; Rodgers et al., 2005). In conjunction, SIRTI-mediated 
deacetylation of FOXO1, that causes its retention in the nucleus, promotes FOXO1- 
mediated transcription of genes involved in gluconeogenesis (Frescas et al., 2005). 
Moreover, during fasting, SIRTI deacetylates SREBP-lc thus inhibiting its transcriptional 
activity responsible for liver lipogenesis and thus attenuating liver steatosis in diet-induced 
and genetically obese mice (Ponugoti et al., 2010). SIRTI also regulates hepatic 
cholesterol and bile acid homeostasis through direct modulation of the liver X receptor and 
farnesoid X receptor (Kemper et al., 2009; Li et al., 2007). 
In white adipose tissue, SIRTI interacts with PPARy, a nuclear transcription factor 
receptor that controls adipogenesis. SIRTI deacetylation was proposed to repress PPARy 
activity and promote free fatty acid mobilization in adipocytes (Picard et al., 2004). In 
addition, in adipocytes SIRT 1-catalyzed deacetylation/activation of FOXO 1 increases the 
transcription of the adiponectin gene (Qiao and Shao, 2006). Furthermore SIRTI was 
shown to positively regulate insulin secretion in pancreatic ß cells repressing the 
uncoupling protein 2 (UCP2) (Bordone et al., 2006). 
SIRT1 and DNA damage repair 
Recent experimental evidence suggests that SIRTI is involved in response to DNA damage 
and in the maintenance of genomic stability. SIRTI overexpression was shown to enhance 
repair of DNA strand breakages produced by radiation through deacetylation of Ku70 
(Jeong et al., 2007). Moreover, SIRT1 plays an important role in the regulation of both the 
nucleotide excision repair pathway, through modulation of XPA acetylation status (Fan 
and Luo, 2010), and the DNA double-strand break repair maintaining NBS 1 in a 
hypoacetylated state (Yuan et al., 2007). 
Stress resistance and apoptosis 
SIRTI has a role in control cell survival and apoptosis. In ß-pancreatic cells 
overexpression of SIRT1 counteracted cytokine toxicity and reduced induction of nitic 
oxygen (NO) synthetase by suppressing NF-Kb signalling pathway (Lee et al., 2009). On 
the other hand, SIRTI was shown to bind and deacetylate the tumor suppressor protein p53 
at lysine 382 causing the accumulation of p53 in the cytoplasm rather than in the nucleus. 
Under ROS stimulation, cytoplasmic p53 translocates into mitochondria and enhances 
apoptosis (Han et al., 2008). 
SIRT2 
SIRT2 is localized in both the cytoplasm and in the nucleus. SIRT2 is reported to be the 
most abundant sirtuin in adipocytes, found in white and brown adipose tissue. It is also 
highly expressed in the brain and nervous system (Kelly, 2010). SIRT2 was proposed to 
have a role in cell cycle regulation. In Saos2 cells, SIRT2 overexpression delayed the 
progression through the mitotic phase of the cell cycle and in synchronized cells SIRT2 
accumulates in mitosis particularly at the G2/M transition, delaying exit from mitosis 
(Dryden et al., 2003). One proposed mechanism through which SIRT2 may regulate the 
cell cycle is that H4K16 deacetylation during mitosis could affect chromatin packaging 
(Vaquero et al., 2006). 
FOXO1 and FOXO3a are two transcriptional factor targets of SIRT2. SIRT2-dependent 
deacetylation of FOXO1 enhances localization of FOXO1 to the nucleus by altering its 
level of phosphorylation, a post-translational modification that normally causes FOXOs to 
localize to the cytosol where it is inactive (Jing et al., 2007). FOXOI is an inhibitor of 
adipocyte differentiation and inhibiting SIRT2 was reported to accelerate adipocyte 
differentiation (Jing et al., 2007). Hypoacetylation of FOXO3a by SIRT2 overexpression in 
kidney cells provided resistance to ROS through increased transcription of FOXO3a genes 
(e. g. Bim, Mn SOD) (Wang et al., 2007). 
-62- 
SIRT3 
SIRT3 is a mitochondrial protein expressed in various tissues, at especially high 
levels in 
brain, kidney, brown adipose tissue, heart, liver and muscle (Shi et al., 2005). SIRT3 is a 
major mitochondrial deacetylase, indeed SIRT3 knock-out (KO) mice exhibit striking 
mitochondrial protein hyperacetylation, differently from KO mice of the other two 
mitochondrial sirtuins, SIRT4 and SIRT5 (Lombard et al., 2007). 
The first biological role identified for SIRT3 was its involvement in the activation of 
thermogenesis in brown adipocytes by enhancing expression of PGC 1a and UCPI (Shi et 
at., 2005). More recently, a feedback loop has been proposed between SIRT3 and PGCIa 
since PGCla was shown to stimulate SIRT3 expression (Kong et al., 2010). AceCS2 is 
another target of SIRT3-mediated deacetylation. Deacetylated AceCS2 accelerates 
conversion of mitochondrial acetate to acetyl-CoA in the presence of ATP (Schlicker et al., 
2008). Moreover the discovery that glutamate dehydrogenase (GDH) and isocitrate 
dehydrogenase are substrates of SIRT3, has shed light on the putative role of SIRT3 in 
regulating citric acid cycle and in mitochondrial energy metabolism. Moreover, complex II 
and succinate dehydrogenase flavoprotein are other probable targets of SIRT3 that explain 
why SIRT3 deficiency is associated with mitochondrial loss of performance in electron 
transport and weak ATP production (Cimen et at., 2010). Decrease in SIRT3 is also 
associated with increased ROS formation and hepatocyte death (Bao et al., 2010). 
With its central role in mitochondria) biology, SIRT3 contributes to cell survival by 
modulating oxidative stress pathways. Benigni et al. demonstrated that KO mice of the 
angiotensin II type 1 receptor, a gene responsible for promoting high blood pressure and 
various pathological conditions, such as heart, kidney and brain diseases, promoted 
longevity in mice. The lack of this receptor was associated with increased numbers of 
mitochondria, attenuation of oxidative stress, and upregulation of Nampt and SIRT3 levels. 
SIRT3 protects cardiomyocytes and HeLa cells from genotoxic and oxidative stress- 
mediated cell death. By binding to and deacetylating Ku70, SIRT3 augments Ku70-Bax 
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interactions, which in turn prevents Bax translocation to the mitochondria, and prevents 
apoptosis during stress-mediated conditions (Benigni et al., 2009). SIRT3 has also a role in 
lipid metabolism regulation. During fasting, livers from SIRT3 KO mice experienced 
increased fat accumulation versus wild-type, suggesting a deficiency in fat processing 
(Hirschey et al., 2010). 
SIRT4 
SIRT4 is another mitochondrial protein highly expressed in kidney, heart, liver and brain 
(Michishita et al., 2005; Haigis et al., 2006). The only known substrate of SIRT4 is GDH, 
an enzyme that regulates the usage of amino acids into energy production (Haigis et al., 
2006). In early work, it was shown that SIRT4 interacts with GDH and suppresses its 
activity via ADP-ribosylation (Haigis et al., 2006). GDH promotes the metabolism of 
glutamate and glutamine, generating ATP, which promotes insulin secretion. Consistently, 
loss of SIRT4 in insulinoma cells activates GDH, thereby upregulating amino acid- 
stimulated insulin secretion. Furthermore, isolated pancreatic islets from SIRT4 KO mice 
have higher GDH activity than wild-type mice and treatment of wild-type mitochondrial 
lysates with phosphodiesterase, which cleaves the AMP moiety of ADP-ribosylated 
proteins, increases GDH activity to the level of SIRT4 KO lysates (Haigis et al., 2006). 
Moreover, in SIRT4 KO mice increased insulin secretion was observed in response to 
glucose and glutamine (Haigis et al., 2006). In another study, depletion of SIRT4 from 
insulin-producing INS-lE cells resulted in increased insulin secretion in response to 
glucose, while overexpression of SIRT4 in the same cultured cells suppresses insulin 
secretion (Ahuja et al., 2007). Recently, SIRT4 inhibition was also shown to increase fatty 
acid oxidation in liver and mitochondrial gene expression in muscle cells, although the 
mechanisms underlying these phenotypes are still unclear (Nasrin et al., 2010). 
SIRT5 
SIRT5 is a -mitochondria] protein with few known substrates. SIRT5 is expressed 
predominantly in brain, heart, liver and kidney (Michishita et al., 2005; Nakagawa et al., 
2009). One putative in vitro target of SIRT5 is cytochrome c but the interaction currently 
requires verification in vivo (Nakagawa et al., 2009). Recently, SIRT5 was shown to 
deacetylate carbamoyl phosphate synthetase 1 (CPS 1), a regulated enzyme that commits 
ammonia and bicarbonate to the first step of the urea cycle forming carbamoyl phosphate. 
SIRT5-mediated CPS I deacetylation, without any change in protein level, enhances CPS1 
function. Further evidence has corroborated the hypothesis that SIRT5 could have a role in 
nitrogen metabolism during fasting. Indeed the protein under fasting is upregulated in liver 
(Ogura et al., 2010), acetylation of CPS 1 decreases, and CPSI activity increases. Under 
fasting increased amino acid catabolism increases ammonia production that could be 
poorly compensated in SIRT5 KO mice (Nakagawa et al., 2009). Consistently, SIRT5 KO 
mice under fasting became hyperammonemic. On the other hand, CPSI was 
hypoacetylated and CPS 1 activity and urea production were significantly higher than 
control mice, in livers of transgenic mice overexpressing SIRT5 (Ogura et al., 2010). 
Although these findings provide some possible insights into SIRT5 function, further 
studies should better elucidate this mechanism whilst also evaluating the involvement of 
NAD+ that is also increased during fasting (Yang et al., 2007a). 
SIRT6 
SIRT6 is located in the nuclear compartment and is associated with chromatin. SIRT6 is 
broadly expressed, with the highest levels in adipose tissue, skeletal muscle, brain and 
heart (Kelly, 2010). SIRT6 KO mice have a phenotype that involves instability of the 
genome suggesting that SIRT6 functions in DNA repair pathways. SIRT6 -/- (i. e. knocked 
out) cells were found to be deficient in base excision repair pathways (Mostoslavsky et al., 
2006). SIRT6 -/- cells also displayed abnormalities to the telomeres such as sequence loss, 
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and shortening of telomeres can limit replicative lifespan in mammals. Consistently, 
SIRT6 -/- cells undergo premature senescence in culture (Michishita et al., 2008). SIRT6 
have also been implicated in regulation of double strand breaks. SIRT6 KO cells have 
higher levels of broken DNA upon neocarzinostatin treatment versus control cells 
(McCord et al., 2009). 
SIRT6 also has a role in metabolism. SIRT6 downregulates a subset of PPAR1 target genes 
suppressing fat synthesis (Kanfi et al., 2010). SIRT6 also deacetylates histone H3K9(Ac) 
at chromatin promoter sites recognized by HIFIa, represses HIFIa signalling (Zhong et 
al., 2010). HIF lot is a known positive regulator of cell survival in low oxygen stress, which 
generally causes cells to shift to a glycolytic metabolism. Consistently SIRT6 KO mice 
have a hypoglycaemic phenotype although SIRT6 also showed a role in inflammatory 
signalling by suppressing NFkB transcriptional activities (Kawahara et al., 2009). 
SIRT7 
SIRT7 is found in many cells including adipocytes and cardiomyocytes (Kelly, 2010). 
SIRT7 is located in the nucleolus where it has been reported to activate RNA polymerase I 
(RNA Pol I) transcription. SIRT7 overexpression led to increased transcription of rDNA 
stimulating Poll association with DNA (Ford et al., 2006). In a more recent work, the 
interaction between SIRT7 and Poll was shown to be important for the resumption of 
rDNA transcription after exit from mitosis (Grob et al., 2009). In this work, it has also been 
observed that SIRT7 is finely regulated by phosphorylation during mitosis. Further studies 
should elucidate SIRT7 physiological function, in particular in the heart, since SIRT7 KO 
mice have a shorter life span due to cardiac hypertrophy. 
BIOLOGICAL 
PROTEIN LOCALIZATION ACTIVITY TARGET EFFECT 
PPAR-y, PGC-la, Metabolism 
FOXOs, AMPK, Stress resistance 
SIRTI Nucleus, cytosol Deacetylase SREBP-1, UCP2, apoptosis 
p53, NF-KB, DNA repair 
H4K16, TUBULIN, Cell cycle 
SIRT2 Cytosol, nucleus Deacetylase FOXOs metabolism 
Thermogenesis, 
PGC I a, 
Deacetylase, Mitochondrial 
SIRT3 Mitochondria ACS2, GDH , ART biogenesis and 
Complex I 
metabolism 
SIRT4 Mitochondria ART GDH Insulin secretion 
SIRT5 Mitochondria Deacetylase CPS I Urea cycle 
Deacetylase, Base excision repair 
SIRT6 Nucleus H3, NF-KB 
ART Metabolism 
SIRT7 Nucleolus Deacetylase Pol I rDNA transcription 
TABLE 1.1. Function and tissue localization of mammalian sirtuins. 
Abbreviations: ART, ADP-ribosyltransferase; PPAR-y, peroxisome proliferator-activated 
receptor y; PGC-la, peroxisome proliferator-activated receptor y coactivator I a; FOXO, 
forkhead box 0; AMPK, AMP-activated protein kinases; SREBP-1, sterol regulatory 
element-binding protein gene; UCP2, uncoupling protein 2; NF-NB, nuclear factor kappa 
B; ACS2, acetyl-CoA synthetase; GDH, glutamate dehydrogenase; CPS], carbamoyl 
phosphate synthetase 1; Pol, DNA polymerase 1. 
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PROTEIN VIABILITY PHENOTYPE REF. 
SIRTI Lethal on inbred - Are smaller and often sterile (Sequeira et 
background - Frequently have craniofacial at., 2008; 
(129/J), viable on abnormalities, and develop an eyelid McBurney et 
outbred genetic inflammatory condition al., 2003) 
background. - Some develop a disease resembling 
diabetes insipidus at 2 years of age. 
SIRT2 NA Normal (Vaquero et 
at., 2006) 
SIRT3 NA - No metabolic relevant problems (reduced (Lombard et 
ATP production, decreased rates of fatty al., 2007; 
acid oxidation and ketone body production, Sundaresan et 
and fatty liver. al., 2009) 
- Show signs of cardiac hypertrophy and 
interstitial fibrosis at 8 weeks of age 
SIRT4 NA - No phenotypic abnormalities, higher (Nasrin et at., 
circulating insulin levels 2010) 
SIRT5 NA - Hyperammonemia under fasting (Nakagawa et 
al., 2009) 
SIRT6 Die during the early - Premature ageing including lipodystrophy, (Mostoslavsky 
postnatal period bone defects, colitis and severe apoptosis in et al., 2006) 
lymphocytes. 
- Metabolic defects such as low serum IGF- 
I levels and hepatic steatosis in the liver 
SIRT7 7.5 month (mean - Cardiac dysfunction in the form of (Vakhrusheva 
lifetime) degenerative cardiac hypertrophy et al., 2008b) 
accompanied by cardiac myocyte 
enlargement and cardiac fibrosis, 
- 200% increased apoptosis in the 
myocardium. 
TABLE 1.2. Summary of phenotypes of sirtuin full body knockout mice. 
Abbreviations: NA, not available (i. e. no visible defect). 
1.2.2. SIRTUINS INVOLVEMENT IN AGEING AND AGE-RELATED DISEASES 
1.2.2.1. Sirtuins involvement in crieini 
The role of sirtuins in ageing was initially discovered in yeast. Sir2p in S. cerevisiae was 
shown to extend the life span of the budding yeast by repressing genome instability 
(Kaeberlein et al., 1999). Experimental evidence showed that the addition of an extra copy 
of the SIR2 gene extended replicative life span (the number of cell divisions undergone by 
a mother cell before it stops dividing) by -30% while deleting SIR2 resulted in a much 
shorter life span (approximately 50% of the control) (Kaeberlein et al., 1999). Starting 
from this finding, the conserved functional role of SIR2 homologues in ageing has become 
evident from studies involving more complex laboratory organisms, such as 
Caenorhabditis elegans (Tissenbaum and Guarente, 2001) and Drosophila melanogaster 
(Rogina and Helfand, 2004). Some experimental evidence has suggested that the activation 
of sirtuins, either by restricting calories or by pharmacological means, extends the life span 
and promotes the health of a wide variety of organisms from yeast to mammals (Westphal 
et al., 2007). 
To date, knock-out mice for all the 7 sirtuins have been developed. Interestingly, amongst 
these, SIRT6 KO mice present an ageing phenotype. SIRT6-deficient mice are smaller and 
at 2-3 weeks of age develop abnormalities that include profound lymphopenia, loss of 
subcutaneous fat, lordokyphosis, and severe metabolic defects, eventually dying at about 4 
weeks (Mostoslavsky et al., 2006). Although having different phenotypes, SIRTI and 
SIRT7 KO mice also display a shortened lifespan. Conversely mice that overexpress 
SIRTI have an extended lifespan and maintain lower cholesterol, blood glucose, and 
insulin levels (Vinciguerra et al., 2010). 
Sirtuin, calorie restriction and life span promotion 
Calorie restriction (CR), a dietary regimen that restricts calorie intake without malnutrition, 
was shown to extend the life span in a wide range of organisms, including rotifers, spiders, 
worms, fish, mice and rats (Weindruch, 1996). The role of CR in lifespan in such a diverse 
group of organisms suggests that the mechanism by which CR regulates longevity is an 
ancient and well conserved pathway. However, although CR has also proved to be 
beneficial in non-human primates (Colman et at., 2009), a CR protocol would not be easily 
applicable to humans because of its physical and psychological side effect (Dirks and 
Leeuwenburgh, 2006). A major interest has arisen in studying CR molecular mechanisms 
and finding CR mimetics, molecules that could produce the same pro-longevity effects that 
CR provides, but without reducing calorie intake. 
CR was hypothesized to be a stress stimulus that causes an adaptive response in different 
tissues which in turn induces changes in gene expression. Several studies have shown that 
CR primarily affects metabolic pathways such as insulin/insulin-like growth factor I (IGF- 
1) and the target of rapamycin (TOR) pathways (Fontana et al., 2010). Besides these 
pathways, increasing evidence supports the involvement of sirtuins in mediating CR 
effects. Indeed, in yeast, life span extension by moderate CR requires SIR2 (Fabrizio et al., 
2005). In mammals, although the scenario is much more complex, preliminary evidence 
also suggests the involvement of sirtuins. Different authors reported that CR modulates 
SIRTI expression levels in a variety of tissues. For example, Rodgers and colleagues 
showed that under fasting conditions such as CR, murine SIRTI protein level is increased 
in liver where this enzyme interacts and deacetylates the transcriptional coactivator PGC- 
1a inducing gluconeogenic genes and repressing glycolytic genes (Rodgers et al., 2005). 
Overall, it seems that in mice CR-mediated regulation of SIRTI expression could be tissue 
and brain region specific (Chen et al., 2008). In humans SIRT 1 gene expression also 
appears to be responsive to caloric intake (Kelly, 2010). CR also was shown to induce the 
mammalian SIRT2, SIRT3 and SIRT5 in some tissues (Kelly, 2010) (table 1.3). Moreover, 
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sirtuin activation could be critically affected by changes in NAD+/NAM ratio in tissues 
and CR has also been shown to increase NAD+ levels (e. g. in the liver) (Kelly, 2010). 
GENE 
SIR Ti 
SIRT2 
SIR T3 
SIR TS 
Adipose tissue 
Liver, skeletal muscle 
Liver 
Down-regulation 
Hypothalamus 
NA 
NA 
NA 
TABLE 1.3. Regulation of sirtuin expression levels under calorie restriction. 
Taken from (Kelly, 2010). 
Further evidence of SIRTI involvement in CR came from transgenic mice that moderately 
overexpressed mouse SIRTI in several tissues including white and brown adipose tissues. 
These mice displayed phenotypes that mimic some of the physiological changes in 
response to CR (i. e. they are leaner than littermate controls; more metabolically active; 
display reductions in blood cholesterol, adipokines, insulin and fasted glucose; exhibited 
more glucose tolerance; perform better on a rotaroad challenge, and display delayed 
reproduction) (Bordone et al., 2007). In another study, in a SIRT1-deficient mouse model, 
it was shown that at least the CR-induced increase in physical activity (PA) requires SIRT1 
(Chen et al., 2005a). However, in the same study, SIRT1 deficiency did not prevent the 
reduction in blood of triglycerides, insulin-like growth factorl and glucose levels observed 
in response to CR (Chen et al., 2005a). In another study, CR did not extend lifespan of 
SIRTI-deficient mice (Kelly, 2010). 
Given these and other experimental findings, STACs were proposed as calorie restriction 
mimetics (Baur, 2010). Pathway analysis of genome-wide expression profiles revealed that 
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Up-regulation 
Liver, kidney, intestines, skeletal muscle, white adipose 
about half of pathways altered by CR overlapped with the pathways modulated by RES in 
the livers of mice (Baur et al., 2006). Furthermore, gene expression data from hearts, 
skeletal muscles, and brains of mice indicated that RES mirrors CR in terms of alteration 
of gene transcriptions in vivo (Barger et al., 2008; Pearson et al., 2008). Overall, although 
SIRTI overexpression or its pharmacological activation by STACs were proved to mimic 
CR, the life prolonging effect of CR was not recapitulated in these models (Pearson et al., 
2008). However, although RES did not extend mice lifespan in a standard-chow diet, under 
a high-fat diet was reported to increase life expectancy probably protecting mice against 
some of the deleterious physiological effects of a high-fat diet. 
1.2.2.2. Sirtuins and aye-related diseases 
Ageing increases susceptibility to a variety of diseases, such as diabetes, cardiovascular 
diseases, cancer, neurodegenerative diseases, and inflammation. Sirtuins are emerging as 
therapeutic targets to treat age-related diseases. 
Metabolic imbalance, such as insulin resistance, is observed with increasing frequency 
during ageing. Abnormal metabolic homeostasis can have severe consequences and often 
manifests as syndromes such as obesity and T2D. By virtue of their NAD+-dependency, 
sirtuins were hypothesized to be sensors of nutrient availability. Moreover, increasing 
evidence shows that sirtuins could have an evolutionary conserved role in metabolic 
homeostasis under fasting and calorie restriction (cfr. 1.2.2.1). 
Several studies have implicated SIRTI in glucose homeostasis and lipid metabolism in 
various tissues including adipose tissues, liver, pancreas, and skeletal muscle (Kelly, 2010) 
while SIRT1 also affects insulin signalling and is involved in insulin secretion. In vivo 
evidence showed that SIRTI-transgenic mice display some phenotypic similarities to 
littermate control mice on CR, they are leaner and more metabolically active. They also 
have lower blood cholesterol, adipokine levels, insulin, and fasting glucose, and are more 
glucose tolerant (Bordone et al., 2007). Moreover,, mice with moderate overexpression of 
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SIRTI exhibit fat mass gain similar to wild-type controls when exposed to a high-fat diet 
due to a higher energy expenditure and also show lower lipid-induced inflammation as 
well as better glucose tolerance, and are almost entirely protected from hepatic steatosis 
(Feige et al., 2008; Pfluger et al., 2008). In a recent study, SIRTI and SIRT4 have been 
confirmed to be associated with homeostasis of glucose/lipid metabolism in humans. 
Indeed, the expression of SIRTI and SIRT4 was lower in peripheral blood leukocytes from 
T2D patients than in normal control group. Moreover a negative correlation was found 
between SIRTI and SIRT4 mRNA levels and fasting plasma glucose (Song et al., 2011). 
Sirtuins are also being investigated in relation to cancer. SIRTI and SIRT3, by virtue of 
their role in regulating both cell death and survival, have been focused upon and there has 
emerged in the literature interesting debate about their roles as tumor promoters and/or 
tumor suppressors. In tumor samples, heterogeneous SIRTI and SIRT3 levels have been 
observed in subsets of tumours, and therefore, the stage of the tumor, the type of tumor, 
and the varying cellular environments and signals might all contribute to whether sirtuin 
has tumor suppressor or oncogenic functions. For example SIRT3 was found to be 
upregulated in oral cancer and in anoikis-resistant oral squamous cell carcinoma cells, 
whereas SIRT3 was downregulated in human breast cancer cells compared to normal 
controls breast tissue. Indeed SIRT3-/- mice developed mammary tumours over a 24- 
month period (Alhazzazi et al., 2011). 
A potential involvement in cardiovascular diseases is also emerging with interesting 
findings. Alcendor et al. reported that increasing SIRT 1 activity could retard ageing and 
confer stress resistance to the heart in vivo, but this beneficial effect can be observed only 
at low to moderate increases in SIRTI (2.5-7.5 fold) expression (Alcendor et al., 2007). 
SIRT7 was also shown to increase stress resistance of cardiomyocytes and prevent 
apoptosis and inflammatory cardiomyopathy in mice. Consistently, SIRT7-deficient mice 
developed hypertrophy of, the heart and inflammatory cardiomyopathy with extensive 
fibrosis in the heart (Vakhrusheva et al., 2008a). SIRT3 was reported to have a role in 
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cardiac hypertrophy by augmenting FOXO3a-dependent antioxidant mechanisms. In fact, 
SIRT3-deficient mice showed signs of cardiac hypertrophy and interstitial fibrosis. 
Application of hypertrophic stimuli to these mice produced severe cardiac hypertrophy, 
whereas SIRT3-expressing transgenic mice were protected from similar stimuli 
(Sundaresan et al., 2009). 
Increasing evidence has shed light on the role of sirtuins in inflammation. Inflammation is 
an important factor in the pathogenesis of several age-related degenerative diseases. NFKB 
has a central role in the innate immunity (Salminen et al., 2008). Two different sirtuins, 
SIRTI and SIRT6, inhibit transcription of genes by NFKB. By damping the activation of 
NFKB, SIRTI augmented apoptosis in response to the pro-inflammatory factor TNFa 
(Yeung et al., 2004), and protected pancreatic ß cells against cytokine toxicity, NO 
production and iNOS expression (Lee et al., 2009). SIRT6 attenuates NFKB signalling by 
deacetylating histone H3k9 at NFKB promoter (Kawahara et al., 2009). Blockade of NFKB 
may protect against pro-inflammatory diseases. 
Sirtuins and neurodezeneration 
Sirtuins appear to play very different roles and respond in different ways to stress and 
toxicity. Growing evidence suggests that sirtuins are involved with opposing effects in the 
regulation of neuronal survival. For example, Pfister et al. reported that in cerebellar 
granule neurons SIRTI had a protective effect against apoptosis induced by low potassium 
treatment while SIRT2, SIRT3, and SIRT6 induced apoptosis in otherwise healthy 
neurons. SIRTS has a dual role depending on the subcellular localization. Moreover, in the 
same study SIRT6 was modestly protective in HT-22 neuroblastoma cells treated with 
homocysteic acid toxicity (Pfister et al., 2008). 
At present, most research is focused on SIRTI and SIRT2. SIRT1 is ubiquitously present 
in areas of the brain that are especially susceptible to age-related neurodegenerative states 
(e. g., the prefrontal cortex, hippocampus, and basal ganglia) (Zakhary et al., 2010). 
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Moreover, SIRT1 KO mice exhibit decreases in dendritic branching, branch length and 
complexity of dendritic arbours, and these mice show impaired cognitive abilities (Michan 
et al., 2010). The first evidence of SIRT1 neuroprotective role was seen in primary dorsal 
root ganglion neurons infected with lentivirus expressing slow Wallerian degeneration 
(Wlds) protein. This protein is a chimeric nuclear protein spontaneously generated by an 
autosomic dominant mutation in what are called the Wlds mice that resulted in delayed 
axonal degeneration. Axonopathy is a critical feature of peripheral neuropathies as well as 
neurodegenerative disorders (Raff et al., 2002). Akari and colleagues found that Wlds 
protein increases Nmnat activity, an enzyme involved in NAD biosynthesis, leading to 
axonal protection and that SIRT1 is the downstream effector of this phenomenon (Araki et 
al., 2004). In a more recent study in C. elegans, the genetic overexpression or 
pharmacological activation by RES of the homologous of SIRTI, rescued early neuronal 
dysfunction phenotypes induced by the expression of the polyglutamine (polyQ) fragment 
of the Huntington disease-associated protein huntingtin (htt) in C. elegans. Moreover RES, 
in neuronal cell lines derived from the striatum of HdhQ 111 KO mice, decreased cell death 
due to the expression of mutant htt (109Q). This effect appears to have been mediated by 
sirtuins since the effect was prevented by sirtinol or NAM (Parker et al., 2005). SIRT1 was 
also shown to protect neurons expressing mutant SOD 1-G37R, a model of amyotrophic 
lateral sclerosis (Lee et al., 2010). 
SIRT2 is highly expressed in the brain, particularly in oligodendrocytes, post-mitotic 
neurons and glial cells (Tang and Chua, 2008). SIRT2 downregulation in neurons by 
pharmacological treatment (with AK-1 and AGK2), rescued primary midbrain cultures 
from cell death caused by a mutant a-synuclein (A53T) (Outeiro et al., 2007). More 
recently, SIRT2 inhibition was shown to provide protection in a Huntington's disease 
model. As observed in Parkinson's disease models, SIRT2 inhibitors were neuroprotective 
in a D. melanogaster transgenic model expressing a Q93 repeat of the pathogenic human 
Htt and in a C. elegans Huntington's disease model (Luthi-Carter et al., 2010). 
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SIRT1 and Alzheimer's disease 
SIRTI and APP metabolism 
SIRTI is upregulated in the brain in a mouse model of AD (Kim et al., 2007). However, in 
another model of AD reductions of cortical levels of SIRTI coincided with the 
accumulation of tau (Julien et al., 2009). In humans with AD, SIRTI levels are reportedly 
decreased in the parietal cortex which is affected by AD pathology but not in the 
cerebellum which is generally spared of AD pathology. Moreover, lower cortical levels of 
SIRTI were found to be correlated with the duration of symptoms, lower global cognition 
scores, and accumulation of Aß and tau in the cerebral cortex (Julien et al., 2009). 
SIRT1 involvement in AD has been initially investigated in the context of CR. 
Epidemiological evidence suggests that individuals who maintain a low calorific diet have 
a reduced risk of developing AD (Luchsinger et al., 2002). Moreover it has been 
demonstrated that CR prevents AD neuropathology in an AD-like mouse model (Wang et 
al., 2005b). Pasinetti's group explored the involvement of SIRTI in CR-mediated 
prevention of AD generation and deposition in SPs. Pharmacologically activating SIRT1 in 
neuronal cultures by NAD+ and RES treatment, reflected by reduced content of H4-kl6ac, 
the accumulation of AD40 and Aß42 peptides was prevented thus reproducing what they 
had previously found with CR (Wang et al., 2005b; Qin et al., 2006b). The mechanism 
proposed involved the regulation of the serine/threonine Rho kinase ROCK 1, known in 
part for its role in the inhibition of the non-amyloidogenic u-secretase processing of APP. 
The same group found that under CR, FOXO3a was hyperphosphorylated and excluded 
from the nucleus and that nuclear FOXO3a was deacetylated by SIRTI and its activity is 
inhibited. FOXO3a is a transcription factor, these two events lead to the repression of 
ROCK1 expression (Qin et al., 2008). Also in a non-human primate model, CR decreased 
cortical AD40 and AD42 and this reduction was inversely correlated to an increase in 
SIRT1 and a-secretase in the same brain regions. These were associated with a reduction 
in ROCKI (Qin et al., 2006a). 
More recently, it was also demonstrated by Guarente's group that SIRTI overexpression in 
vivo activates the transcription of ADAM10, the gene encoding a-secretase, through a 
mechanism involving deacetylation of the retinoic acid receptor ß, a known regulator of 
ADAM transcription. ADAM10 activation by SIRTI results in reduced production of Aß 
and plaques in AD-like mouse model. Moreover increased a-secretase activity induced the 
Notch pathway, which is known to repair neuronal damage in the brain (Donmez et al., 
2010; Qin et al., 2008). 
SIRTI and Aß-induced inflammation 
In mixed cortical cultures, Aß exposure was shown to cause microglia-dependent toxicity 
through strong activation of NFKB signalling that was proposed to activate target genes, 
including cathepsin B and iNOS that are directly responsible for causing neuronal injury. 
In this model Aß42 exposure was proposed to increase acetylation of ReIA/p65 resulting in 
NFKB transcriptional activation in microglia. SIRTI overexpression with lentivirus or its 
pharmacological activation by RES treatment, specifically deacetylated Lys 310 of 
ReIA/p65 thus preventing NFKB activation and counteracting neuronal death induced by 
Aß42 challenge (Chen et al., 2005b). 
SIRTI and Tau 
In a recent study tau protein was found to be acetylated in primary neuronal cultures 
treated with low level of oligomeric A. Tau acetylation was shown to be mediated by 
p300 while SIRTI has been proposed to deacetylate tau in vitro. Furthermore, SIRTI 
inhibition increases tau acetylation and this event blocks tau polyubiquitination and its 
degradation via the ubiquitin-proteasome system, resulting in p-tau accumulation (Min et 
al., 2010). SIRT1 deacetylation of tau, although not yet demonstrated in vivo, could be an 
additional mechanism through which SIRTI could counteract AD pathology. 
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1.3. AIMS OF THE STUDY 
The overall purpose of this research was to investigate, for the first time, the involvement 
of all? known sirtuins (SIRT 1-7) in AD through a number of complementary experimental 
approaches. These included gene mutation analysis and genetic association studies; the 
application of a non-pharmacological therapeutic protocol in vivo to the APP23 mouse 
model of AD and the use of in vitro analyses to explore the potential role of SIRT1 in the 
pathogenesis of AD. 
Specific aims 
GENETIC STUDIES SECTION 
1. To conduct a mutational analysis of coding regions of sirtuin genes in relation to 
possible association with AD susceptibility. (chapter 3) 
II. To test using a case-control cross-sectional approach the extent of the association 
between sirtuin gene common variants (previously known and newly identified) and AD 
risk. (chapter 4) 
IN VIVO SECTION 
III. To investigate the effectiveness of an environmental enrichment protocol in 
delaying progression of AD-like pathology in a mouse model (APP23) of AD and in turn 
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assess sirtuin expression levels, in relevant regions of the brain affected by AD pathology. 
(chapter 5) 
IN VITRO SECTION 
IV. To investigate the potential role of SIRTI in promoting cell survival response 
against exposure of SK-N-BE(2) cells to different stress stimuli that are commonly linked 
to AD etiopathogenesis. (chapter 6) 
CHAPTER 2: 
GENERAL MATERIALS AND METHODS 
In this section I will describe the general materials and methods I have used during my 
experiments. Specific methods will be discussed in detail in subsequent associated 
chapters. 
2.1. SUPPLIERS 
Abcam (Cambridge, UK) 
Abnova (Taipei, Taiwan) 
Ambion (Austin, Texas, USA) 
Applied Biosystems (Foster City, California, USA) 
Asahi Techno Glass (Funabashi City, Chiba) 
Axxora Life Sciences (San Diego, California, USA) 
Bio-Rad Laboratories (Hercules, California, USA) 
Biotium (Hayward, California, USA) 
Charles River Laboratories (Wilmington, Massachusetts, USA) 
Chemicon (Temecula, California, USA) 
Eppendorf (Hamburg, Germany) 
Immuno-Biological Laboratories (Fujioka, Japan) 
Invitrogen (Carlsbad, California, USA) 
Leica Microsystems (Wetzlar, Germany) 
Lillico Biotechnology (Surrey, UK) 
MBL (Woburn, Massachusetts, USA) 
Millipore (Billerica, Massachusetts, USA) 
MityFlex (ANKO, Bradenton, Florida, USA) 
Molecular Devices (Sunnyvale, California, USA) 
Olympus (Tokyo, Japan) 
Pierce-Thermo Scientific (Waltham, Massachusetts, USA) 
Promega (Madison, Wisconsin, USA) 
Sigma-Aldrich (St. Louis, Missouri, USA) 
Signet Covance (Princeton, New Jersey, USA) 
Termo Fisher Scientific (Waltham, Massachusetts, USA) 
Transgenomic (Omaha, Nebraska, USA) 
Upstate (Charlottesville, Virginia, USA) 
Vector Laboratories (Burlingame, California, USA) 
Veeco Instruments (Plainview, New York, USA) 
Waters (Milford, Massachusetts, USA) 
2.2. GENETIC STUDIES SECTION 
2.2.1. RECRUITMENT OF AD PATIENTS AND CONTROLS 
All the subjects involved in this work were recruited from the Northern Italy and Italian 
Canton of Switzerland. Briefly they derived from "Luigi Sacco" hospital in Milan (Italy), 
"Beata Vergine" hospital in Mendrisio (Italian-speaking canton of Switzerland), "S. 
Antonio Abate" hospital in Gallarate (Italy) and "Centro S. Giovanni di Dio- 
Fatebenefratelli" hospital in Brescia (Italy). The demographics of each cohort are described 
in the materials and methods sections of chapters 3 and 4. Informed consent was obtained 
from all subjects. 
Patients were diagnosed according to DSM-IV, and National Institute of Neurologic and 
Communicative Disorders and Stroke-AD and Related Disorders Association (NINCDS- 
ADRDA) criteria for probable AD (McKhann et al., 1984), and had an age at onset greater 
than 60 years. Control subjects (CT) were recruited including elderly subjects cognitively 
healthy. 
MMSE was employed both in AD and CT groups to confirm or exclude the presence of 
cognitive decline. CT subjects were selected with a MMSE score higher than 23 points. 
2.2.2. GENOMIC DNA ISOLATION FROM PERIPHERAL BLOOD SAMPLES 
For each subject included in the study 5 mL of peripheral blood was collected in tubes with 
ethylenediaminetetraacetic acid (EDTA) and stored on ice. The blood was then sub- 
aliquoted into smaller volumes of 200 . tL and stored at -20 °C until it was necessary. 
Genomic DNA (gDNA) from 150 µL of blood was extracted using standard procedures by 
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a semi-automated vacuum-based nucleic acid extractor ABI PRISM" 6100 Nucleic Acid 
PrepStation (Applied Byosistems). Then, it was eluted in 200 µL of nuclease free water 
and the sample concentration determined by Nanodrop 1000 (Thermo Fisher Scientific). 
The resultant DNA samples were then stored at 4 T. 
2.2.3. POLYMERASE CHAIN REACTION 
Polymerase chain reaction (PCR) was used to amplify gDNA for further analysis. PCR 
amplification was usually carried out in a reaction volume of 20 µL containing: 
-1 µL template DNA - 40 ng/µL 
-I µL of both forward and reverse primer 10 µM (Invitrogen) 
-2 pL dTNPs 2.5 mM (Thermo Fisher Scientific) 
- 0.2 gL Taq polymerise 5 U/µL (Thermo Fisher Scientific) 
-2 pL PCR buffer 200 mM Tris-HCI, 500 mM KCl (Thermo Fisher Scientific) 
- 0.6 µL MgCl2 25 mM (Thermo Fisher Scientific) 
- 12.2 µL deionised water 
The following PCR programs were employed for PCR reactions on thermocyclers 
(Eppendorf). In most of the cases, the conventional 3 step PCR protocol was applied 
whereas, when the difference between the annealing temperatures of the two primers was 
higher than 3 °C, the touchdown PCR protocol was used to reduce non-specific PCR 
products. 
The standard PCR cycle consisted of 1 cycle at 95 °C for 5 min, followed by 30-35 cycles 
of 30 s at 95 °C (denaturation), 30 s at 50-68 °C (annealing) and 45-120 s at 72 °C 
(extension), and finished with 10 min at 72 °C. 
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The touchdown PCR protocol consisted of a denaturation step at 95 °C for 5 min, followed 
by 14 cycles at 95 °C for 30 s, 50-68 °C for 30 s and 72 °C for 30 s. The annealing 
temperature was dropped by 0.5 degrees each cycle, then samples underwent 19 cycles at 
95 °C for 30 s, 50-68 °C for 30 s and 72 °C for 1 min. Finally, 10 min at 72 °C. 
The PCR protocols used were issued from free online software Optimase 
ProtocolWriterTM, provided by 
e. httll: //www. mutationdiscovery. com/md/MD. com/home pa R 
Transgenomic`(I at 
The specific annealing temperatures and extension time, for each DNA sequence amplified 
in this thesis, will be reported in the relevant results chapters. 
Primer design and synthesis Oligonucleotide primers for PCR were designed to amplify 
DNA from regions of interest. Starting from gene sequences obtained from the Entrez 
Nucleotide database at the National Centre of Biotechnology Information website 
(http: //www. ncbi. nlm. nih. gov/nuccore), sense and antisense primer sequences were 
designed with the free online primer design software 'Primer 3' at 
http: //frodo. wi. mit. edu/cgi-bin/primer3/primer3. Primer lengths ranged from 20 to 25 
nucleotides. Primers were provided lyophilised by Invitrogen and were resuspended in 
DNase free water to a final concentration of 100 pM before use. 
2.2.4. AGAROSE GEL ELECROPHORESIS OF DNA 
gDNAs and PCR products were resolved on agarose gels at 0.6% and 1 %, respectively. 
Agarose (Thermo Fisher Scientific) was melted in lx TAE buffer from 50x stock solution 
(242 g Trizma base, 100 mL 0.5 mM EDTA, 57.1 mL glacial acetic acid) in a microwave. 
-86- 
The gel mixture was left to cool for 10 min and then Gel Red (Biotium) was added to the 
agarose solution at 1: 30 dilution for DNA labelling. Gel mixture was then poured into the 
gel tray and the combs inserted. The gel was left to set for 20 min before being placed into 
the electrophoresis tank (Bio-Rad Laboratories). The tank was filled with 1x TAE buffer. 
DNA size standard ladder and the samples for genotyping were loaded and the gel was run 
at 10 V/cm (interelectrode distance), while the electrophoresis time was dependent on the 
size of the fragments to be resolved. The gel was then viewed using a UV box (Thermo 
Fisher Scientific) and photographed. 
Individual samples to be loaded were prepared by mixing 5gL of DNA sample with I µL 
loading buffer starting from IOx stock solution (500 µL glycerol, 40 µL bromophenol blue 
or xylene cyanol 10%, 418 µL H202). 
The DNA size standard ladder comprised 100 bp (fragments ranging in length from 100 to 
1.5 kbp) or I kbp DNA ladder (fragments ranging in length from 250 to 10 kbp) (Promega) 
and was used to decipher the size of DNA bands visualised on agarose gels. 
2.2.5. dHPLC ANALYSIS 
dHPLC was used to identify polymorphisms within PCR-amplified DNA fragments. In this 
technique the PCR amplified fragments (i. e. amplicons) were denatured (95 °C for 10 min) 
and slowly cooled to allow the formation of homoduplexes and, if a polymorphism was 
present heteroduplexes. The renatured PCR products (5-8 µL) were then injected into a 
HPLC column that contained a DNASep (Transgenomic) cartridge and triethylammonium 
acetate buffer. The DNASep cartridge is based on ion-pair-reversed phase HPLC 
methodology. The positive charges on the triethylammonium ions interact with the 
negative charges on the phosphodiester backbone of the DNA giving the DNA molecules a 
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hydrophobic coating. These hydrophobic trialkyl groups interact with the hydrophobic 
surface of the DNASep matrix and immobilize the DNA in a size-dependent manner. 
During the experiment the concentration of acetonitrile running through the column was 
gradually increased and the DNA was eluted from the column in a size-dependent manner. 
The DNASep cartridge also has the abililty to resolve two fragments of the same size but 
different helical content. A UV sensor then detects eluted samples. At a given melting 
temperature, samples containing heteroduplexes will denature before homoduplexes and 
will therefore elute from the column first (figure 2.1). Chromatographic profiles are 
generated for each fragment based on the time it eluted from the column and its absorption, 
allowing the detection of samples containing polymorphisms. The presence of a 
polymorphism was then confirmed and characterised by direct sequencing. 
0 i 
FIGURE 2.1. Examples of dHPLC chromatographic profiles. 
A. Single peak dHPLC profile: B. Aberrant dHPLC profile. 
The dHPLC machine uses four buffers: Buffer A (5 mM triethylammonium acetate 
[TEAA][Transgenomic], 0.25% acetonitrile [ACN][BDH] in H2O), Buffer B (5 mM 
TEAA, 25% ACN in H2O), Buffer C (75% ACN in H2O) and Buffer D (8% ACN in H2O). 
Buffers A and B were used in fragment analysis and throughout the run the ratio of buffer 
B to buffer A is increased to elute the DNA from the column. Buffer C is used to clean the 
system after use and Buffer D to wash the syringe before use. Before each run the system 
was equilibrated for 10-20 min by washing the column at 0.9 mL/min with Buffer A. 
Setting of melting temperature. Amplicons analysed by dHPLC were shorter than 600 
bp. Prior to the sample injection of each DNA fragment, the expected `wild-type' sequence 
(usually uploaded from the Entrez Gene database at the NCBI website 
(http: //www. ncbi. nim. nih. gov/, Qene), was analysed using WAVEMAKERTM v. 3.4 
(Transgenomic). This software identifies the temperature at which domains within the 
fragment were approximately 75% helical. A sequence may have one or a number of 
domains, each with different temperatures at which this helical state is achieved. All of the 
temperatures determined by the programs were used. The setting up of the melting 
temperature was determined by running the renatured PCR product with a temperature 
gradient around the theoretical melting temperature suggested by the software. Analysis 
methods for each melting temperature were then created using WAVEMAKER M 
2.2.6. DIRECT SEQUENCING 
PCR products were purified using a commercial kit (PCR clean up system) according to 
the customer indications. DNA samples were resuspended in 50 µL nuclease-free water 
(Promega). The amount of DNA was quantified by spettrophotometric analysis (Nanodrop 
1000, Thermo Fisher Scientific). A concentration of gDNA (10 ng for each 100 bases 
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transcript to be sequenced) and 12.8 µL of the specific primer (10 µM) were outsourced to 
a sequencing facility (Primm, http: //www. primmbiotech. com). After having received raw 
data, chromatograms were analysed using Chromas Lite software (freely available at 
http: //www. technelysium. com. au/chromas lite. html). The presence of overlapping peaks 
in resultant chromatograms identifies heterozygous substitution at individual base locations 
(figure 2.2). Identified substitutions were later characterized referring to NCBI reference 
sequences (chromosome position, nucleotide position along the gene and eventual codon 
change for substitution in the coding regions). 
FIGURE 2.2. Sequencing chromatogram of a heterozygote sample. 
Example of a PCR amplicon with a heterozygous SNP highlighted by the presence of two 
overlapping peaks. In this case, one allele carries a T, while the other has an A. Both 
peaks are present, but at roughly half the height they would ordinarily be at if they were 
homozygous. 
2.2.7. SEQUENOM MassARRAYT" " 
Sequenom MassARRAYTM platform (Sequenom) allows the high-throughput SNP 
genotyping of up to 40 SNPs simultaneously within a single well of a 384-well plate. The 
principle of the MassARRAY system is the extension of an oligonucleotide probe over a 
SNP site in a PCR product, with a mixture of deoxynucleotides and dideoxynucleotides, to 
produce different size products for each allele of a SNP. The extended products are 
analyzed by Sequenom with matrix assisted laser desorption/ionization-Time-of-Flight 
mass spectrometry (MALDI-TOF), and the time-of-flight is proportional to mass, thereby 
allowing precise determination of the size of products generated, which can be converted 
into genotype information (figure 2.3). For this project the sequenom analysis was 
performed by dr. Mayhaus from Saarland University, Germany. 
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The assay consists of the initial annealing of an oligonucleotide primer immediately 
upstream of the polymorphic site of interest. This step is followed by single base extension 
using mass-modified dideoxynucleotide terminators. Only the complementary base to the 
polymorphic nucleotide (Allele 2) will allow primer extention. Using MALDI-TOF mass 
spectrometry, the distinct mass of the extended primer identifies the SNP allele. 
2.2.8. ALLELIC DISCRIMINATION BY REAL TIME-PCR 
Allelic discrimination genotyping was performed by Real Time-PCR (RT-PCR) (7300 RT- 
PCR system, Applied Biosystems). Pre-developed TagMan"" MGB probes [C71547 for 
SIRT2 rs10410544 or C904973 and C 3084793 for APOE rs7412 and rs429358, 
respectively], along with TagMan® Genotyping Master mix (Applied Byosistem) were 
used. Custom TagMari MGB probes were labelled with a 5' reporter dye (allele I FAM, 
allele 2 VIC) and a 3' non-fluorescent quencher. 
PCR reactions were carried out under the following conditions: denaturation at 95 °C for 
10 min followed by a 15 s annealing at 92 °C and aI min extention at 60 °C that were 
repeated for 40 cycles. We performed a pre-read (background fluorescence) and a post- 
read after the PCR run, according to customer instructions outlined in the ABI 7300 User 
Manual. Each sample was characterized as either homozygote for FAM or VIC or 
heterozygote. A positive control for each genotype was run in the plate together with a 
blank. 
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FIGURE 2.4. RT-PCR Allelic Discrimination assay for genotyping APOE. 
Allelic discrimination cluster plots of the two SNPs that together determine the three main 
genetic variants of APOE. In the table, to the way in which APOE genotypes are 
determined from the two different assays are illustrated. 
2.3. IN VIVO STUDIES 
2.3.1. MOUSE MODEL: APP23 
The animals used for the in vivo section of this thesis were APP23 transgenic mice and 
their wild-type (WT) littermates. 
APP23 mice are hemizygous for the human full length APP (APP751), harbouring the 
"Swedish" double mutation at position 670/671 (KM --> NL), under the murine Thy-1 
promoter (figure 2.5. A). These mice display a 7-fold overexpression of the transgene in the 
neocortex and hippocampus (figure 2.5. B) (Sturchler-Pierrat et al., 1997). These mice were 
kindly provided by dr. Matthias Staufenbiel (Novartis Pharma). 
A 
APP 23 
K670N/M671L 
A 
ikb 
hAPP751 L^- 
FIGURE 2.5. Transgenic transcription unit and expression in APP23 transgene mice 
A. Transcription unit 
, 
for APP23 transgenic mice. Hatched boxes represent the marine 
Thy-I exons. hAPP751 cDNA is shown as open box with vertical line marking the position 
of the "Swedish " mutation (K670N/M671 L). B. Expression of'APP mRNA assessed by in 
situ hybridization in 24-month-old APP23 mice. Figure modified from (Sturehler-Pierrat et 
al., 1997). 
APP23 transgenic mice, originally established in a C57BL/6xDBA2 background 
(Sturchler-Pierrat et al., 1997), were back-crossed into the C57BL/6N genetic background, 
by crossing APP23 with C57BL/6N purchased from Charles River Laboratories, for more 
than six generations. 
Procedures involving animals and their care were conducted and conformed with the 
institutional guidelines in compliance with national (D. L. n. 116, G. U., suppl. 40, Feb. 18, 
1992) and international laws and policies (EEC Council Directive 86/609, OJ L 358,1, 
Dec. 12,1987; Guide for the Care and Use of Laboratory Animals, U. S. National Research 
Council, 1996). 
2.3.2. MOUSE GENOTYPING 
Genotyping was performed on genomic DNA (gDNA) obtained from tail biopsies of mice 
at weaning age. A small terminal portion of the mouse tail was completely digested by 
overnight incubation at 55 °C with a lysis buffer containing 0.1 mg/mL Proteinase K 
(Promega). gDNA was then extracted with WizardR SV Genomic DNA Purification 
System (Promega), according to the manufacturer's instructions. The presence of the 
human APP transgene was verified by PCR analysis (cfr. 2.2.3). Mice (3-globin gene was 
also amplified a control of DNA quality. 
The primer sequences used are reported in table A. 6. in the appendix. 
2.3.3. ENVIRONMENTAL ENRICHMENT PROTOCOL 
Mice were weaned at 1 month of age and caged in standard housing conditions. At 3 
months of age, mice were moved to enriched cages. Enrichment cages (44 x 52 x 28 cm) 
were approximately double the dimension of standard cages (26 x 42 x 18 cm). They were 
furnished with a variety of different coloured plastic objects (e. g. crawling balls, igloos, 
tunnels purchased from Lillico Biotechnology) and hydraulic tubes. The objects were 
combined together to provide a more complex environment and were re-positioned or 
changed twice per week to provide novel stimulation. Environmental enrichment lasted till 
the end of the experiment (i. e. mice sacrifice). 
Mice which has experienced the enriched environment `enriched mice' were compared to 
mice housed under standard conditions for the duration of the experiment. 
Standard and enriched cages each housed a maximum of 4 mice. All cages were kept in the 
same room, were maintained on the same 12: 12 h light: dark cycle, and were exposed to the 
same level of intrusions from experimenter and the presence of caretaker in the room. Food 
and water were provided ad libitum. 
2.3.4. BEHAVIORAL TESTS 
2.3.4.1. Morris Water Maze 
Animals were trained in a circular water tank (1.5 m in diameter and 0.5 m high) which 
was filled with water that was maintained at 22 °C. Four points on the perimeter of the 
pool were designated north (N), east (E), south (S) and west (W), thus dividing the pool 
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into four quadrants (NW, NE, SE, SW). A 10x10 cm white platform was hidden in the 
centre of SW quadrant with the top of the platform submerged 1 cm below the surface of 
the water. A nontoxic white powder was added to the water to facilitate tracking the black 
mice and to obscure the platform. The pool was in the centre of a room containing various 
salient visual cues. Illumination was held constant. A tracking system was used to record 
mouse behaviour (EthoVision® XT, Noldus). The camera was mounted directly over the 
centre of the maze. 
All animals were initially trained in the Morris maze for 10 days. Each day consisted of 
four trials with an approximate 30 min inter-trial interval. During training trials, the 
submerged platform remained at a fixed position. Each day of training, the direction from 
which the animal started was varied during the 4 training trials (i. e. N, S, W and E) to 
prevent the association of the platform location with a single constellation of cues. Latency 
from immersion into the pool to escape onto the platform was recorded automatically by 
the tracking system. If the animal located the platform during the 1 min trial, it was 
allowed to remain on the platform for an additional 10 s. If the animal did not find the 
platform within the allotted 1 min, then the animal was guided to the platform, where it 
remained for 10 s before being removed from the pool. 
The probe trial was performed at the 11th day (24 h after the last training trial) by removing 
the platform and measuring the time spent in the four quadrants within 1 min trial. 
Learning (acquisition) was infered by plotting escape latencies against day of training. 
Memory (retention) was expressed as the percentage of time spent in the correct quadrant 
(SW) in the probe trial. 
2.3.4.2. Object recognition test 
Mice were tested in an open-square gray arena (40 x 40 cm), 30 cm high, with the floor 
divided into 25 squares by black lines. The following objects were used: a black plastic 
cylinder (4 x5 cm), a glass vial with a white cup (3 x6 cm), and a metal cube (3 x5 cm). 
The task started with a habituation trial during which the animals were placed in the empty 
arena in the absence of any specific stimulus for 5 min, and their movements were 
recorded as the number of line crossings. Outer quadrant (anxious behaviour) and inner 
quadrant (self-confident behaviour) crossing were counted separately. 
The next day, mice were again placed in the same arena containing two identical objects 
(familiarization phase). Exploration was recorded in a 10-min trial. Sniffing, touching, and 
stretching the head toward the object at a distance not more than 2 cm were scored as 
object investigation. 
Twenty-four h later (test phase) mice were again placed in the arena containing two 
objects: one identical to one of the objects presented during the familiarization phase 
(familiar object), and a new, different one (novel object), and the time spent exploring the 
two objects was recorded for 10 min. Memory was expressed as a discrimination index (IE 
_ (seconds on novel - seconds on familiar object)/(seconds on novel + seconds on familiar 
object). 
The positions of the objects were randomly permuted for each animal from an 
experimental group and the arena was cleaned between trials with EtOH diluted in water. 
2.3.5. DISSECTION OF MOUSE CORTICES AND HIPPOCAMPI FOR 
BIOCHEMICAL ANALYSES 
Mice were anaesthetized by intraperitoneal injection of avertin 2.5% (400 mg/kg) and 
sacrificed by decapitation. The brains were removed from the skull and laid on an ice- 
chilled dish; the cerebellum was removed and discarded. The brain was cut along the 
sagittal line. The two hippocampi and the two cortices were dissected and weighted. Tissue 
samples were also taken and homogenized for biochemical analyses. 
2.3.6. RNA EXTRACTION AND RELATIVE QUANTITATIVE RT-PCR 
Total RNA was extracted from tissue lysates with SV Total RNA Isolation System 
(Promega). 
Tissues (- 10 mg weight) were resuspended in 175 . tL lysis buffer and homogenated by a 
syringe needle. Lysates were then cleared by centrifugation at 14 000 rpm for 15 min at 4 
°C. Supernatants were processed to obtain RNA according to the manufacturer's 
instructions. 
RNA concentration was measured by capillary electrophoresis and sample purity was 
determined by 260 nm/280 nm absorbance ratio readings. RNA was aliquoted and stored at 
-80 °C until use. 
All steps were carried out at room temperature with RNase-Zap (Ambion). 
A total of I . tg RNA was reversed transcribed into cDNA in a 20 . tL reaction mixture with 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the 
manufacturer's instructions. 
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RT-PCR assays were run on the Applied Biosystems 7300 RT-PCR System under the 
following thermal conditions: 10 min at 95 °C once, and 40 cycles of 15 s at 95 °C and 1 
min at 60 °C. 
RT-PCR were prepared using 50 ng of cDNA, 2x TagMan'Master mix and 20x TagMan" 
gene expression assays (Applied Biosystems, cfr table A. 4. in the appendix). 
The fluorescence emitted after each cycle was measured and plotted (in log scale) against 
the cycle number. A posteriori the threshold was determined and the raw data (threshold 
cycle, CT) were used for the analysis of mRNA expression. The relative expression of each 
gene was calculated by the delta delta CT method (AACT) (Livak and Schmittgen, 2001) 
according to the following formula: 
Amount of target= 
AACT 2 
Where AL CT= [(CT, target gene- 
CT, 
reference gene)Q - 
(CT, target gene- CT, reference gene) CB] 
Q= any sample (e. g. treated cells) and CB= calibrator (i. e. control condition). 
All samples were run in triplicate in the same 96-well plate. 
1 
2.3.7. PROTEIN ANALYSES 
2.3.7.1. Protein extraction from tissues. 
Ice-cold Lysis Buffer pH 7.4 (50 mM Tris/HCI, 150 mM NaCl, 0.5 mM EDTA and 1% 
Triton X-100) was prepared. A further 1% of a broad-range protease inhibitor cocktail and 
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1 mM Sodium Butyrate (inhibitor of class I and II deacetylase) (Sigma-Aldrich) was also 
added. 
Tissues were homogenated by a Teflon-on-glass homogeniser with 1 mL/g of tissue ice- 
cold lysis buffer. Lysates were then cleared by centrifugation at 14 000 rpm for 15 min at 4 
°C. Supernatants were sub-aliquoted and stored at -80°. Small aliquots were taken for 
protein quantification. 
Protein concentration of supernatants was measured by BCA protein assay (Pierce-Thermo 
Scientific) according to the manufacturer's instructions. 
2.3.7.2. SDS-polyacrplamide eel electrophoresis and western blotting 
Sample preparation - 10 µg of tissue lysates were denatured by boiling in SDS sample 
buffer (125 mM Tris-HCI pH 6.8, SDS 10%, glycerol 10%, bromophenol blue 0.006 %) 
added with 0.1 M DTT at 95 °C for 5 min. 
Electrophoresis and western blotting (WB) - Proteins were electrophoresed on 6-12% 
polyacrylamide gels using the Mini-PROTEAN® gel electrophoresis system (Bio-Rad 
Laboratories). Gel electrophoresis was carried out in Ix running buffer for about 1.5 h at 
25 mA. Bio-Rad Dual Color standard ladder (Bio-Rad Laboratories) was also loaded to 
confirm the sizes of the proteins being investigated. 
Proteins were electroblotted onto a 0.2 . tM nitrocellulose membrane using a Mini- 
Transblot® apparatus (Bio-Rad Laboratories) in lx transfer buffer for 1.5 h at 350 mA. 
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2.3.7.3. Slot blot 
A total of 5 µg of tissue lysates were diluted in TBS at a final volume of 200 µL. Samples 
were loaded onto a 0.2 µM nitrocellulose membrane using a Bio-Dotrk (slot format, SB) 
apparatus (Bio-Rad Laboratories) integrated with a vacuum pump. 
2.3.7.4. Immunodetection 
The nitrocellulose membranes after WB or SB were blocked with 5% skim milk powder 
(Sigma-Aldrich) in Ix TBS supplemented with 0.1% Tween-20 (TBS-T) for Ih with 
gentle shaking. Membranes were then incubated with the specific primary antibody in 5% 
skimmed milk/TBS-T solution overnight at 4 °C with gentle shaking. The following day, 
membranes were washed 3x5 min in TBS-T and probed with the appropriate secondary 
antibody (HRP-conjugated Ig antibody) for 1h at room temperature with gentle shaking. 
Membranes were washed 2x 15 min in TBS-T and placed in ECI. substrate reagent 
(Millipore) for 4 min. Membranes were exposed to a Kodakon film in a dark room. 
Films were scanned on an Epson scanner and band intensities measured using Image J 
(National Institutes of Health). The obtained values were normalized to the corresponding 
ß-globin band intensity and expressed as percentage of the basal value registered in the 
control sample. 
2.3.7.5. Enzyme-linked immunosorbent assay 
Human Amyloidß (1-40) (N) and Human Amyloidß (1-42) (N) Enzyme-Linked 
ImmunoSorbent Assay (ELISA) (IBL) were used to measure Aß40 and Aß42 amyloid 
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peptides. A pilot experiment was carried out on two samples at four different 
dilutions 
ranging from 1: 10 to 1: 100 to estimate the appropriate dilution of tissue protein 
homogenates for the final experiment. 
The ELISA assays were performed on tissue homogenates according to manufacturer's 
instructions. 
2.3.8. INTRACARDIAC BRAIN PERFUSION 
For mice for which the brain was processed for immunohistochemistry (Ili) they were 
perfused as follows. Mice were anaesthetized by intraperitoneal injection of avertin 2.5% 
(400 mg/kg) and, after mice were unresponsive to a foot pinch, secured on a silicon 
support. The chest cavity was opened by cutting across the abdomen just below the 
sternum and then the diaphragm was carefully cut. The body cavity was exposed by 
clamping the ribs on each side and, where necessary, connective tissue was cut to free the 
heart from the chest cavity. A butterfly needle (25 gauge) was inserted into the left 
ventricle, the right auricle was cut and the animal was slowly perfused. The needle was 
connected, by a plastic tube, to a peristaltic pump (Mityflex) that allows a controlled-speed 
efflux of the perfusion solutions into the whole body. Ice-cold Phosphate Buffer Saline 
(PBS) was first delivered for 2 min to wash out blood 'and then 4% paraformaldehyde 
(PFA) for 4 min allowed the cross-linking of tissues, therefore their preservation. After 
perfusion was completed, the animal was decapitated and the brain quickly explanted and 
placed in 4% PFA for 2-3 h in post-fixation. The tissue was finally placed overnight in a 
solution of 20% sucrose and then for a second overnight incubation in a solution of 30% 
sucrose to ensure cryoprotection and quickly frozen in-pentan at - 45 °C. 
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2.3.9. IMMUNOHISTOCHEMISTRY 
Sagittal sections (30 µm) of the whole frozen brain (cfr. 2.2.4) were cut using a cryostat 
(Leica Microsystems) and dipped in 24-well plates containing PBS. Free-floating sections 
were incubated in 0.6% H202 solution in PBS for 10 min to inactivate the endogenous 
peroxidases. After washing in PBS, the slices were incubated for 30 min in 0.1% Triton X- 
100,3% normal goat serum (Vector Laboratories). Then, the slices were incubated 
overnight at 4 °C with 6E 10 primary antibody (diluted 1: 200, Chemicon). The next day, 
after three washes in PBS, the sections were incubated with the secondary biotinylated goat 
anti-mouse antibody (1: 400, Vector Laboratories) for Ih at room temperature. Then, 1% 
avidin-biotin horseradish peroxidase complex (Vector Laboratories) was added for I h. 
Peroxidase activity was determined by reaction with a solution containing 
Diaminobenzidine (Sigma-Aldrich) and nickel ammonium sulfate (Sigma-Aldrich). 
The sections were mounted on slides, dried, dehydrated and covered with mounting 
medium (Thermo Fisher Scientific). 
Briefly, using a light microscope (BX5 1, Olympus), I OX images (219x 164 µm size) were 
captured with a video camera (Olympus), and projected onto a computer monitor. Plaque 
load quantification was performed with ImageJ (National Institutes of Health) by executing 
a macro specifically written in our laboratory. Four sections per animal were counted and 
averaged to obtain the mean ± standard error of the mean (SEM) for each animal. 
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2.4. IN VITRO CELLULAR SECTION 
2.4.1. CELL CULTURE: SK-N-BE(2) 
SK-N-BE(2) (ECACC 95011815) cell line is established from a bone marrow biopsy of a 
22-month-old Caucasian male with disseminated neuroblastoma. SK-N-BE(2) cells were 
cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% 
Foetal Bovine Serum, 2 mM L-glutamine, 100 U\mL penicillin and 100 µg\mL 
streptomycin (Invitrogen). 
SK-N-BE(2) cells were grown as monolayer in flask. Cells were incubated at 37 °C in 5% 
CO2 humified atmosphere. SK-N-BE(2) cells were routinely split by removing medium 
from confluent flasks. After washing with PBS (Invitrogen), to remove any trace of serum. 
cells were incubated with a minimal volume (500 . tL\25 cm2 flask) of trypsin\EDTA 
solution (0.05% trypsin and 0.02% EDTA in PBS) for 1 min at 37 °C. Trypsin was 
inhibited by adding 2.5 mL of fresh medium and cells were seeded in the appropriate 
flasks. 
SK-N-BE(2) cells were differentiated into a neuronal-like phenotype with retinoic acid 
(RA) (Sigma-Aldrich). 
Cells were seeded in multi-well plates (Asahi Techno Glass) in complete medium. After 4 
h, the medium was removed and 200 µL of freshly prepared medium without serum and 
supplemented with 10 iM RA was added. After 4-5 days cells showed a differentiated 
phenotype (figure 2.6. ). All specific treatments started on the 5th day after RA 
supplementation. RA was renewed 2 days after cell seeding, and just before the starting of 
cell treatments. 
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FIGURE 2.6. Differentiated SK-N-BE(2) by retinoic acid treatment. 
2.4.2. CELL VIABILITY ASSAY 
Cell viability was assessed with the CellTiter 96*ý Aqueous One Solution Cell Proliferation 
Assay (Promega) that contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; (MTS)] and an 
electron coupling reagent (phenazine ethosulfate; PES) in a unique aqueous reagent. Cell 
viability was assessed by measuring the level of cellular conversion of MTS into a water- 
soluble colored formazan product. The assay was performed by adding the reagent (10%) 
directly to culture medium, incubating for 4h at 37 °C and then recording the absorbance 
at 490 nm with a plate reader (Molecular Devices). The absorbance recorded was directly 
proportional to the number of living cells in culture. Data were presented as the percentage 
of viable cells in the treated group with respect to untreated control cultures. All cell 
viability assays were performed in triplicate. 
2.4.3. APOPTOTIC NUCLEAR STAINING 
Apoptosis was revealed by nuclear fragmentation following DNA staining using the 
fluorescent dye Hoechst 33342 (Sigma-Aldrich). Apoptotic cells were counted under a 
fluorecence microscope and expressed as percentage of total nuclei count. 
2.4.4. ASSESSMENT OF INTRACELLULAR ROS 
Intracellular oxidative stress was measured using the nonfluorescent compound 2'-7'- 
dichlorofluorescein diacetate (DCFH-DA) (Sigma-Aldrich). Viable cells deacetylate 
DCFH-DA to 2'-7' -dichlorofluorescin, and in presence of ROS to the fluorescent dye 2'- 
7'-dichlorofluorescein, which remains trapped within the cell and can be measured with a 
fluorescence plate reader (excitation at 480 nm, emission at 530 nm). Cells were pre- 
loaded with 10 µM DCFH-DA 1h before oxidative stress induction and 7'- 
dichlorofluorescein was measured after 24 h. ROS levels were expressed as percentage of 
the fluorescence intensity of the baseline ROS in the control group. 
2.4.5. RESVERATROL UPTAKE 
Resveratrol (RES) uptake was assessed in dr. Silvio Caccia's laboratory ("Mario Negri" 
Institute, Milano, Italy) by HPLC-MS-MS. A total of 3.5 - 106 SK-N-BE(2) cells were 
seeded and treated by RES as described in section 6.2.2. At 16,20 and 44 h from the first 
RES treatment, RES intracellular content was measured. Cells were harvested, counted by 
erythrosine-dye exclusion assay and centrifuged. The washed pellet was frozen and then 
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resuspended in a solution containing 70% acetonitrile, 10% formic acid in presence of 
zeranol (10 . ig/mL) as internal standard. After centrifugation at 15 000 g for 10 min, an 
aliquot of a 1: 5 water dilution of the supernatant in presence of 0.05% acetic acid was 
injected into an HPLC-MS-MS system (Waters). RES content was quantified as described 
byWang et al. with minor modifications (Wang et al., 2005a). The limit of detection was 
0.04 µg/mL and the assay was linear up to 2µg/mL; coefficients of variation were between 
10-20%. 
2.4.6. Aß42 SYNTHESIS 
Aß42 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) was 
synthesized in dr. Mario Salmona's laboratory ("Mario Negri" Institute, Milano, Italy) by 
solid-phase peptide synthesis (SPPS) and purified by reverse phase HPLC. Peptide identity 
was confirmed by MALDI-TOF analysis (Salmona et al., 2003). A(42 was stored at -80 °C 
as a powder. 
2.4.7. FLUORIMETRIC BINDING ASSAY 
Binding of RES to Aß was examined by dr. Mario Salmona's laboratory ("Mario Negri" 
Institute, Milano, Italy) with a fluorimetric binding assay as described by Ahn et al. (Ahn 
et al., 2007) with minor modifications. This assay took advantage of RES intrinsic 
fluorescence (excitation at 320 nm, emission at 395 nm) and registered emission spectra 
between 300 and 600 nm. RES emission length was compared with and without incubation 
of the molecule with A. 
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2.4.8. ATOMIC FORCE MICROSCOPY 
Atomic force microscopy (AFM) was carried out by dr. Mario Salmona's laboratory 
("Mario Negri" Institute, Milano, Italy). 
Aß42 was incubated in presence or absence of RES (ratio 1: 1.5) at 37 °C for increasing 
time intervals (0.5,6 and 24 h). Each sample was diluted to I µM with PBS 10 mM, pH 
7.4 and incubated for 0.5 min on a freshly cleaved Muscovite mica disk. After the 
incubation time, the disk was washed with H2O and dried under gentle nitrogen stream. 
The sample was mounted onto a Multimode AFM with a NanoScope V system operating 
in Tapping Mode using standard phosphorus-doped silicon probes (T: 3.5-4.5 µm, L: 115- 
135 µm, W: 30-40 µm, K: 20-80 N/m) (Veeco Instruments). 
2.4.9. RNA EXTRACTION AND RELATIVE QUANTITATIVE RT-PCR 
Total RNA was extracted from cell lysates with SV Total RNA Isolation System 
(Promega). 
Cells were cultured in multi-well plates and treated according to the specific experimental 
protocol. At the end of the experiment, cells were harvested by trypsinisation and lysed 
with 175 µL lysis buffer provided within the commercial kit used. 
Tissues (- 10 mg weight) were resuspended in 175 µL lysis buffer and homogenated by a 
syringe needle. 
All steps were carried out at room temperature with RNase-Zap (Ambion). 
A total of 1 µg RNA was reversed transcribed into cDNA and RT-PCR assays were run as 
described in section 2.3.6.2 using TagMan`' gene expression assays (Applied Biosystems, 
table A. 4. ). 
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2.4.10. PROTEIN ANALYSES 
2.4.10.1. Protein extraction from cell line. 
Ice-cold Lysis Buffer pH 7.4 (50 mM Tris/HCI, 150 mM NaCl, 0.5 mM EDTA and 1% 
Triton X-100) was prepared. A further 1% of a broad-range protease inhibitor cocktail and 
1 mM Sodium Butyrate (inhibitor of class I and II deacetylase) (Sigma-Aldrich) was also 
added. 
Cells were cultured in multi-well plates and treated according to the specific experimental 
protocol. At the end of the experiment, supernatants were aspirated, cells were washed 
with PBS and subsequently incubated at 4 °C for 30 min with 100 pt/well of ice-cold lysis 
buffer. Cells were scraped on ice, and centrifuged at 14 000 rpm for 5 min at 4 °C. 
Supernatants were sub-aliquoted and stored at -80 °C. Small aliquots were taken for 
protein quantification. 
Protein concentration of supernatants was measured by BCA protein assay according to the 
manufacturer's instructions. 
2.4.10.2. SDS-polyacrylamide gel electrophoresis and western blotting 
Sample preparation - 30 gg of cellular lysates, were denatured by boiling in SDS sample 
buffer (125 mM Tris-HC1 pH 6.8, SDS 10%, glycerol 10%, bromophenol blue 0.006%) 
added with 0.1 M DTT at 95 °C for 5 min. 
Proteins were electrophoresed and electroblotted onto a 0.2 µM nitrocellulose membrane 
as described in section 2.3.7.2. 
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Immunodetection was performed as described in section 2.3.7.4. 
2.4.11. IMMUNOCYTOCHEMISTRY 
Cells were cultured in a plastic chamber slide (Thermo Fisher Scientific) multi-well plates 
and treated according to the specific experimental protocol. At the end of the experiment, 
culture medium was removed and after 2 washes with PBS cells were fixed with 4% PFA 
and permeabilized using 0.5% Triton X-100. After 2 washes with PBS and Ih block with 
10% horse serum in PBS, cells were incubated overnight at 4 °C with the specific primary 
antibody at the appropriate dilution in PBS+1% horse serum. The next day, cells were 
incubated with Alexa Fluor ® 488-conjugated secondary antibody (Invitrogen) diluted 
1: 200 in PBS. Cells were then analyzed with a fluorescence microscope coupled to a 
digital camera (Olympus). 
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PAGE 
NUMBERING 
AS 
ORIGINAL 
SECTION A: BACKGROUND 
As previously described, recent GWAs have identified over 40 candidate novel genetic loci 
related to AD, in addition to APOE c4. However, only a few of these loci (e. g. near CLU, 
CR1, PICALM and BIN] genes) have shown consistent replication (Bertram, 2011) and 
these variants collectively do not entirely explain the genetic predisposition to all forms of 
SAD. Furthermore, since the role of interactions between genes and other factors are 
increasingly likely to contribute to AD risk and progression, investigations remain ongoing 
to find new genetic variants that could be implicated. 
The 7 mammalian sirtuin proteins currently know in humans are each encoded by separate 
genes SIRTI-7. Increasing evidence has highlighted the involvement of mammalian 
sirtuins in ageing and age-associated disorders such as metabolic diseases, cancer, 
cardiovascular disease, neurodegeneration and inflammation. Thus it is possible, if not 
probable, that sirtuins are implicated in the various mechanisms and may also serve as 
therapeutic targets against age-linked pathologies. These findings have prompted a number 
of investigations into whether common allelic variations in some of the SIRT genes are 
associated with longevity and age-related diseases in humans. Interestingly, a silent 
variation on SIRT3 gene was reported to be associated with survivorship in elderly males 
(Rose et al., 2003). This genetic variant was later found to be linked with, a variable 
number of tandem repeats (VNTR) polymorphism, with a putative enhancer function 
revealed by functional studies. Consistently with the previous study, the allele lacking the 
enhancer activity was found to be absent in males older than 90 years (Bellizzi et al., 
2005). 
Genetic variants spanning the SIR TI gene, the most extensively studied sirtuin to date, 
were found to be associated with different aspects of human metabolism such as body mass 
index (BMI), LDL cholesterol levels basal energy expenditure and risk of obesity, and with 
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cardiovascular mortality (Kuningas et al., 2007; Weyrich et al., 2008; Zillikens et al., 
2009a, 2009b). These genetic findings supported the involvement of SIRTI in age-related 
metabolism homeostasis, which had already been suggested by substantial evidence from 
in vitro and in vivo studies. A weak genetic association was also found between SIRT4 
gene, encoding a mitochondrial sirtuin, and T2D (Reiling et al., 2009). Anyway, further 
studies could depict a relation between other genetic variants in mitochondrial sirtuins and 
metabolic parameters. 
Sirtuins have been found to mediate disease-modifying effects in various models of 
neurodegeneration such as in AD, Parkinson's disease, Huntington's disease and 
amyotrophic lateral sclerosis. SIRTI in particular, has been proposed to be a putative risk 
factor in relation to AD because of its biological function and its location on chromosome 
10 in a region that was previously reported in linkage studies to confer susceptibility for 
LOAD (Bertram et al., 2000). However, no evidence supporting an association between 
SIRTI variation and AD risk was found in studies derived from a British population and in 
another one in a Finnish cohort (Helisalmi et al., 2008; Morgan et al., 2007). Only a weak 
positive association with AD, that still requires replication, was reported in Finnish women 
older than 65 years (Helisalmi et al., 2008). 
None of the other sirtuin genes (SIRT2-SIRT7) have been investigated in AD and given the 
increasing data showing the relevance of sirtuins in the brain and neurodegenerative 
diseases, a comprehensive study on sirtpin genetic variation and LOAD was deemed 
timely and worthwhile. 
The overall aim of chapter 3 and 4 was to explore whether genetic variation in a number of 
sirtuins was associated with AD risk. To this concern, a three-stage study was designed 
including: 
(i) A pilot dHPLC screening to investigate the presence of sirtuin variation in a population 
of Caucasians in relation to AD. 
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(ii) An initial case-control association study to quantify the extent, if any, of genetic 
association between identified sirtuin common polymorphisms and AD risk. 
(iii) A replication case-control association study, in an independent cohort, to seek 
verification of the original association found and with the scope offered by increased 
sample size a better overview of the effect size of any observed association. 
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CHAPTER 3: POLYMORPHISM 
SCREENING IN SIR TUIN GENES BY 
dHPL C ANAL YSIS 
3.1. SYNOPSIS 
The aim of this study was to screen sirtuin common genetic variations in relation to AD. 
To achieve this, all 7 sirtuin genes were assessed to search for common polymorphisms 
(i. e. frequency higher than 20% in the population) rather than rare variants, in accordance 
with the idea that common diseases are more probably caused by common polymorphisms 
in the population (common disease-common variants theory) (Schork et al., 2009). As 
such, 96 subjects were screened (48 AD and 48 CT) for each of the 62 amplicons of 
interest. 
The assessment of sirtuin variation was initially performed by dHPLC and suggested 
polymorphisms identified were then validated and characterised by direct DNA 
sequencing. To increase the likelihood of finding more functionally relevant SNPs dHPLC 
screening focused on the coding regions and small intronic flanking portions of all of the 
sirtuin genes (SIRTI -7). 
Overall, 29 SNPs were identified across the 7 genes of which 18 resided in the intronic 
portions flanking the exons and 11 in protein coding regions (cSNPs) of the amplicons 
assessed. Among the cSNPs identified (3 novel SNPs and 8 already reported in the NCBI 
SNP database), 3 variants were silent SNPs, I was a nonsense SNP, leading to the 
premature truncation of SIRT5 protein and 7 were missense variants. In particular, 4 
cSNPs lead to substitutions that could, at least locally, affect protein structure. However, in 
most instances, the cSNPs were of low frequency being restricted to one subject, and as 
such were more likely to be rare mutations than polymorphisms. Only 2 cSNPs were more 
frequent and interestingly one of these appeared to be have a slightly different genotype 
pattern between the ADs and CTs screened. Of the non-coding SNPs identified (8 novel 
SNPs and 10 already reported in the NCBI SNP database), many were frequent variants 
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and some of these were more present in one but not both of the two sample groups 
investigated thereby making them worthy of further investigations. 
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3.2. MATERIALS AND METHODS 
3.2.1. SAMPLE POPULATION 
As mentioned the population selected for the dHPLC screening was composed by 48 AD 
and 48 CT subjects. Both AD and CT were recruited at the "Luigi Sacco" Hospital in 
Milan (Italy) and at the "Beata Vergine" Hospital in Mendrisio (CH - Italian Canton). The 
sample size was such that it should identify variants in heterozygosis with a frequency 
higher than 1% (i. e. I in N=96 patient would correspond to 1%). The equal numbers of 
ADs and CTs also offered an initial screen to explore differences between the cases and 
controls for the most common variants identied. 
The demographic data of AD and CT groups are summarized in table 3.1. AD and CT were 
gender-, and age-matched (p > 0.5 Student t-test for any comparison between AD and CT). 
Conversely, AD patients showed a MMSE score significantly lower than CT subjects (p < 
0.01 t-test), highlighting a cognitive deficit. 
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Cohorts 
"Luigi Sacco" 
Hospital 
"Beata Vergine" 
Hospital 
Diagnose (N°) 
CT (24) 
AD (24) 
CT (24) 
AD (24) 
Gende 
r 
M(%) 
29 
25 
30 
22 
Mean age 
(years f SD) 
78.3 f 9.0 
77.9 ± 5.3 
79.4 ± 8.2 
78.1 ± 6.0 
Mean MMSE 
(score ± SD) 
28.9 ± 1.5 
15.1 ± 4.7 * 
28.2 f 1.5 
16.0 t 3.9 * 
TABLE 3.1. Demographics of the cohorts included in the dHPLC analysis. 
Abbreviations: AD, sporadic Alzheimer's disease; CT healthy controls: Al, males; SD, 
standard deviation; MMSE, Mini Mental State Examination; *p<0.01 vs. CT- Student 
test. 
3.2.2. dHPLC ANALYSIS 
In the design stage of the study, a variable number of amplicons were defined for each 
SIRT gene. In the majority of the cases, amplicons included an exon and a small section of 
flanking intronic sequence taking into account intron/exon splicing sites. When an exon 
was too long and fell outside the optimal range for investigations by dHPLC (> 350 bp), 
and/or its melting profile was highly non-homogeneous, more than one overlapping 
amplicon was designed. For each amplicon a pair of primers was designed and the PCR 
amplification conditions were optimised. Each amplicon was amplified by PCR and the 
resultant product was analyzed by dHPLC with the appropriate melting temperature (table 
A. 3. in the appendix) 
GENE NAME NUMBER OF EXONS NUMBER OF AMPLICONS 
SIRTI 9 10 
SIRT2 16 16 
SIRT3 7 7 
SIR T4 3 3 
SIR TS 8 8 
SIR T6 8 8 
SIRT7 10 10 
TABLE 3.2. Number of amplicons screened in the dHPLC study for SIRTI-7 genes. 
Summary of the number of exons and amplicons screened in the dHPLC study. Cfr. table 
A. 3 in the appendix of the thesis for the extra detail on primer sequences, and condition of 
the dHPLC analysis. 
Samples with atypical chromatographic profiles, potentially indicative of the presence of 
polymorphism, were sequenced to identify if a substitution was present and characterise 
the nature of it. For the relevant regions, some samples with single-peak dHPLC profiles 
were also sequenced for comparison purposes. 
3.2.3. INSILICO ANALYSIS 
Genetic variants were characterised by comparing genomic contiguous (`contig') 
sequences from the National Institute for Biotechnology website (NCBI) Entrez gene (NC 
reference sequences (table A. I. in the appendix) with the corresponding sequences 
obtained by direct sequencing. Chromosomal position and the position within the gene 
structure were defined taking advantage of Gene Table display setting. Protein reference 
sequences available were also examined for any coding SNPs found to determine if 
polymorphism resulted in any amino acid changes. The identification of SNPs already 
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published was performed using BLAST SNP. Sirtuin NCBI reference sequences are 
summarized in table A. 1 in the appendix. Multiple alignment was performed by Clustal W 
software using the slow/accurate pairwise alignment method with a gap penalty of 10.00 
and gap length of 0.10 and GONNET 250 as protein weight matrix. 
3.3. RESULTS 
3.3.1. IDENTIFICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS 
dHPLC screening of the 62 sirtuin amplicons designed, revealed several atypical profiles 
indicative of putative heterozygote substitutions within the sample population investigated 
(48 AD and 48 CT, cfr. chapter 3.2.1. ). The subsequent direct sequencing of these gene 
regions, revealed 29 different SNPs. All the identified SNPs were verified to be absent in a 
subset of samples displaying single-peak dHPLC profiles for the relevant gene region 
which were sequenced at the same time. 
The characterisation of the SNPs by in silico analysis elucidated the precise nature of the 
substitutions observed. In table 3.3, the identified SNPs are reported together with the 
corresponding chromosome position, exonlintron location across sirtuin genes, and the 
nucleotide change occurred. Previously described variants (18 out of the 29 SNPs) are 
denoted by the existing reference SNP (rs) number from NCBI Variation Database 
(dbSNP) (http: //www. ncbi. nlm. nih. gov/projects/SNP/). Among the 29 identified SNPs, 11 
resided in exons (cSNPs) whereas 18 were in the flanking intronic sequences. 
SNP (NCBI dbSNP) Gene Chromosome 
position 
Exon/Intro 
n 
Nucleotide 
change 
SNP I (rs2236318) 69648569 IVS II -71 T>A 
SNP 2 (rs10823103) 69650969 IVS III -191 A>G 
SNP 3 (rs7896005) SIRTI 69651125 IVS III -35 A>G 
SNP 4 (rs2273773) 69666598 EXON V T>C 
SNP 5 (rs116040871) 69672479 EXON VIII G>A 
SNP 6 39374844 IVS III +61 G>A 
SNP 7 39374982 IVS III -91 C>T 
SNP 8 SIRT2 39378618 IVS V -21 C>T 
SNP 9 39378836 IVS VI -21 C>G 
SNP 10 (rs11879010) 39379855 IVS VII -60 T>C 
SNP II (rs45496398) 39370217 IVS XIV C>G 
SNP 12 (rs11246020) 233067 EXON III G>A 
SNP 13 (rs547025) 232855 IVS III +128 A>G 
SNP 14 (rs61748606) SIRT3 230474 EXON IV C>A 
SNP 15 224004 IVS V +73 G>A 
SNP 16 (rs511744) 219089 IVS V -48 G>A 
SNP 17 219060 IVS V -18 C>T 
SNP 18 (rs2261612) SIRT4 120750239 IVS I -20 G>A 
SNP 19 13599900 F, XON I C>T 
SNP 20 (rs3734674) SIRT5 13592135 IVS III +9 C>T 
SNP 21 (rs34162626) 13612078 EXON VIII A>G 
SNP 22 (rs34786277) 4180901 EXON II C>"I' 
SNP 23 (rs352493) 4180836 EXON II A>G 
SNP 24 (rs115_54579) SIRT6 4179250 EXON III A>G 
SNP 25 4179056 EXON III G>A 
SNP 26 4176044 IVS III +17 G>A 
SNP 27 (rs7246235) 4175785 IVS V -28 C>A 
SNP 28 SIRT7 79870250 IVS II -11 C>T 
SNP 29 79870325 EXON III C>1' 
TABLE 3.3. List and description of the identified SNPs. 
Abbreviations: SNP, single nucleotide polymorphism; IVS, inironic variance sequence. 
* Chromosome positions and the position of coding SNPs within sirluin transcripts refer to 
NCBI reference sequences NC_ and NM (full length isgform) respectively (tahle A. 1. in 
the appendix). 
cSNPs were mapped with BlastX (http: //blast. ncbi. nlm. nih. gov/Blast. cgi) to search for the 
corresponding amino acid substitution. We found that 3 of the 11 cSNPs where silent 
SNPs, since they caused a codon change that did not affect the resultant amino acid. A 
further 7 cSNPs were missense SNPs and the remaining SNP was a nonsense substitution 
leading to the insertion of a "stop" codon and should have resulted in the premature 
truncation of the SIRT5 mRNA message. In table 3.4, the cSNPs in the sirtuin genes are 
reported with the amino acid change occurred and the biochemical feature of the 
substitution. 
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cSNP I PROTEIN CODON AMINO CONVERSION 
Rs code 
SNP 4 
rs2273773 
SNP 5 
rs1160-f 0871 
SNP 12 
rs11246020 
SNP 14 
rs61748606 
SNP 19 
SNP 21 
rs3-1162626 
SNP 22 
rs3-1786Z77 
SNP 23 
rs352493 
SNP 24 
rs1155-1579 
SNP 25 
SNP 29 
(NP) 
SIR TI 
SIRTI 
SIR T3 
SIR T3 
SIR T5 
SIR T5 
CHANGE CHANGE 
TTG > CTG L332L Synonymous 
Negative charged GAA > AAA E536K 
positive charged 
GTC > ATC ['2081 Aliphatic 
CCC > CAC P262H 
Small > positive 
charged 
CAG > TAG RIO* Non sense 
Negative charged GAA > GGA E305G 
hYdrophohic 
SIRT6 
, 
TTC > T77' 
, 
F24F Synonymous 
SIRT6 AGT > AAT S46N Small, polar 
__ __ ---- -- --- i 
SIRT6 CGA > CGG R 76R Synonymous 
SIR TO j CGC > CAC 1 R121 H Positive charged 
SIR T7, G(-'(-'> GTC Ayy6' 
Small, 
hydrophobic 
TABLE 3.4. List of the cSNPs and related amino acid substitutions. 
Abbreviations: cSNP, coding single nucleotide polymorphism: rs, reference SNP. 
Amino acid substitutions are referred to full length proteins NC reference sequences are 
listed in table A. 1. in the appendix. 
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FIGURE 3.1. Multiple alignment between the 7 human sirtuins (SIRTI-7) and Sir2p 
of S. cerevisiae, the founding member of sirtuin protein family. 
Blue box: sirtuin core domain; residues underscored in yellow: coding SNPs. Nucleotides: 
red= small + hydrophobic (incl. aromatic - Y) (A VFPMIL W); blue = acidic (DE); 
magenta= basic (RHK); Green= Hydroxyl + Amine + Basic +Q (STYHCNGQ). "*" 
identical residues, conserved residues, semi-conserved residues in all sequences in 
the alignment. 
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FIGURE 3.2. Multiple alignment among ortholog sirtuins. 
Red boxes identify the position of the residue of interest. 
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3.3.3. SNP FREQUENCIES 
The heterozygote frequencies of each variant were calculated for the entire screening 
sample (i. e. the number of samples with an altered dHPLC profile/total samples). For 
previously known SNPs, as a form of validation we compared the frequencies obtained in 
the control group with the reported distributions in other geographically related population 
datasets available. The SNPs identified in our study involved ones that were highly 
frequent but there were also rare substitutions present in only one of the subjects screened 
which may more likely be rare mutations rather than polymorphisms. SNP frequency was 
also calculated in CT and AD groups separately where 6 SNPs (SNPs 4,7,10,11,15 and 
18) revealed suggestive differences in the genotype distributions observed between AD 
and CT (table 3.5). 
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SNP (NCBI code) 
SNP 
n (%) 
total 
SNP 
n (%) 
AD 
SNP 
n (%) 
CT 
Genotypic distribution (%) 
111222 
Source population 
SNP 1 (rs2236318) 48 (50) 27(56) 21 (44) 23 40 37 EGP CEPII PANEL * 
SNP 2 (rs10823103) 47 (49) 25 (52) 22 (46) 6.9 45.1 48 TSIc 
SNP 3 (rs7896005) 42(44) 19(40) 23(48) 10.1 42.4 47.5 TSISti 
SNP 4 (rs2273773) 8 (8) 6 (13) 2(4) 0 12.7 87.3 TSI 
SNP 5 (rs116040871) 1 (1) 1 (2) 0 (0) NA 
SNP 6 1 (1) 0(0) 1 (2) - 
SNP 7 4(4) 0(0) 4(8) - 
SNP 8 3 (3) 0 (0) 3 (6) - 
SNP 9 1 (1) 1 (2) 0 (0) - 
SNP 10 (rs11879010) 12(13) 9(19) 3(6) NA 
SNP 11 (rs45496398) 7 (7) 7 (15) 0 (0) NA 
SNP 12 (rs11246020) 33 (34) 16(33) 17(35) 4.9 39.2 55.9 TS15ý 
SNP 13 (rs547025) 10(10) 4(8) 6(13) NA 
SNP 14 (rs61748606) 1 (1) 1 (2) 0 (0) NA 
SNP 15 47 (49) 19 (40) 28 (58) - 
SNP 16 (rs511744) 44(46) 23(48) 21 (44) 7.8 49 43.1 TSIýý 
SNP 17 1 (1) 0(0) 1 (2) - 
SNP 18 (rs2261612) 32(33) 10(21) 22(46) 11.8 36.3 52 TSI§ 
SNP 19 1 (1) 0 (0) 1 (2) - 
SNP 20 (rs3734674) 46 (48) 24 (50) 22 (46) NA 
SNP 21 (rs34162626) 1 (1) 1 (2) 0 (0) 03 97 CEUS 
SNP 22 (rs34786277) 1 (1) 0 (0) 1 (2) 03 97 AGI ASP PANEL* 
SNP 23 (rs352493) 2(2) 1(2) 1 (2) 1 12.7 86.3 TSI* 
SNP 24 (rs11554579) 2 (2) 2 (4) 0 (0) NA 
SNP 25 1 (1) 0 (0) 1 (2) - 
SNP 26 1(1) 1(2) 0(0) - 
SNP 27 (rs7246235) 10 (10) 6 (13) 4 (8) 0 1.7 98.3 C'EU* 
SNP 28 4(4) 2(4) 2(4) - 
SNP 29 1 (1) 0(0) 1 (2) - 
TABLE 3.5. Heterozygote frequency of the SNPs identified in the the dHPLC 
screening and corresponding genotype distributions where available from NCBI. 
Abbreviations: NA, not available. Source population from NCBI* 
(http: //www. ncbi. nlm. nih. gov/projects/SNP/snp_ind. cgi? ind id=239) or HapMaP§ 
(http: //www. broadinstitute. org/ debakker/p3. html). 
3.4. DISCUSSION 
The dHPLC screening study aimed to investigate levels of sirtuin genetic variation. The 
screening study revealed 29 SNPs residing in coding and small intronic (non-coding) 
flanking regions across the various SIRT genes studied. Notably, this approach revealed 11 
novel SNPs which have not yet been reported. On the other hand, we did not detect in our 
screening sample several other reported SNPs which have a low frequency. However, we 
are confident that our overall method of polymorphism identification was effective since 1) 
we were able to identify the most frequent SNPs reported in the assessed gene portions, 
and 2) we confirmed the effective absence of nucleotide substitutions in a pool of samples 
with single peak dHPLC profile. Hence, our approach was useful to characterize sirtuin 
genetic variation of our sample population avoiding 1) the need of evaluating all the 
annoted SNPs known to date and 2) having significantly larger direct sequencing costs 
(which were still current at the moment we conducted the analysis). 
From this study, 11 of the 29 SNPs identified resided in the protein-coding regions 
(cSNPs). 3 cSNPs were silent changes (scSNPs) already been reported in NCBI dbSNP: 
SIRTI L332L rs2273773, SIRT6 F24F rs34786277, and SIRT6 R76R rsl 1554579. 
Although silent SNPs do not affect the amino acid sequence, they deserve attention 
because they could alter translational efficiency as a consequence of codon usage bias. To 
this concern, at least in the case of SNP4 SIRTI L332L, it seems that the codon change 
occurred is not detrimental. In fact, referring to codon usage in Homo sapiens, leucin is 
more frequently encoded for by CTG (41%) rather than TTG (13%) which is the canonical 
codon at 332 position in SIRTI. However scSNPs, altering the mRNA secondary structure, 
could affect mRNA stability, translation and even protein structure. For example, it was 
demonstrated that scSNPs can lead to the synthesis of protein product with the same amino 
acid sequence but different structural and functional properties (Komar, 2007). A final 
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reason for considering these scSNPs is that even if in themselves they contribute no known 
biological effects, they may still serve as markers for association with disease through 
associations (by linkage disequilibrium) they may have with other adjacent SNPs which 
may mediate phenotype-associated affects. 
The remaining 8 cSNPs were also found to affect changes to protein sequence, which are 
non-synonymous coding SNPs - nscSNPs. In particular 7 cSNPs were missense 
substitutions leading to a change in the relevant amino acid codons, and 1 cSNP was a 
`nonsense' substitution giving rise to a "STOP" codon. Overall, with the exception of 
SIRT5 R10* and SIRT5 E305G, all of the other nscSNPs reside within the sirtuin 
conserved core domain (blue box in figure 3.1). Among nscSNPs, conservative missense 
substitutions (i. e. the canonical amino acid is changed with a novel one with similar 
biochemical properties), are SIRT3 V2081, SIRT6 S46N, SIRT6 R121 H and SIRT7 A99V 
These substitutions lie in non-conserved positions within the sirtuin core domain (denoted 
by * in figure 3.1). However, SIRT6 S46N is of particular interest because it is seven 
residues upstream the GAGIS motif and therefore could alter the microenvironment of the 
catalytic site. 
Other missense substitutions were SIR Ti E536K, SIRT3 P262H and SIRTS E305G. In the 
case of SIRTI E536K, a negatively charged amino acid is substituted with a positively 
charged one, whereas in the SIRT5 E305G change, a hydrophobic residue replaces a 
positively charged amino acid. For SIRT3 P262H, a proline substitutes a positively charged 
amino acid presumably conferring rigidity to the structure. These amino acid substitutions 
could affect sirtuin protein function. 
To begin to explore this possibility we performed multiple alignment between paralogue or 
orthologue sirtuins. Multiple alignment between human paralogue sirtuins highlighted the 
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more important residues for sirtuin family, such as the consensus GAG[I/V]S where serine 
is reported to be fundamental for sirtuin catalytic activity, where the sirtuin catalytic 
conserved domain was reported to reside. None of the identified SNPs apparently resided 
in conserved positions fundamental for sirtuin enzymatic activity (figure 3.1). However, 
multiple alignment between orthologue sirtuins showed an high conservation rate. SIRTI 
E536K and SIRT3 P262H are located in conserved positions that appear to be important for 
the specific sirtuin class which might for example be of relevance for substrate interaction 
(figure 3.2). However, to avoid being overly speculative, the best means to try to clarify 
these questions would be to conduct appropriate functional studies which fell beyond the 
scope of this thesis. 
The interesting substitution found in SIRT5 was that of the introduction of a TGA (STOP 
codon) in place of the normal CGA codon. The is presumed to cause the truncation of 
SIRT5 translation after the 10th amino acid residue position. Since this substitution was 
found to be heterozygotic in the subject carrying this mutation and as a result they could 
have only one functional SIRTS allele. However a detailed medical history was not 
available to identify if there were any unusual phenotypic aspects that might be related to 
this. Yet, this again would have a considerable degree of speculation which could be 
perhaps better unpicked through relevant functional work to ascertain the important of 
SIRT5 and whether there was sufficient redundancy in its function such that a single copy 
would have been sufficient for normal activity. 
Of the 18 SNPs identified by dHPLC which resided in the flanking intronic portions 
included in the analysis, none of ncSNPs apparently seem to cause aberrant splicing since 
they lie outside the splice site consensus sequences. Overall, we observed a higher number 
of variants in the SIRTI, SIRT2, SIRT3 and SIRT6 genes while few SNPs were found in 
SIRT4, SIRT5 and SIRT7. No relationship between this difference in SNP frequency among 
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sirtuins and their putative phylogenetic evolution can be noticed. For example, SIRT6 and 
SIRT7 both belonging to Class IV (cfr. phylogenetic tree in section 1.2.1.1, figure 1.8) are 
extremely different in the number of variants. Furthermore, there was a high range of 
frequencies for the identified allelic variants. There were substitutions present in only l 
subject (-1%) which were more probably rare mutations rather than common 
polymorphisms, there were also variants present at low to moderate levels (under 25%) and 
more common variants (up to 50% frequency in the population). The more frequent 
polymorphisms occurred within SIRT], SIRT3 and SIRTS genes; instead SIRT2, SIRT4, 
SIRT6 and SIRT7 were characterized by variants with a frequency lower than 10%. 
Overall, the most common variants in the population were mostly intronic. Indeed, in 
introns there are a lot of variants which usually have low or questionable functional 
importance. This is the reason why we decided to exclude intronic regions from our 
analysis and focus our attention on gene-coding portions. The majority of the protein- 
coding variants identified had a frequency lower than 10%, given the exception of SNP12 
which in our screening sample was present in heterozygote form in 33% of cases. The 
remaining coding SNPs were low frequency variants, mostly likely to be rare mutations 
rather than polymorphisms, since they were found only in one subject. For most of the 
variants reported (5 out of 7) these constituted missense substitutions however this screen 
did not detect the majority, of the cSNPs reported in dbSNP. This might be explained by 
the fact that our approach was set up to highlight more common variants whereas missense 
cSNPs are more likely to be rare mutations rather than polymorphisms since they alter the 
amino acid sequence but have also been reported in other ethnic groups which may not be 
as closely related to our population. However, we were able to identify rsl 1246020, which 
is highly frequent in the Caucasian population. 
Of the the 29 identified SNPs, 11 were novel SNPs and the remaining 18 were already 
recorded in the NCBI SNP database (http: //www. ncbi. nlm. nih. gov/SNP). The newly 
discovered SNPs were perhaps unsurprisingly mostly low frequency polymorphisms 
whereas those already known were generally more frequent. Furthermore, the more 
common variants were represented at comparable levels in both CT and AD groups of our 
screening sample with the only exceptions being SNPs 15 and 18 which were differently 
distributed between the two groups. Amongst the lower frequency variants, we found 
interesting differences in distribution between the AD and CT groups for SNPs 4,7,10, 
and 11. Potentially of most relevance from these is SNP4 because it is a cSNP, even if does 
not alter the amino acid sequence. Overall, only simple descriptive analysis was performed 
on the frequency data obtained from the screening study, since we designed dHPLC 
screening as a rapid qualitative approach only able to detect SNPs in heterozygosis and 
focused on a relatively small cohort (i. e. 48 subjects per group of interest). The differences 
found, however, deserved more investigation and as such a quantitative case-control 
approach (the main topic of chapter 4) was designed and conducted to clarify if following 
more rigourous testing in larger sample sizes there remained any evidence of associations 
between these SNPs and AD. 
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CHAPTER 4. CASE-CONTROL GENETIC 
ASSOCIA TION STUD Y OF SIR TUIN 
VARIANTS IN ALZHEIMER DISEASE 
4.1. SYNOPSIS 
A case-control study was performed to investigate the genotype and allele distribution of 
several genetic variants in the sirtuin genes in an initial sample of 219 cases and 343 
controls. With this sample size, the study was powered to highlight even small associations 
with AD (OR - 1.3). Based on GWAs studies reported in literature, it has been suggested 
that it would be unlikely to identify any further genetic variants that would have an 
association with odds ratio (OR) higher than 1.5 for a complex disease like AD (Ku et al., 
2010). 
For this study of the sirtuin genes, 34 SNPs residing on the sirtuin genes were selected 
according to different criteria. First, and for the majority of SNPs we selected them using a 
tagSNP approach to assess the genetic variation of the gene regions with high linkage 
disequilibrium (LD). We also included 6 SNPs which were felt to be of interest from the 
pilot dHPLC screening (cfr. chapter 3). Genotyping of SNPs was performed using 
Sequenom MassARRAYTM platform, in collaboration with Saarland University, Germany. 
The sample population included in this initial case-control study was also genotyped for 
APOE gene by RT-PCR. Overall, evidence of a marginal association between AD and 
rs10410544 SNP in the SIRT2 gene (p= 0.05) was found. This association was found to be 
stronger in the APOE c4 non-carriers, than before stratification by APOE genotype and 
I 
was actually absent in the APOE s4 carriers. 
The preliminary result obtained was then further investigated in an independent replication 
sample of 316 cases and 298 controls. A similar pattern of association was found in the 
replication study but which on this occasion did not reach the nominal statistical 
significance. However, following the combination of the initial and the replication cohorts. 
in order to increase the power of the analysis, evidence of association between the 
rs10410544 SNP and AD in the whole sample (p= 0.03) was found. Furthermore, this 
0 
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association was only present in non-APOE c4 carriers (OR=1.29,95% Cl 1.04-1.59, p= 
0.01) and not in APOE c4 carriers (p= 0.43). Overall, we found evidence that rs10410544 
T allele in the SIRT2 gene may be a new risk factor for AD which acts independent of 
APOE c4. 
4.2. MATERIALS AND METHODS 
4.2.1. SAMPLE POPULATION 
The subjects included in the initial and replication case-control studies were recruited from 
unrelated clinical centres. A total of 561 subjects were included in the initial case-control 
study. The population selected was composed by 219 AD and 343 CT samples. Blood 
samples from LOAD patients were collected from two clinical centres: the "Luigi Sacco" 
hospital in Milan (Italy) and the "Beata Vergine" hospital in Mendrisio (Italian-speaking 
canton of Switzerland). Controls were recruited from "S. Antonio Abate" hospital in 
Gallarate (Italy). The three centres were within a distance of 50 km. A total of 614 subjects 
were also selected for the case-control replication study: 316 AD and 298 CT. For all 
subjects blood samples were collected from "Centro S. Giovanni di Dio-Fatebenefratelli" 
hospital in Brescia (Italy). 
The summary demographic characteristics of the cases and controls used in the initial and 
replication studies are summarized in table 4.1. In both studies, AD and CT subjects were 
gender-matched (p> 0.5 Student t-test). Moreover, AD patients showed a MMSE score 
significantly lower than CT subjects (p< 0.01 Student t-test), evidence of AD cognitive 
decline. In the initial case-control study, controls were older than cases (p< 0.01 Student t- 
test) since they were included after a3 years follow-up evaluation to exclude any possible 
neurological disorder. 
Diagnose (No) 
Initial case- 
control study 
CT (343) 
AD (219) 
Replication 
study 
CT (298) 
AD (316) 
Gender 
M(%) 
119 (34.8) 
63 (28.8) 
135 (45) 
127 (40) 
Mean age I Mean MMSE 
(years ± SD) I (score ± SD) 
86.8 ± 4.0 
77.5 ± 7.8* 
rt 
25.6 ± 3.2 
19.3 ± 3.8* 
70.76 ± 8.22 
71.64 ± 9.10 
26.4 ± 5.3 
16.88 ý: 4.8* 
TABLE 4.1. Demographics of the cohorts selected for the initial case-control study 
and the replication study. 
AD: Alzheimer's disease patients; CT: healthy controls; M: males: SD: standard 
deviation: MMSE: Mini Mental State Examination; *p< 0.01 vs. CT Student t-test. 
4.2.2. SIRTUIN SNP SELECTION 
The SNPs selected for the case-control association study are summarized in table 4.2. In 
most of the cases only SNPs were examined since they are the most frequent form of 
variants in the human genome. Furthermore, common polymorphisms were preferred 
rather than rare variants because they are more likely to explain a common disease like AD 
(Schork et al., 2009). With the intention of covering the majority of genetic variation 
across the 7 sirtuin genes, 25 SNPs were chosen based on the genotype data available from 
the international HapMap Project (HMP) (http: //hapmap. org/). 
The HMP validated the millions of SNPs that were identified during and after the 
completion of the human Genome Project, and then characterized their correlation and 
measured their extent of linkage disequilibrium (LD) patterns in populations of European, 
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Asian and African ancestry. Thus far HMP have resulted in the validation and 
characterization of the LD patterns of more than 4 million SNPs. In doing this the HMP 
has shown that the existence of LD significantly reduces the number of SNPs that need to 
be genotyped in GWAs (e. g. tagSNPs tag entire LD blocks). Currently. HMP is in the 
process of repeating the validation exercises in an increased number of DNA samples (i. e. 
from the 270 and 4 representative populations) to 1301 samples from 11 different human 
populations. 
For this project 13 sirtuin gene SNPs were selected from a tagSNP approach which was 
performed by querying the HapMap Genome Browser plug-in: tag SNP picker track 
(release 27 PhaseII+III, Feb09, on NCBI B36 assembly, dbSNP b126), configuring the 
tagger multimarker method and adopting a R2 cut off of 0.8 and a MAF cut off of 0.2. The 
HapMap TSI panel was selected as reference population. The TSI (`Toscani in Italia) 
dataset is composed by 117 unrelated subjects resident in Tuscany (Centre of Italy). 
http: //hapmap. ncbi. nlm. nih. gov/. A further 6 SNPs were also included in the study; these 
SNPs were deemed the most interesting ones from the dHPLC screening analysis (i. e. 
those with the highest frequency that displayed an apparenent difference in SNP frequency 
between AD and CT which was greater than 8% in heterozygosity). Moreover, in some 
instances, SNP position was taken into account to attempt to give some coverage to regions 
of sirtuin genes with low LD coverage. 
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Gene/ 
chr n° 
SNP ID NCBI 
Chromosome 
position 
Exon/ 
Intron 
NT change Choice criteria 
SIRTI/ I rs7896005 69651125 IVS III A>G tagSNP 
2 rs2273773 69666598 Exon V T>C dHPLC 
10 3 rs16924945 69674347 1VS VIII A>G positional 
4 rs7897909 69676434 3'UTR G>A positional 
5 rs2015 39369369 3'UTR A>C taýýSNP 
SIRT2/ 6 rs11880757 39375632 IVS VIII C>T positional 
19 
7 rs11879010 39379855 IVS VII G>A dHPLC 
8 rs11667030 39380030 IVS VII C>T tagSNP 
9 rs10410544 39385532 IVS II T>C tagSNP 
SIRT3/ 10 rs3825075 217140 IVS VI G>A tagSNP 
11 NA 224004 IVS V G>A dHPLC 
I1 12 rs536715 230368 IVS IV G>A positional 
13 rs4980329 232598 IVS III G>A tagSNP 
SIR T41 14 rs12307919 120741668 Exon I C>T positional 
12 
15 rs7137625 120746377 IVS II C>T positional 
16 rs2261612 120750239 IVS III A>G dHPLC/tagSNP 
17 rs9382227 13579084 IVS I G>T tagSNP 
SIRT5/ 
18 rs2804919 13585142 IVS III G>A tagSNP 
19 rs9370232 13589873 IVS IV G>C tagSNP 
6 20 rs4712047 13590185 IVS IV A>G tagSNP 
21 rs2253217 13600459 IVS VIII A>G tagSNP 
22 rs2841517 13610188 IVS IX G>A tagSNP 
23 rs350846 4174398 3' UTR G>C positional 
SIR T61 24 rs107251 4176085 IVS IV C>T positional 
25 rs350844 4177051 IVS F v- positional 
19 26 rs352492 4179636 IVS 11 C>T positional 
27 rs352493 4180836 Exon ll T>C dHPLC 
28 rs4807546 4182060 IVS I T>C positional 
29 NA 79870250 IVS 11 C>T dHPLC 
SIR T71 
30 NA 79870325 Exon III C>T dI1PLC 
31 rs11559052 79873326 Exon V A>T positional 
17 32 rs34241371 79872527/8 Exon VI del/C positional 
33 rs1879568 79872129 IVS VII G>A positional 
34 rs36043502 79870835/6 IVS IX del/G positional 
TABLE 4.2. List of the SNPs' included in the case-control study. 
Abbreviations: chr n°, chromosome number; ID, IDentifier; NT, NucleoTide: IVS, Intronic 
Variant Sequence; del, deletion. 
List of the S11Ps genotyped with the corresponding NCBI's reference SNP number, 
chromosome positions according to genome build 37.2 (cfr. Table A. 1. for chromosome 
reference sequences), intron/exon position within the gene and kind of substitution. In the 
last column it is reported the criteria of inclusion: tagging SNP (tagSNP), SNP chosen 
from the dHPLC study topic of chapter 3 or SNP chosen for their position. 
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4.2.3. DATA QUALITY CONTROLS 
SNP genotyping in the initial case-control study was carried on by Sequenom 
MassARRAYTM (Sequenom Inc. ) MALDI-TOF system, in collaboration with dr. Mayhaus 
from Saarland University, Germany. 
After genotype data was collected, several different quality control (QC) cut-offs were 
adopted. SNPs with genotype information lower than 90% (suggestive of difficulties in 
genotyping) were removed from the analysis and samples with a consistently low call rate 
(those who were genotyped unsuccessfully in more than 10% of the SNPs that passed the 
first QC) were eliminated (poor sample quality). Furthermore, to try to reduce the impact 
of genotyping errors, 1) Hardy-Weinberg equilibrium was taken into account for all SNPs 
and we excluded those SNPs whose genotype distributions was not in Hardy-Weinberg 
equilibrium (both in AD and CT group) (p< 0.05). For reference the included SNP 
genotype and allele frequency distributions were assessed for comparability between the 
cohorts studied here and the corresponding available data from the HapMap TSI panel to 
ensure that there were no obvious discrepancies which might be indicative of genotyping 
problems. 
4.2.4. SNP GENOTYPING 
The subjects included in the case-control studies: 561 in the initial study and 614 in the 
replication one, were all genotyped for the commonest polymorphisms in the APOE gene 
(c2, c3, c4) by RT-PCR using two pre-designed TaqMan ' SNP genotyping Allelic 
Discrimination assays (Applied Biosystems). Only rs10410544 SNP which went through 
to the replication study for further investigation from the initial case-control study where 
Sequenom was used was determined using a pre-designed TagMank Allelic Discrimination 
Assays (Applied Biosystems). 
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4.2.5. EXPRESSION QUANTITATIVE TRAIT LOCUS ANALYSIS 
Expression Quantitative Trait Locus (eQTL) analysis for rs10410544 SNP was performed 
querying the eQTL browser (http: //egtl. uchicago. edu/cgi-bin/gbrowse/eqtl/). 
4.2.6. STATISTICAL ANALYSIS 
Demographic data were compared between cases and controls using the Student t-test. 
The allele frequencies and the distribution of genotypes were compared using Pearson's 
goodness-of-fit x2 test (df= I and df= 2 respectively). Likewise, the deviation from Hardy- 
Weinberg equilibrium was evaluated by x2 test (df= 1). 
A priori power analysis was performed with G power software v. 3.0 
(http: //www. psycho. uni-duesseldorfde/abteilungen/aap/gpower3) to ascertain a useful 
sample size for the analysis of sirtuin variants and association with AD. The sample size 
was based on the assumption of being able to detect an association between a `disease 
allele' and an outcome variable (i. e. presence of AD) with an effect size of 0.14 
(corresponding to an OR of 1.3) (Chinn, 2000), with 1 degree of freedom x2-test. The 
power (ß) of detecting the association was set at 0.8 and the alpha-error (a) at 0.05. 
Univariate logistic regression analysis was performed to investigate a correlation between 
each genotyped SNP and AD susceptibility. ORs were calculated with 95% confidence 
intervals (CI). Multivariate logistic regression was used to assess the ORs adjusted for the 
effects of a number of potential confounders (i. e. gender, age and APOE genotype). 
Pairwise LD between SNPs located on a same gene was evaluated with the HaploView 
program v. 4.2 (freely available at http: //www. broad. mit. edu/mpg/haploview/) starting 
from our genotype data or from data available from the HapMap Project. Haplotypes were 
inferred with the PHASE v. 2.1 software using a coalescent process with recombination. 
The reconstructed haplotypes were tested for association with the disease outcome with 
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1000 permutations. Haplotypes below 0.05 frequency were excluded from the statistical 
analysis. For all analyses a p-value < 0.05 was considered to be significant. 
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4.3. RESULTS 
The a priori power analysis suggested that at least 401 subjects, with the case: control ratio 
set to be 0.4: 0.6, would have a power of 0.8 to detect associations with an OR of 1.3 
between the SNPs investigated and AD. Given this results, we included 219 cases and 343 
controls in the initial case-control study. The study design in this manner had an effective 
power of 0.91 and 0.65 to detect an association with an OR of 1.3 and 1.2 respectively. 
4.3.1. APOE F4 DISTRIBUTION 
For all cases and controls and for the purposes of allowing for necessary stratification of 
sirtuin SNP data in due course we investigated the allele distributions of APOE main 
variants (c2,0, s4) both in the initial case-control sample population and in the replication 
cohort. We found a significantly different distribution of APOE s4 allele between cases 
and controls (table 4.3, p< 0.001). The AD cases were nearly 6 fold more likely to carry an 
c4 allele than controls (OR= 5.77 95% CI 3.75-8.86, OR= 5.34 95% Cl 3.65-7.81 in the 
case-control sample and in the replication sample, respectively, p< 0.0001). 
APOE GENOTYPE 
Initial case- 
control study 
Replication study 
Total sample 
AD CASES (%) 
E4 - 
116 
(55.5) 
+ 0 
93 
(44.5) 
CONTROLS (%) 
E4 - 
288 
(87.8) 
E4 + 
40 
(12.2) 
155 1 159 1 250 1 48 
(49.5) 1 (50.6) 1 (83.9) 1 (16.1) 
271 
(51.8) 
252 
(48.2) 
538 
(85.9) 
88 
(14.1) 
TABLE 4.3. APOE r4 distribution between cases and controls. 
OR (95% CI) 
p-value 
S. 77 (3.75-8.86) 
p< 0.001 
5.34 (3.65-7.81) 
p< 0.001 
5.6f3 (4.28-7.54) 
p< 0.001 
Subjects were divided on the basis of APOE genotype into APOE f., 4 carriers and non 
carriers (F4+ and e4- respectively). 
4.3.2. IMPACT OF QUALITY CONTROL FILTERS ON THE INITIAL CASE- 
CONTROL STUDY DATA 
Genotyping by Sequenom platform produced raw data to which quality controls filters 
were applied as previously described. In the first instance, 5 out of the 34 SNPs 
investigated (rsl 1559052, rs34241371, rs36043502, SNP 11, SNP 29) were removed from 
the statistical analysis since they failed to be genotyped in more than 10% of the samples. 
Furthermore, 21 out of the 561 samples genotyped were excluded for not consistently 
being amplified for at least 10% of the remaining 29 SNPs and the corresponding subjects 
were removed from the study (9 cases and 12 controls). A further 7 SNPs (rsl879568, 
rs7137625, rs7897909, rs11880757, rs12307919, rs16924945, SNP30) out of the 
remaining 29 successfully genotyped SNPs were found to be monomorphic (i. e. having 
-151- 
only one genotype). Statistical analysis was the performed on the remaining 22 SNPs. All 
of these SNPs were found to be in Hardy-Weinberg Equilibrium, both in cases and controls 
(p> 0.05). Moreover, the genotype and allele frequencies in the studied population were 
similar to those of the TSI reference population taken from HapMap (p> 0.05) which was 
reassuring since the two populations are closely related both geographically and 
historically. 
4.3.3. SINGLE MARKER ANALYSIS 
The distributions of SIRT alleles and genotypes is displayed in table 4.4. Overall, 21 of the 
22 SNPs for wich the statistical analysis was performed, were not found significantly 
different between cases and controls in genotype and allele frequencies. The only 
exception was rs10410544 SNP in the SIRT2 gene where the T allele was present more in 
ADs than in CTs at a level that was borderline significant. From this it was observed that 
the AD cases were nearly 1.3 fold more likely to carry aT allele than controls (OR, 1.27 
95% Cl 0.99-1.64, p= 0.05). This allelic difference appeared to be driven mainly by an 
excess of TT homozygotes and a reduction in CC genotypes that were more frequent in 
AD cases than in controls. Conversely, no difference in the heterozygote frequency was 
found. Indeed, comparing the prevalence of the different genotypes between the AD and 
CT groups, we found that the OR for the CG genotype' compared to the two homozygous 
groups was 1.14 (95% Cl 0.77-1.69, p= 0.53) and that for the TT genotype compared to the 
other genotypes was 1.73 (95% CI 1.03-2.91, p= 0.03). 
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SNP 
ID NCBI 
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CT 
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AD 
X- 
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Table 4.4. Genotype and allele frequency of the investigated SNPs in the initial case- 
control population (continue in the next page). 
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SNP 
ID NCBI 
SNP 17 
rs9382227 
SNP 18 
rs2804919 
SNP 19 
rs 93 70232 
SNP 20 
rs-17120-17 
SNP 21 
rs2253217 
SNP 22 
rs28-11517 
SNP 24 
rs 107251 
SNP 25 
rs350844 
SNP 26 
rs352492 
SNP 27 
rs352493 
SNP 28 
rs4807546 
Genotype 
G, ýIG 
G//T 
T//T 
G//G 
A//G 
A//A 
G//G 
C//G 
C//C 
A//A 
A//G 
G//G 
A//A 
A//G 
G//G 
G//G 
A//G 
A//A 
G//G 
A//G 
C A//A 
C//C 
C//T 
T//T 
T//T 
C//T 
C//C 
T//T 
C//T 
C//C 
genotype 
CT 
49.36 
40.06 
10.58 
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TABLE 4.4. Genotype and allele frequency of the investigated SNPs in the initial 
case-control population. 
A multivariate logistic regression model was built to calculate the OR for rs10410544 SNP 
adjusted for confounders. Age, s4 allele of APOE and gender were taken into account. The 
resultant adjusted OR was 1.35 (95% Cl 0.96-1.90, p= 0.08). 
We also stratified the initial study sample data for AD major risk factor APOE c4 allele 
and found that the association between AD and the T allele of rs10410544 SNP was not 
evident in APOE s4 carriers (OR= 1.57,95% CI 0.90-2.75; p= 0.10) but was present in 
APOE s4 non-carriers (OR= 1.36,95% CI 1.00-1.86; p= 0.04) (table 4.5). 
SIR T2 
rs10410544 
Allele 
C 
T 
CNT 
60.31 
39.69 
APOE c4 - 
AD x2 (p-value) 
52.60 
47.39 
APDE E4 + 
CNT j AD x2 (p-value) 
i 4.83 (0.04) 1 68.75 11 58.24 i, 2.59 (0.10) i 
Iý ---- - ---- __ 
1.36 [1.00-1.86] 1 31.25 I 41.76 1.57 [0.90-2.75] 
TABLE 4.5. Allele frequency of rs10410544 SNP in APOE E4- and c4+ carriers in the 
case-control sample. 
To attempt to replicate verify a previously published association between SIR Ti 
polymorphisms and AD in females older than 65 years (Helisalmi et al., 2008), we 
stratified our sample according to gender. In particular, we focused our attention on SIRTI 
rs2273773 since the same polymorphism for which the previous association was reported. 
We found no difference neither in the genotype nor in the allele frequency of this SNP 
between female cases and controls (table 4.7). 
Total 
sample 
Mean age 
(years f 
SD) 
n° F 
(% of total 
sample) 
n° F> 65 
genotype 
'%, 
allele 
CT (463) 69.6 278 T//T 74 T 86 
5.1 (60.0) C//T 23 C 14 
222 C//C 3 
(326) Al) 72.1 221 T//T 63 T 80 
6.9 (69.0) C//T 34 C 20 
187 C//C 
O 
Il 
TABLE 4.6. Genotype and allele frequency of rs2273773 polymorphism in females 
older than 65 years of age in Helisalmi et al. study. 
Abbreviations: n°, number: F, females. 
Demographics of the Finnish sample population in Helisalmi et al. study and genotype and 
allele frequencies of rs2273773 in females older than 65 years of age. 
Genotype genotype 
CT 
SIRT1 
Rs2273773 
T//'F 
C//T 
genotype 
AD 
83.41 86.28 
__-- , -- -- -- -- ý 
Z, 
[p- 
value] 
4.318 
13.82 13.72 
[0.11 
C//C ! 2.76 ý0ý 
()IZ 
(9ä'% Cl) 
p-value 
1.517 
(1.05- 
?. 19) 
p< 0.05 
(1 
0 
Allele allele allele 
CT Al) 
90 I" 
1O 
93 
7 
, Z' 
IP- 
value 
1.82 
10.171 
TABLE 4.7. Genotype and allele frequency of rs2273773 polymorphism in females 
older than 65 years of age in the case-control study. 
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4.3.4. HAPLOTYPE ANALYSIS 
Although most of the SNPs selected for this study were chosen as tagSNP of different LD 
blocks (i. e. with low LD between each other), some strong pairwise LD were found. 
represented in figure 4.2 by red boxes. In particular, a strong LD was found between the 
two markers investigated of the SIRTI gene that were 5Kb distant from each other. 
Moreover, SIRT6 showed a unique LD block according to the HaploView program, 
consisting of all six markers genotyped. On the contrary, no sufficient information were 
available to build up an LD map for SIRT4 and SIRT7 genes. Finally, SIRT2, SIRT3 and 
SIRT5 showed an high LD between two nearby markers. Particularly interesting is the case 
of SIRT5 where an high LD was found between two markers distant 9 Kb. 
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FIGURE 4.1. Pairwise linkage disequilibrium (LD) between SIRT markers. 
Graphs showing the genotyped SNPs according to the position along the gene and their 
pairwise LD pattern as measured by D' values. Red colour is suggestive of high D'. The 
identified LD blocks (defined by the confidence interval algorithm). are highlighted by 
black boxes. 
72 
79 56 
When we estimated the haplotype frequencies in the different haplotype blocks, we found 
that the haplotype distributions did not significantly differ between cases and controls. 
HAPLOTYPE CT AD x2 
P-VALUE 
(1000 permutations) 
SIR Ti B1 
TG 0.67 0.66 0.01 1 
TA 0.25 0.27 0.40 0.99 
CA 0.08 0.07 1.01 0.64 
SIR T2 BI 
GC 0.52 0.54 0.69 0.68 
GT 0.4 0.38 0.46 0.77 
AC 0.08 0.8 0.09 0.94 
SIRT3 B1 
GG 0.63 0.62 0.53 0.76 
GA 0.27 0.26 0.07 0.96 
AG 0.1 0.12 2.32 0.27 
SIRTS B1 
AA 0.43 0.41 0.37 0.81 
GG 0.33 0.31 0.29 0.85 
AG 0.24 0.28 1.93 0.36 
SIRT6 B1 
GCGCTT 0.84 0.84 0.03 1.00 
CTACTC 0.10 0.10 0.36 0.90 
GCGTCT 0.05 0.05 0.02 1.00 
TABLE 4.8. Estimated haplotype frequencies of SIRT LD blocks. 
Abbreviations: B1, block 1 
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4.3.5. REPLICATION STUDY 
Given the suggestive evidence of association from the initial case-control study for 
rs10410544 we sought to investigate it further in an independent sample. genotyping 316 
cases and 298 controls. In this replication sample we observed the same tendency of a 
lower CC genotype in AD patients compared to CTs. However, this time the 'I'T genotype 
was not as over-represented as was seen in the initial case-control cohort and overall the T 
allele was higher in cases than in controls but not to the extent of being statistically 
significant (OR was 1.15,95% Cl 0.92-1.45, p= 0.2). 
Genotype genotype 
SIRT2 
Rs10"t 10544 
genotype 
AD 
Z, 
l p- 
valuel 
df=2 
I 
li 
oý 
Allele allele 
% 
allele 
CT AD 
i 
Ip- 
valucJ 
df=1 
C//C 38.25 32.59 61.9 1 58.3 
ý_ 
2.15 I 
C//T 47.3 _ 1 51.58 _C 38.0 . 41.6 
T//'1' 14.42 1 5.82 
1.59 
[0.34] 10.20 1 
TABLE 4.9. Genotype and allele frequency of rs10410544 polymorphism in S/RT2 
gene in the replication study. 
Combining the initial and replication case-control populations, so as to increase the sample 
size, we again found a significant difference in the allele frequency of SIRT2 rs10410544 
between AD and CT (table 4.10). Here the T-allele carriers of SIRT2 rs10410544 had an 
OR of 1.20 (95% CI 1.01-1.41, p= 0.03). We corrected the raw OR liar gender. age and 
APOE F4 allele, and we found that the association between SIRT2 rs10410544 T allele and 
AD was confirmed OR= 1.23 (95% Cl 1.02-1.5, p= 0.02). 
%% 
SIRT2 
rs10410544 
, 
X 0/ 
/0 
0/ 
/0 
x2 
Genotype genotype genotype 
]P- 
Allele allele allele 
]p- 
value] value] CT AD CT AD 
df=2 df=l 
C//C 
C HT 
37.22 32.00 T 61.5 57.2 
4.7 
- --- I ._ý -- _- ----- 
4.6 
48.72 50.48 C -- 38.4 42.71 
T//T 14.06 1 17.52 
[0.09] 
-'ý 
[0.03 1 
TABLE 4.10. Genotype and allele frequency of rs10410544 polymorphism in SIRT2 
in the two studies combined. 
Stratifying the SIRT2 rs10410544 data by APOE c4 status, the association between 
rs10410544 T allele and AD was present in APOE c4 non-carriers only (df= 1, APOE c4 
non-carriers x2= 5.78, p= 0.01; APOE c4 carriers x2= 0.70, p= 0.39) (table 4.11). 
Furthermore, among AD lacking APOE c4 allele, SIRT2 rs10410544 T allele carriers had a 
higher risk of developing AD of - 1.3 in comparison to C allele carriers (OR= 1.29,95% 
CI 1.04-1.59, p= 0.01) - even higher than in the total unstratified AD sample. 
SIRT2 I APOE E4 -I APOE E4 + 
rs10410544 
Allele 
C 
T 
CNT AD 72 (p-value) 
OR [95°/o CIi 
61.4 55 .2 
38.5 
5.78 (0.01) 
CNT AD x2 (p-value) 
('/1) (%) OR [95% ci1 
62.0 58.4 0.7 (0.39) 
I )orina_i54i1 
i 
44.7 .. " ý.. ..., 1 37.9 41.5 1.16 [0.81-1.65] 
TABLE 4.11. Allele frequency of rs10410544 polymorphism in APOE E4- and *4+ 
carriers in the two studies combined. 
4.3.6. EXPRESSION QUANTITATIVE TRAIT LOCUS ANALYSIS 
To highlight a potential functional role for rs10410544 SNP, it was assessed whether this 
variant could regulate the transcript levels of other genes. Taking advantage of a public 
available eQTL browser, rs 10410544 SNP was found to regulate in cis the transcript levels 
of the mitochondrial seryl-tRNA synthethase (SARS2) (score = 6.28) in lymphoblastoid 
cell lines from the HapMap CEU population (60 unrelated Utah residents with ancestry 
from Northern and Western Europe) (Stranger et al., 2005). 
4.4. DISCUSSION 
We performed a case-control association study to assess the impact of sirtuin common 
polymorphisms on LOAD risk. We adopted a tagSNP approach, which is a powerful and 
cost effective method to measure genetic variation within gene regions with high LD 
(Stram, 2004). Overall, our approach was useful to reduce the number of SNPs that needed 
to be tested without it detrimentally effecting having a good level of coverage of sirtuin 
gene variation. 
This approach did miss some regions with low LD and\or variants with low minor allele 
frequency (MAF). Interestingly, in accordance with data reported in dbSNP database from 
NCBI, SIRT7 was found to be monomorphic for all of the variants studied. In contrast to 
SIRT7, we confirmed the strong LD of SIRTI, where the variation could be summarized by 
a single SNP (e. g in our case rs7896005). Also SIRT6 revealed a unique LD block in our 
sample population. This LD block was not revealed querying I-lapMap tagSNP browser, 
since we set the minor allele frequency (MAF) cut off at 0.2, and SIRT6 SNPs all have a 
MAF of about 0.1. 
Based on previously reported GWAs, the identification of any genetic susceptibility factors 
was not expected to yield an OR greater than 1.5 for AD (Ku et al., 2010). Thus, this study 
was powered so as to highlight even weak associations between the SNPs investigated and 
AD which might have an OR- 1.3). In this, we were able to confirm the association 
between AD and APOE c4 allele, already reported in literature also for the Italian 
population (Scacchi et al., 1999; Sorbi et al., 1994). Moreover, we found a lack of 
association between SIRTI variation and AD, as previously reported (Morgan et al., 2007; 
Helisalmi et al., 2008). Also we did not reproduce the gender-based association found by 
Helisalmi et al., between rs2273773 SNP (included in our study) and AD in the subgroup 
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of women older than 65 years. The lack of association in our sample suggests that the 
result reported in the previous work, as also argued by the author, may have been a false 
positive association due to stratification by gender and age. Indeed, applying the 
Bonferroni correction for the number of tests performed, the association reported was lost 
(Helisalmi et al., 2008). 
Unlike SIRTI, the other sirtuins have been less studied in the context of AD. However, 
emerging data are highlighting the role of sirtuins in neurodegenerative diseases. For the 
first time, we investigated the potential impact of SNPs in the SIRT2-7 genes in modulating 
AD susceptibility. We found evidence of a new association between rs10410544 SNP in 
SIRT2 and AD in a population with Caucasian ancestors. This association was found in the 
initial case-control study with marginal statistical significance (p= 0.05). Although not 
confirmed in the separate replication analysis, the association was again present and 
stronger after combining the two study samples. The combination was possible because the 
two sample sets were geographically related. The post hoc analysis revealed that our 
sample size, in both studies separately, had a power of about 0.65 to detect associations 
with an OR around 1.2. Instead, combining the two studies we had a power higher than 
0.90 to find the reported association. This could explain why we did not find the 
association in the replication study. 
Overall, even if with a small effect size, allele T of the rs10410544 SNP might contribute 
to explain a percentage of SAD susceptibility. The small risk modulation identified (OR 
1.2) is consistent with previously reported data suggesting that, apart from APOE c4, only 
associations with this magnitude are likely to be discovered in relation to AD. However, it 
is possible that our finding is a statistical false positive. Indeed, the observed association 
would not survive the Bonferroni's correction for multiple testing particularly given the 
current sample size. Furthermore, this eventuality is supported by the lack of any 
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associations between AD and the SNPs near SIRT2 in a number of recent large GWAs. 
Otherwise, another reason why this association was not found in previous GWAs could 
depend on the fact that, despite thousands of samples, the GWAs are still underpowered to 
identify OR of this entity. Moreover, since this polymorphism does not lie in a conserved 
LD block, it is not represented in several commercial arrays (e. g. Illumina 500 K). 
However, imputation methods and GWAs meta-analysis studies are overcoming these 
limitations. 
Noteworthy, this novel association does not arise from a false positive association due to 
an higher prevalence of APOE E4 in the case group since the association was still present 
in APOE E4 non-carrier subjects after stratification. Moreover, the association was not 
present in APOE E4 carriers. This feature could be of interest in depicting a genetic risk 
profile in APOE e4 non-carrier subjects, where no evident genetic factors are playing a 
predisposing role. Another explanation is that the sample size in APOE f: 4 subjects is not 
sufficient to highlight the association. 
SIRT2 rs10410544 is an intronic variant, so whether it has a functional role is difficult to 
interpret. For example, in several cases, intronic variants could have a functional 
importance because their location may coincide with some regulatory elements (Wang et 
al., 2008), either already known or yet to be characterized, such as enhancers, insulators, 
transcription factor binding sites and sequences encoding for microRNA. To assess 
whether this intronic region might modulate the transcription rate of other genes, we 
queried an eQTL browser and we found that rs10410544 SNP is an eQTL acting in cis for 
SARS2 gene, in the HapMap-CEU population (Stranger et al., 2005). This evidence is not 
easily linkable to AD, since SARS2 gene encodes the mitochondrial seryl-tRNA 
synthethase. However, it was recently reported that a homozygous coding point mutation 
in SARS2 (Asp390Gly) was responsible for a severe multisystemic mitochondrial 
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cytopathy of infancy, so this gene has a pathogenic potential that in the context of aging 
might lead to different clinical syndromes (Belostotsky et al., 2011). Nonetheless, for now 
given this data, SIRT2 rs10410544 SNP could mediate effects over the transcription levels 
of other not yet investigated genes. Alternatively, and perhaps more likely, since we 
selected this SNP guided by LD information, this SNP could be the surrogate marker 
tagging for a more relevant variant that is important in AD. 
In summary, we found no differences in gene variations in the SIRTI and SIR7s 3-7 
between AD and CT to support any roles of their corresponding proteins in the 
pathogenesis of AD. However we found evidence of a new association that deserves more 
attention and independent replications. This association, which links SIRT2 and AD, may 
help clarify some of the molecular mechanisms underlying AD etiology. 
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SECTION B: IN VIVO STUDIES 
CHAPTER 5: ENVIRONMENTAL 
ENRICHMENT IN APP23 MOUSE 
MODEL OF ALZHEIMER'S DISEASE 
SECTION B: BACKGROUND 
I. Mouse models of AD 
Given the high prevalence and poor prognosis of the AD, the development of animal 
models that mimic certain aspects of the disease has been a research priority to understand 
AD-like pathogenic mechanisms and to develop and test therapeutic strategies (Götz and 
Ittner, 2008). 
The majority of transgenic mouse models of AD were generated based on information 
gathered from familial forms of the disease, which is far less common than sporadic 
disease and which is largely indistinguishable from a clinical and histopathological point of 
view. At the present time, transgenic models overexpressing the amyloid precursor protein 
(APP) and/or presenilins (PSEN], PSEN2) harbouring one or more mutations that have 
been found in familial AD are available (table 5.1). These mice develop age-dependent 
AD-like pathology including amyloid deposits in the brain parenchyma. However, these 
models fail to develop detectable NFTs and consistent neuronal loss (Götz and loner, 
2008). On the other hand, mouse models expressing human Microtubule-Associated 
Protein Tau (MAPT) gene with mutations found in FTD (Ballatore et al., 2007) develop 
both neurofibrillary tangles and neuronal loss in the absence of amyloid plaques. Triple 
transgenic model (3xTg-AD), harbouring three mutated transgenes: PSENI (M146V), APP 
(K670M/N671L) and MAPT (P301 L), have been generated trying to recapitulate both 
amyloid and tangle-related features. This model accumulates intraneuronal Al and 
subsequently forms amyloid plaques and MAPT lesions in an age-dependent fashion. 
These mice also develop age-dependent synaptic dysfunctions, including long-term 
potentiation deficits and memory deficits that correlate with the accumulation of 
intraneuronal Aß (Oddo et al., 2003). However, these mice do not recapitulate all human 
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AD traits, for example they do not display neuronal loss and more recently the models 
have not been shown to be as reliable as previously suggested (Ferrington et al., 2011). 
Altogether the current mouse models, although not fully replicating the whole spectrum of 
AD-like pathologies, have provided valuable insights into disease mechanisms as well as 
opportunities to test therapeutic approaches. 
Hyperphos- Neurofi- 
Mouse Intraneuronal Parenchymal phorylated brillary Neuronal Synaptic 
model Gene (mutation) AP Aß plaques Tau tangles loss loss CAA 
PDAPP APP (V717F) 
Tg2576 APP (K670N1M671 L) 
TgCRND8 APP (K670N/M671L, V717F) 
APP/PS1 APP (K670WM671L), 
PS1 M146L 
APP23 APP (K670NrM671 L) 
Yes Yes No No Yes 
Yes Yes -- No No 
Yes - No No - 
Yes ---- 
Yes Yes No Little Yes Yes 
Tg-SwDI APP (E693Q, D694N) - Yes 
APPDutch APP (E693Q) - Little 
APPDutchIPS1 APP (E693Q), Yes 
PSI(G384A) 
hAPP-Arc APP (E693G, K670WM6711. - Yes 
V717F) 
Tg-ArcSwe APP (E693G, K670N/M671L) Yes Yes 
APPArc APP (E693G) - Yes 
TAPP APP (K670WM671 L), - Yes - Yes 
Tau (P301 U 
3xTg-AD APP (K670WM671L), Yes Yes Yes Yes - No 
Tau (P301 L), 
P51 (M146V) 
APP, /P51 APP (K670WM6711, V7171), Yes Yes 
P51 (M146L) 
APP/P51Ki APP (K670N+M671L, V7171), Yes Yes 
P51 (M233T/L235P) 
Yes Yes 
Yes Yes 
5xFAD APP (K670t*M671 L 1716V, Yes Yes - Yes Yes 
V7171), 
PSI (M146UL286V) 
Yes 
Yes 
Little 
Little 
Yes 
Yes 
TABLE 5.1. Neuropathological features of the main transgenic mouse models of AD. 
Table from (Schaeffer et al., 2011). 
Dash (-) = not reported. 
In the black box the human-like AD neuropathological features of APP23 (the 
experimental model used in this thesis) are highlighted 
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II. Environmental enrichment in AD 
The current lack of preventative and long term-acting therapies for AD provides a strong 
incentive for the ongoing search for more effective interventions. Besides the large amount 
of studies assessing novel `disease-modifying' drugs, the efficacy of non-pharmacological 
treatments in delaying or preventing the onset of AD is also being examined. Non- 
pharmacological treatments are supported from epidemiological evidence that several 
lifestyle habits are risk factors for AD (diet, sedentary lifestyle, etc. ). In contrast, people 
who have an healthy lifestyle (e. g. increased physical, mental and social activity) are less 
likely to develop an age-related dementia in later life (Abbott et al., 2004; Weuve et al., 
2004; Friedland et al., 2001; Wilson et al., 2002). 
Some lifestyle habits can be reproduced to some extent in the laboratory with animal 
models to allow more careful study. Housing mice in larger cages equipped with different 
interactive objects (i. e. tunnels, nesting material, toys and running wheels) is reported to 
enhance sensory, cognitive, motor and social stimulation with respect to standard housing 
conditions (van Praag et al., 2000). During the last decade, a large number of studies using 
transgenic mouse models of neurodegenerative disorders have strongly supported the 
beneficial effect of an enriched environment (Nithianantharajah and Hannan, 2006). 
In AD mouse models, the "Environmental Enrichment" paradigm (EE) was shown to 
impact a variety of processes related to AD pathogenesis. For example, EE altered the 
enzymatic activity of the Aß-degrading endopeptidase, neprilysin (Lazarov et al., 2005), 
decreased Aß1-42/Aß1-40 ratio (Mirochnic et al., 2009), altered expression of genes 
related to Aß sequestration (Costa et al., 2007), and Aß receptor/transporter molecules 
(Herring et al., 2008). Furthermore, EE was recently shown to induce changes in levels of 
hyperphosphorylated tau and oligomeric Aß, the precursors of hallmark plaques and NFTs 
(Hu et al., 2010). 
Moreover, EE was shown to increase the expression of neurotrophic factors, such as 
BDNF and NT-3 (Wolf et at., 2006; Berardi et al., 2007). growth factors, such as NGF 
(Levi et al., 2003; Berardi et al., 2007), increased synaptic proteins (Cracchiolo et al., 
2007; Levi et al., 2003) and expression of various molecules associated with synaptic 
plasticity, neurogenesis, dendritic branching and axonal transport (Costa et al., 2007; 
Herring et al., 2009; Hu et al., 2010). 
However, some controversial points still remain. In fact, varying outcomes have been 
reported for EE depending on the AD-like mouse model, the age of the mice, the duration 
of exposure and the type of the intervention used (Nithianantharajah and Hannan, 2006). 
For example, EE has been shown in different studies to have opposing and even null 
effects on Aß plaque related pathology (Lazarov et al., 2005) (Arendash et al., 2004) 
(Jankowsky et al., 2003). Moreover, different effects of EE on mice cognitive performance 
have been observed: some studies have shown improvements (Levi et al., 2003) and others 
have reported no change (Görtz et al., 2008). 
Finally, controversial results were reported about EE-induced cellular plasticity and 
neurogenesis. In some cases, EE was shown to effectively increase proliferation and/or the 
number of mature new-born hippocampal neurons (Wolf et al., 2006; Herring et al., 2009; 
Mirochnic et al., 2009; Hu et al., 2010). Others have shown that while enrichment can 
increase the rate of neural progenitor proliferation, it does not affect an impairment in 
survival of neural progenitor cells, thus resulting in fewer new neurons being generated in 
the hippocampus of AD mouse models (Wen et al., 2004; Catlow et al., 2009). In contrast, 
there is also evidence for a lack of hippocampal plasticity and deficiency in enrichment- 
induced proliferation (Choi et al., 2008) and/or neurogenesis in the dentate gyrus (Cotel et 
al., 2010). 
Overall, EE is an attractive and promising approach that may provide therapeutic benefits 
and as such deserves more attention and further investigations. 
III. Sirtuin involvement in environmental paradigms. 
Sirtuins have an important role in modulating metabolic processes in response to 
environmental changes. Sirtuins have been related largely to calorie restriction (CR), a 
protocol already proved to be beneficial in counteracting ageing and age-related diseases 
[topic of chapter 1.2.2.1. ]. More recently, there as been growing evidence that this protein 
family is implicated in physical activity (PA). Exercise slows the deleterious effects of 
ageing in rats by increasing SIRTI levels and activity in skeletal muscle (Suwa et al., 
2008; Koltai et al., 2010) and heart (Ferrara et al., 2008). Moreover, PA was also shown to 
reduces SIRT6 levels in rat muscles (Koltai et al., 2010). Furthermore, endurance exercise 
in humans counteracted observed decreases in SIRT3 levels in muscle tissue from aged 
people with a sedentary lifestyle (Lanza et al., 2008). However, despite the suggested 
beneficial effects to the brain observed with environmental paradigm, few studies have 
analysed the level of sirtuins in the brain tissue after exposure to external stimula such as 
CR and PA (Kelly, 2010; Steiner et al., 2011). It is noteworthy that environmental 
paradigms such as CR, PA and EE were proposed to share common pathways able to 
counteract ageing and age-related diseases (Mattson et al., 2002). 
5.1. SYNOPSIS 
The overall aim of the work presented in this chapter was to set up a protocol of long 
lasting environmental enrichment (EE) in adult mice and assess whether this protocol was 
able to counteract the cognitive decline and the progressive pathological changes that 
normally occur in APP23 AD-like mouse model. In this context, the involvement of 
sirtuins was investigated by assessing mRNA and protein levels. 
To achieve these goals, APP23 TG mice were moved to EE cages (TG-EEs) starting form 
2-3 months of age. TG-EEs were compared to TG mice housed in standard cages (TG- 
SHs) and wild-type littermates in the two housing conditions (WT-EEs and WT-SHs) were 
also included as reference groups. At 6-7 months of age mice were tested for behavioural 
performance with Morris Water Maze (MWM) and visual Object Recognition Test 
(vORT) and then sacrificed at 8 months of age for biochemical analyses (8-10 mice per 
group) or at 18 months of age for plaque load assessment (4 mice per group). 
At 6-7 months TG-SHs displayed an impaired behavioural performance in Morris Water 
Maze (MWM) test and visual Object Recognition Test (vORT) which reflected disturbance 
to spatial and recognition memory, respectively. EE was able to significantly restore mice 
behavioural performance in the TG mice. Moreover EE, although not affecting the 
expression of total soluble APP and its processing in 8-month-old mice, partially 
counteracted Aß deposition in 18-month-old TG mice. In contrast, Aß production was 
apparently not affected by EE. Finally, the application of an EE protocol did not modulate 
sirtuin mRNA and protein levels nor in WT neither in TG mice. 
5.2. MATERIALS AND METHODS 
5.2.1. EXPERIMENTAL SCHEME 
All the experiments presented in this chapter were performed on heterozygous male APP23 
mice and male wild-type littermates. Four groups were defined (n = 12-14 mice per group): 
TG housed in standard condition (TG-SHs), TG housed in enriched cages (TG-EEs), WT 
in standard cages (WT-SHs) and WT enriched cages (WT-EEs). 
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Behavioral APP metabolism 
tests sirtuin levels 
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Plaque load 
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Cognitive 
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FIGURE 5.1. Experimental scheme of the adopted environmental enrichment 
protocol. 
Mice were weaned at I month of age and housed in standard cages. At 2-3 months of'age, 
mice were randomly assigned to either enriched or standard cages. Enrichment lasted till 
the end of the experiment. Mice were assessed. 1br behavioural performance at 6-7 months 
of age and then sacrificed for biochemical analysis n= 8-10. Another group was carried on 
till 18 months to assess plaque load n= 4. 
- 174- 
5.2.2. STATISTICAL ANALYSIS 
All the analyses reported in this chapter were performed with GraphPad Prism`"' v. 5.0. 
The acquisition session in MWM test was analysed using a repeated measures two-way 
ANOVA with groups as between-subjects factor and trials as within subjects factor 
followed by Bonferroni's post hoc test. 
MWM probe trial, vORT exploration time and discrimination indexes, BDNF mRNA, and 
sirtuin mRNA and protein levels were analysed using a two-way ANOVA with genotype 
as between-subjects factor and housing condition as within subjects factor followed by 
Bonferroni's post hoc test. To directly compare TG-SHs and TG-EEs performance one- 
way ANOVA was adopted followed by Tukey's post hoc test. 
TG-SHs and TG-EEs were directly compared with Student's t-test for all the parameters 
assessed concerning APP metabolism. 
Two-tailed levels of significance were used in all the above mentioned analyses and 
P<0.05 was considered statistically significant. 
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5.3. RESULTS 
5.3.1. EFFECT OF ENVIRONMENTAL ENRICHMENT ON BEHAVIORAL, 
PERFORMANCE 
To investigate whether TG mice behavioural performance compared to the WT counterpart 
was influenced by EE, 6/7-month-old mice housed for4 months in Sl-1 or II cages were 
tested with Morris Water Maze (MWM) and visual Object Recognition 'rest (vOR'T). 
5.3.1.1. Morris Water Maze 
During the acquisition phase of the MWM experiment, the escape latencies of the trained 
mice decreased as a function of the number of days of training (Fdly`(di__9.4XW- 9.99, P. 
0.0001; two-way RM-ANOVA). The statistical analysis showed a significant difference 
between the four experimental groups assessed (Fgroups (ar= 3,480) 9.03, P< 0.000 1, two-way 
RM-ANOVA). Globally all groups improved their performance as a function of days of' 
training. Indeed, no statistically significant interaction effect was visible (days of'training x 
groups: First (df= 27,480)= 0.62, p= 0.93; two-way RM-ANOVA). However, T(; -Sits mice 
performed worse in MWM training task compared to WT-SHs mice at each day of training 
(cfr. figure 5.2. ). This visible tendency reached the statistical significance only at day 6 (P< 
0.05; Bonferroni's post hoc test). Conversely, TG-EEs performed more similarly to W'1' 
mice, although never reaching statistically significant differences compared to T(i-SI-Is. 
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FIGURE 5.2. MWM learning curves. 
Escape latency of 6/7-month-old WT-SHs, WT-EEs, TG-SHs and TG-EEs during days c? f 
training. Each data point represents mean (f SEM) summed results of'. fiour daily trials. 
*p< 0.05 TG-SHs vs WT-SHs; Bonferroni 's post hoc test. 
During the probe trial at day 11,24 h after the last training session, the percentage of' time 
spent in the target quadrant was influenced both by genotype and housing condition 
(Fgenotypc (df= 1,32)= 12.79, P< 0.01 and Fhousing (dam 1,32)= 4.17, P< 0.05; two-way ANOVA). 
Moreover, two-way ANOVA showed that genotype effect on escape latency was 
influenced by housing condition (F; nt(dr (, 32)= 4.17, p< 0.05; two-way ANOVA). Indeed, as 
shown in figure 5.3 TG-SHs mice spent less time in the correct quadrant than W'I'-SI Is (P< 
0.001 TG-SHs vs WT-SHs; Bonferroni's post hoc test) while no significant dit'fcrcncc was 
visible between TG-EEs and WT-EEs (n. s. TG-EEs vs WT-EEs; Bonferroni's post hoc 
test). Moreover, Tukey's post hoc test revealed a significant difference between 'FG-SIIs 
and TG-EEs (P< 0.05 Tukey's post hoc test). 
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FIGURE 5.3. MWM test probe. 
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Proportion of time spent in the target quadrant by 6/7-month-old WT-SHs, WT-EEs, TG- 
SHs and TG-EEs during MWM test probe with 24 h retention time. Bar graph indicates 
mean ± SEM. P< 0.001 TG-SHs vs WT-SHs;. ns. TG-EEs vs WT-EEs; Bonferroni 'S pose 
hoc test. 
5.3.1.2. Obiect Recognition Test (vORT) 
During the training trial (familiarization phase) of vORT, the total exploration time was not 
affected either by genotype and housing condition nor by the interaction of the two 
parameters (Fgenotype (df= 1,32) 0.24, P> 0.05; Fhousing (df 1,32)- 0.01, P> 0.05; and (d, 1,32 
0.01, P> 0.05; Two-way ANOVA; figure 5.4). 
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FIGURE 5.4. Exploration time in the training trial 
Total time spent exploring the two identical objects. Bar graph indicates mean A- SEM. 
In the familiarization phase none of the experimental group exhibited a preference in 
exploring one of the identical objects revealed by the discrimination index (Fgcnotypc (df= 
32)= 0.05, P> 0.05; Fhousing (df 1.32)= 0.05, P> 0.05; and F; nt (dr= l. 32)= 2.01; P> 0.05; Two- 
way ANOVA; figure 5.5). 
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FIGURE 5.5. Discrimination Index in the familiarization phase 
The discrimination index was measured as the time spent exploring the let ohlecl ºninus 
the right object divided for the total exploration time. Bar graph indicates mean -. ' SEM. 
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In the test probe assessing long-term memory (24 h retention time), the four groups 
exhibited different time exploring the two different objects. A discrimination index (DI) 
was calculated as the difference in time exploring the novel object and the familiar one, 
expressed as the ratio of the total time spent exploring the two objects. Both genotype and 
housing condition influenced this discrimination index (Fgenotype (df= 1.32)= 16.23; P< 0.001, 
Fhousing (df= 1,32)= 4.31; P< 0.05; two-way ANOVA). Genotype x housing interaction was 
only marginally significant (Fins (dF 1,32)= 394; p= 0.055). However, post hoc analysis 
revealed that TG-SHs mice had a DI lower than WT-SHs (P< 0.001 TG-SHs vs WI'-SI Is; 
Bonferroni's post hoc test) while no significant difference was visible between TG-EEs 
and WT-EEs (n. s. TG-EEs vs WT-EEs; Bonferroni's post hoc test). Moreover, Tukey's 
post hoc test revealed a significant difference between TG-SHs and TG-EEs (P< 0.05). 
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FIGURE 5.6. Discrimination Index in the probe test 
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Long-term (24 h) discrimination index. for the novel object in 8 month-old mice. But. graph 
indicates mean + SEM. P< 0.001 TG-SHS vs WT-SA; ns= not significant. 7G-El ,. ', v i's 
WT-EEs; Bonferroni s post hoc test. 
5.3.2. BDNF mRNA LEVELS 
BDNF mRNA levels were investigated to verify the effectiveness of the adopted FT', 
protocol since a large body of evidence show that environmental paradigms like EE and 
PA increase BDNF levels (Neeper et al., 1996; Wolf et al., 2006). 
In 8-month-old mice no effect of genotype on BDNF was found both in hippocampus (hp) 
and cortex (cx) (Fhpgenotype (ate 1,32)= 0.04, P> 0.05; Fexgenotype (dt= 1,32) 0.00, P> 0.05). 
Conversely, EE increased BDNF levels as shown in figure 5.7 for these brain areas. The 
EE effect was highly significant in the cortex as revealed by two-way ANOVA (Fcx housing 
(dt= 1,32)= 12.88, P< 0.01; FhPhousing (df= 1,32)= 6.64, p<0.05). Noteworthy, there was no 
evidence of an interaction between EE and genotype which influenced either hippocampal 
or cortical BDNF levels (Fhpgenotype (dam 1,32)= 0.01, P> 0.05; Fcxgenotype (dt= 1,32)= 0. W, P> 
0.05). 
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Murine BDNF mRNA levels in A. hippocampus and B. cortex o1' 8-month-old mice were 
assessed by RT-PCR referring to a-actin as endogenous gene. The results are reported as 
mean fold change vs WT-SHs and are represented as mean + SEM. 
5.3.3. APP METABOLISM 
5.3.3.1 Total APP levels and APP processing 
At 8 months, TG mice showed an overexpression of total APP compared to WT mice in 
hippocampus and cortex, revealed by WB using 22C 11 antibody which recognizes both 
human and murine APP. The increased levels of APP in both brain regions of TG mice 
were not influenced by EE (P> 0.05 TG-SHs vs TG-EEs, Student's t-test). 
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FIGURE 5.8. Full length APP protein levels 
APP protein levels in A. hippocampus and B. cortex o1'8-month-old mice assessed by WB 
with 22011 antibody normalized for murine a-tubulin. The related densitometric 
quantifications are shown below. The results are expressed using TG-SIIs as reference 
group f set at 1, arbitrary units (A U)] and are represented as mean :I SEM. 
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To investigate whether EE could affect APP cleavage by a-secretase, the enrichment in a- 
APP was assessed in hippocampal and cortical brain lysates by WB using 6E10 antibody, 
whose epitope is not present in the sAPPl fragment released after (3-secretase cleavage 
(Qin et al., 2006b). In parallel to the overexpression of full length APP, TG mice also 
showed the overproduction of soluble a-APP compared to WT mice. EE did not affect a- 
APP levels in TG mice both in the hippocampus and cortex (p> 0.05, Student's t-test). 
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a-APP protein levels in A. hippocampus and B. cortex of 8-month-old mice assessed by 
WB with 6E10 antibody normalized for full length APP stained with 22('I1 antibody. The 
related densitometric quantifications are shown in the histogram below. The results are 
expressed using TG-SHs as reference group [set at 1, arbitrary units (A U)/ and are 
represented as mean + SEM. 
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To assess whether EE could affect the production of A040 and A042 peptides by 0- and y- 
secretases, Aß40 and Aß42 were measured in hippocampal and cortical lysates from 8- 
month-old TG mice by ELISA assays. No difference was visible comparing 'I'G-SHs and 
TG-EEs either measuring A040 and Aß42 or Aß42/ Aß40 ratio. 
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FIGURE 5.10. Hippocampal and cortical Aß42, Aß40 and Aß42/Aß40 ratio 
Hippocampal and cortical A. Aß42. B. A/3-I0 and C. Aß42/A/340 ratio of 8-month-old TG 
mice housed in SH or EE conditions measured by ELISA assay. Results are expressed as 
pg of peptide/pg of total proteins assessed by BCA protein quantification ± SEM. 
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5.3.3.2. All olij'omer formation 
To address whether EE could modulate the production of Aß oligomers, hippocampal and 
cortical lysates from 8-month-old TG mice were analysed by Slot Blot with A 11 antibody. 
TG mice showed an intense staining with All antibody revealing the presence of 
oligomeric species. EE did not significantly counteract Aß oligomer production. However, 
although not reaching the statisical significance, a small decrease in A 11 signal was 
registered for cortical lysates (p= 0.15). 
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5.3.3.3. Plaque load in 18-month-old APP23 mice 
To investigate whether EE could counteract A(3 extracellular deposition in plaques, sagittal 
brain section from 18-month-old WT and TG mice were stained with 6E10 antibody. A 
consistent number of plaques was evident in several brain areas of TG mice, including 
neocortex and hippocampus while plaques were absent in the WT littermates of the same 
age. Notably, a reduction of plaque number and total area covered by plaques was 
registered in TG-EEs compared to TG-SHs mice. 
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FIGURE 5.12. AP plaques in 18-month-old mice. 
immunohistochemistry with DAB using 6E10 antibody on sagittal brain slices. Plaques 
were counted in cortex and hippocampus and the area covered by them was quantified. 
Results are espressed as the percentage of TG-SHs ± SEM. *P< 0.05, Student t-test. 
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5.3.4. SIRTUINS LEVELS IN THE BRAIN OF APP23 MICE 
The expression of all 7 SIRT genes was evaluated in adult WT mouse brain by 
comparative RT-PCR measuring the ACt values relative to that for murine a-actin. The 
result revealed interesting differences of expression between the 7 SIRT genes in mouse 
brain. In particular, SIRT2 is the sirtuin with the highest expression in adult mouse brain, 
while SIRT4 has the lowest expression level. Finally, the expression profile of the 7 SIRT 
genes was quite similar in hippocampus and cortex given the exception of SIRT3 gene that 
is more expressed in the cortex compared to the hippocampus (ACthp-ACtcx= 1.5). 
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FIGURE 5.13. Relative expression of the murin SIRT genes in mouse brain. 
Hippocampus and cortex from 8-month-old WT mice were examined. /in- the expression of 
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5.3.5. EXPRESSION OF SIRT GENES AND PROTEINS IN APP23 MICE UNDER 
ENVIRONMENTAL ENRICHMENT 
To evaluate whether the expression of SIRT genes were influenced by the presence of the 
transgene in APP23 mice, or by EE or by the interaction of the two factors, the expression 
of SIRT genes was investigated in 8-month-old mice belonging to WT-SHs, W'l'-l. EIs, 'I'(i- 
SHs and TG-EEs groups by comparative RT-PCR. Overall, no significant differences were 
observed comparing the four groups by two-way ANOVA either in the hippocampus and 
the cortex. 
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FIGURE 5.14. Expression of SIRT genes under EE in API'23 mice. 
Hippocampus and cortex from 8-month-old WT mice were examined for the expression of 
the 7 SIRT genes by the comparative RT-PCR assay in hppocampus and cortex. Data were 
normalized on the murine endogenous gene a-ACTIN and W7-S//s group was used as 
calibrator. Results are expressed ± SEM. 
To explore whether there were any post-translational effects, sirtuin protein levels were 
also assessed by WB. In particular, SIRT1 and SIRT2 showed multi-bands corresponding 
to different isoforms and these were quantified together (figure 5.15) and separately (not 
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shown). Similarly to mRNA levels, no significant differences were observed comparing 
the SIRT protein levels in the four animal groups by two-way ANOVA either in the 
hippocampus and the cortex. 
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FIGURE 5.15. Expression of Sirt proteins under EE in APP23 mice. 
Sirt protein levels in A. hippocampus and B. cortex of 8-month-old mice assessed by Wl3 
normalized for a-tubulin. The related densitometric quantifications are shown helow. The 
results are expressed using WT-SHs as reference group and are represented as mean i 
SEM. 
5.4. DISCUSSION 
The work described in this chapter describes the application of an EE protocol to test 
whether this paradigm could ameliorate AD-like pathology in the APP23 mouse model. 
An EE protocol with an early onset, similarly to Lazarov et al. was employed (Lazarov et 
al., 2005), mimicking a preventative rather than a therapeutic protocol in TG mice. 
Transgenic mice and their wild-type littermates were assigned to EE (TG-111s and Wi - 
EEs) or left in standard housing (TG-SHs and WT-SHs) at 2-3 months of age until they 
were sacrificed. EE mice were housed in cages that were double the dimension of the 
standard ones. This larger size was required because of the space occupied by the objects. 
Furthermore, both EE and SH mice were all caged in groups of 3-4 mice to avoid 
differences due to social interactions. 
In these experiments only male mice were used. No increase in aggressiveness measured 
by the number of wounds was registererd. Our result, supported by other groups (l. azarov 
et al., 2005), is in contrast with some reports suggesting that EE in males increases 
territorial behaviour causing stress for subordinate animals and resulting in an increased 
variability and stress as a confounding variable (Mirochnic et al., 2009). 
The APP23 mouse model was chosen since it reflected several aspects of AD pathology 
and it was characterised by a slow onset and course of the disease. Indeed, it has been 
argued that EE is not able to counteract pathological manifestations in more severe models, 
such as APP/PS 1 KI (Cotel et al., 2010). 
Effect of EE on cognitive function 
After 4 months of EE, mice were tested with two different behavioural tests: MWM and 
vORT. At this stage, APP23 mice already display cognitive impairment in performing 
MWM task (Van Dam et al., 2003). MWM allows the testing of both learning and 
memory, two features affected in human AD patients. Learning, or memory acquisition, is 
reflected in escape latency curves, whereas a probe trial is used to assess storage and 
retrieval after 24 h retention time. Mice were trained for the MWM task for ten days with 
four-trials on each day and escape latencies recorded. During the acquisition phase of the 
MWM experiment, all mice improved their performance in reaching the hidden platform. 
TG-SHs showed the worst learning curve, registering higher escape latencies at each day 
of training. However, only at day 6 the performance of TG-SHs was signiticantly different 
from WT-SHs. Moreover, despite the apparent trends, TG-SHs and 'FG-EEs pertiormanecs 
were never significantly different. The presence of a learning deficit in T6-Slls was 
confirmed during the probe trial, as TG-SHs spent significantly less time in the target 
quadrant than WT-SHs did. Moreover EE significantly recovered mice from learning 
impairment registered at 24 h from the last training section. 
vORT revealed a long-term recognition memory impairment in 'I'G-SHs. This contrasted 
with WT-SHs who showed a net preference for the novel object, TG-SlIs were not able to 
discriminate between the novel and the familiar object [i. e. Descrimination Index (DI) -= 01. 
The EE paradigm counteracted this impairment. Indeed, TG-EEs showed a IN for tile 
novel object not statistically different from their wild-type counterpart. 
preference for the novel object relied on a difference in long-term memory retention. 
Indeed, as revealed in the familiarization phase of vORT task, the training paradigm did 
not introduce any artifactual bias (e. g. due to a preference in the object position within the 
arena). Moreover, the restored performance in TG-EEs was not the result of a different 
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exploration habit of mice housed in enriched conditions. Indeed, total exploration time in 
the familiarization phase was similar in the four experimental groups. 
Overall, MWM and vORT revealed that cognitive impairment in 'IG mice can be reversed 
by exposing mice to an enriched environment. Conversely, EE paradigm did not improve 
learning and memory performance in WT mice revealed with this test. 
Effects of EE on gene transcription and AD-like hallmarks in APP23 
The EE paradigm, similar to physical stimulation, was shown to increase BDNF mRNA 
levels in different experimental AD-like mouse model including APP23 (Wolf' et al.. 
2006). In the present study, BDNF mRNA level was assessed in the hippocampus and 
cortex of the 8-month-old mice previously tested with the behavioural test battery. 'l i-SI Is 
had stable BDNF levels compared to WT-SHs. This result, already reported in literature 
(Wolf et al., 2006) is different to what has been observed in other AD-like mouse models 
(e. g. CRND8 (Peng et al., 2009)) where a decreased BDNF level in TG mice was linked to 
synaptic and cellular loss. In APP23, EE increased BDNF mRNA levels in a genotype- 
independent manner. This result, in line with previously published data (Wol C et al., 2006), 
further confirmed the effect of the adopted EE protocol. Moreover, the increased 13DN l 
mRNA levels observed in WT-EEs also highlighted the effectiveness of FE protocol in 
WT mice, even if no improvement in behavioural performance was registered with 
behavioural tests. 
The memory impairment observed in APP23 TG mice is related to the appearance of Al) 
hallmarks in the cortex and hippocampus (Sturchler-Pierrat et al., 1997). The ability of la: 
to reverse cognitive imparment in TG mice could therefore possibly affect these biological 
markers. APP23 mice are characterised by a 7-fold increase in APP levels, and this 
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overexpression, together with the expression of the "Swedish" mutation, is the triggering 
event that leads to the AD-like manifestations in APP23. 
First, APP total protein levels were assessed by WB and no difference was shown between 
TG-SHs and TG-EEs. Second, because the overexpression of APPswe causes a 
disproportionate shift from normal APP physiological and pathological cleavage. API' 
processing was also evaluated. Soluble aAPP was therefore assessed as a marker of the 
physiological APP processing and levels of A040 and Aß42 as markers of the pathological 
cleavage of APP in 8-month-old mice. Both sets of analyses revealed no effect of E. F, on 
APP processing. EE also did not affect the Aß42/Aß40 ratio, which has been proposed as a 
reliable indicator of neurochemical dementia diagnosis (Weih et al., 2007). 
Aß40 and expecially Aß42 are aggregation-prone peptides. To assess whether El: could 
alter Aß peptide nucleation and growth, levels of Aß oligomers and Ali plaques were 
assessed. Oligomers were recently proposed to be the real toxic species while Ali plaques, 
although having a controversial pathological relevance, are noteworthy because they are 
suggested to be an end point of APP metabolism. 
To detect Aß oligomers in 8-month-old mice, Slot Blots were performed using A 11 
antibody. This antibody was reported to selectively recognize pretibrillar intermediates 
larger than tetramers for many amyloid peptides (Kayed et al., 2003). No significant 
difference in All levels was observed between TG-SHs and TG-EEs, despite a small 
apparent decrease in cortex that may warrant further investigation. At 18-months of age, 
APP23 were also assessed for plaque deposition. At this age, APP23 were reported to have 
consistent plaque deposition (Balducci et al., 2010). The immunohistochemical analysis 
with the anti-Aß 6E10 antibody of sagittal brain slices from TG mice showed a robust 
plaque deposition, whilst there were no plaques in WT mice. Notably, compared to TG- 
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SHs, TG-EEs showed a reduction of both plaque number and the total area covered by 
plaques. This result is in line with that reported by other groups with similar early onset El 
protocols (Lazarov et al., 2005; Adlard et al., 2005; Berardi et al., 2007). However. this 
result is different from two studies in APP23 mice published by Kempermann's group 
(Mirochnic et al., 2009; Wolf et al., 2006): Wolf et al. performed a long-lasting protocol by 
exposing mice to 11 months of EE (starting at 2 months of age), while Mirochnic ct al. 
perfomed a short-lasting protocol (- 1 month starting at 18 months). In both studies no 
change in plaque load was visible, but the differences reported could relate to the gender of 
the mice studied. In fact, these two studies used female mice, whereas males were involved 
in the present work and in literature consistent observations of gender-specific differences 
in Aß deposition are reported independently from EE (Wang et al.. 2003; Schafer et al 
2007). Furthermore, consistently with the results collected in the present study, Lazarov et 
al. registered a decrease in plaque load in male mice under EE. although in a different 
transgenic model (Lazarov et al., 2005). 
EE effect on sirtuins 
Sirtuin expression levels in 8-month-old mice were also assessed. First, the relative sirtuin 
gene expression was investigated in the cortex and hippocampus of WT mice. The seven 
murine sirtuins were all expressed in the cortex and hippocampus similar to that seen in 
human brain (Michishita et al., 2005). However, the gene expression characterization in the 
mice study here revealed that sirtuins have differential expression patterns within the brain. 
In particular, SIRT2 is the sirtuin with the highest expression, suggesting a key role of this 
gene in the brain, while SIRT4 is the sirtuin with the lowest expression level. Finally, no 
differences were visible comparing sirtuins in the cortex and hippocampus except for 
SIRT3 which is expressed more in the cortex. This difference deserves more attention. 
Indeed, it could highlight a prominent role of SIRT3 in the cortex. 
It was also investigated whether transgene or housing condition or the interaction of the 
two parameters could affect sirtuin levels. Indeed, there were few but promising evidence 
that sirtuins could be related with both physical and mental stimulation. However, both 
mRNA and protein assessment failed to show any significant differences in sirtuin levels in 
the four experimental groups assessed. In particular this result did not confirm a previous 
work, where in a different TG mouse model of AD an increase in SIR1'l levels was 
reported in transgenic mice compared to controls (Kim et al.. 2007). 
Summary 
Overall, the present study showed that it is possible to counteract the progression ol` 
cognitive decline and reduce some AD-like pathological hallmarks in the APP-13 mouse 
model of AD by exposing animals to EE. Moreover, preliminary indications suggest that, 
unlike other environmental paradigms, such as CR, EE does not modulate sirtuin 
expression levels in the brain. 
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SECTION C: IN VITRO STUDIES 
CHAPTER 6: ROLE OF SIR Ti 
ACTIVATION BYRESVERA TR OL IN IN 
VITRO MODELS LINKED TO 
ALZHEIMER'S DISEASE 
ETIOPA THOGENESIS 
SECTION C: BACKGROUND 
Oxidative stress is a common feature of many neurodegenerative disorders. including Al) 
(Keating, 2008). The brain in AD appears to accumulate more oxidative damage than 
normal brain and exhibits an increased susceptibility to oxidative stress (Axelsen et al., 
2011). 
Oxidative stress is a recognised phenomenon early in the pathogenesis of' Al), and 
environmental and lifestyle-related risk factors for AD (e. g. aluminum exposure, smoking. 
high calorie intake, lack of exercise, and lack of intellectual activities) were associated 
with an increase in the production of reactive oxygen species and/or a decrease in 
endogenous antioxidant defences (Nunomura et al., 2006). In contrast, more health 
conscious lifestyles such as calorie restriction, exercise, and intellectual activity have been 
shown to promote neuronal survival through an enhancement of endogenous antioxidant 
defences in experimental animal models (Mattson et al., 2002). 
Calorie restriction (CR - i. e. restriction of calorie intake while avoiding malnutrition) is a 
novel paradigm that was shown to increase the resistance of neurons to intracellular and 
extracellular stresses and consequently was proven to be beneficial in different models of 
neurodegenerative diseases, such as AD (Schroeder et al., 2010). Since a C'R protocol is 
not easily applied to humans, there has been interest in attempting to mimick C'R beneticial 
effects with drugs. A body of evidence highlighted the existence of a conserved 
evolutionary pathtway for CR that seemed to involve the members of the sirtuin protein 
family (Haigis and Sinclair, 2010). In particular, SIRTI may have a significant role in CR- 
mediated reduction in stress signaling and enhanced mitochondrial performance (Morris ct 
al., 2011). As such, the sirtuin activator resveratrol (RES) has been proposed as a candidate 
CR mimetic (Barger et al., 2008). 
RES is a naturally occurring phytocompound, found in red wine, that has been proved 
beneficial against cardiovascular diseases and cancer (Bradamante S. Barenghi L. 2004: 
Aggarwal and Shishodia, 2006) and is protective in a variety of experimental paradigms of 
neurodegeneration (Anekonda, 2006). Although the data about the role of RES to activate 
SIRT1 is still conflicting (Hu et al., 2011), several studies reported that RES is able to 
promote neuroprotective effects both in vitro and in vivo, and this capacity is counteracted 
by blocking SIRTI pharmacologically or genetically (Baur, 2010). 
SIRTI (SIRTI, NM012238, NP_036370) is the most investigated member of the sirtuin 
protein family. SIRTI regulates a diverse array of cellular functions related to mammal 
senescence, including metabolism, gene transcription, DNA repair and cellular stress 
response. Recently, SIRTI has also been implicated in neurodegeneration. A 
neuroprotective role of SIRTI was suggested in models of Fluntington's disease (Parker et 
al., 2005), AD (Chen et al., 2005b; Qin et al., 2006b) and amyotrophic lateral sclerosis 
(Kim et al., 2007) 
Despite the growing number of studies, the role of SIRTI in ncuroJegencration is still 
poorly understood. Therefore, the overall aim of this chapter was to better elucidate the 
role of SIRTI activation by RES in pathogenic mechanisms linked to AD etiology in a 
neuroblastoma cell line. 
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6.1. SYNOPSIS 
The first aim was to investigate the neuroprotective role of SIRTI activation by RI'. S 
against oxidative stress, a common feature of many neurodegenerative diseases, including 
AD (Keating, 2008). To achieve this goal, an in vitro model which involved challenging 
the neuroblastoma cell line SK-N-BE(2) with hydrogen peroxide (11202) was set up. SIR1 I 
enzymatic activity was increased by RES (SIRTI activator) and decreased h} sirtinol 
(SIRTI inhibitor), and cell viability was assessed. To further elucidate the involvement of 
SIRTI, its transcriptional levels were also downregulated by a siRNA approach. 
This in vitro model of oxidative challenge, allowed the exploration of the potential 
involvement of SIRTI-related mechanisms in countreracting oxidative stress. From this, 
SIRTI involvement in depleting ROS production under oxidative stress was assessed and, 
for the first time, allowed the study of SIRTI involvement in oxidative stress-mediated 
autophagy. 
The second aim of the work presented in this chapter was to assay the neuroprotective role 
of RES treatment against aggregation prone-protein A042. To achieve this, SK-N-I3I: (2) 
were exposed to Aß42 and subsequent cell viability was assessed. In this model we 
investigated the impact of using the same treatments as before by modulating SIR II by 
RES and sirtinol. 
In summary, this chapter describes studies that show how SIRT1 activation by RFS 
counteracted oxidative stress-induced cell death in SK-N-BE(2). Indeed, pre-treatment of 
SK-N-BE(2) cells with RES increased their viability despite being challenged with II 
whilst both sirtinol and SIRTI gene-silencing reversed this protective effect. Moreover, 
under oxidative stress conditions, SIRTI was involved in RES-mediated depletion of 
intracellular ROS. Furthermore, SIRTI was shown to have a role in 11,0-, -induced 
autophagy, although this did not appear to be responsible for the observed RI. S-induced 
neuroprotection. Finally, RES counteracted cell toxicity and ROS production in SK-N- 
BE(2) cells exposed to Aß42. However, this time RES-mediated protection m as not 
mediated by SIRTI activation but possibly derived from a interaction with Ali fibrils. 
6.2. MATERIALS AND METHODS 
All the experiments presented in this chapter were conducted in undifferentiated SK-N- 
BE(2) cells. The main results were subsequently confirmed with similar observations in 
SK-N-BE(2) cells differentiated by retinoic acid (cfr. chapter 2.4.1). 
All the statistical analyses were performed with GraphPad Prism'. 
6.2.1. CELL SEEDING 
For the experiments described in this chapter, cells were counted with a Burker chamber 
and seeded in the appropriate multi-well at the desired concentration. 
Differentiation NO wells/plate Cell number/ volume of Application 
with RA dimensions/well medium 
Cell viability - 
96 (6.4 min) (0) 30'000/200 µL 
(CV) 
+ 48 (10 mm) (0) 20'000/200 µL 
Immunocytochemistry 8 (9.4 x 10.7 x 6.8 
50'000/200 µL 
(IC) 
+ mm) (w xIx h) 20'000/200 pL 
Western Blotting - 24 (16 mm) (0) 150'000/400 . tL 
(WB) 
+ 12 (22 mm) (0) 80'000/500 t1 
Real Time-PCR - 12 (22 mm) (0) 300'000/500 pL 
RT-PCR 
6 (35 mm) (0) 300'000/800 pL 
TABLE 6.1. Seeding conditions used in the experiments performed. 
RA: retinoic acid; ©. diameter, 
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6.2.2. CELL TREATMENTS 
Oxidative-stress challenge 
To model the effects of oxidative stress on SK-N-BE(2) cells, a dose-response curve as 
plotted using H202. Cells were exposed to increasing doses of 11202. ranging from 25 µM 
to 100 pM for 24 h, and then cell viability was assessed. The following experiments with 
H202 were run with 75 pM H2O2. 
To challenge cells with H202, fresh dilutions were prepared in DMI. M at 100x the final 
concentrations desired and then added to the medium at 1: 100. 
Aß42 challenge 
Before use, Aß42 peptide was dissolved in 0.01 M NaOH to a anal concentration of 44O 
i. M. Working dilutions were made in DMEM medium and Aß42 was added to the cell at 
the desired concentration. Cells were incubated with Aß42 for 24 h. For the dose-response 
experiment cells were exposed to increasing doses of H2O, ranging from 5 µM to 20 µM. 
For the following experiments the final concentration of 10 µM 11,0., was chosen. 
Modulation of SIRT1 activity 
RES (i. e. SIRT1 activator) and sirtinol (i. e. SIRTI inhibitor) were dissolved in I)MSC) at 
the stock concentration of 20 mM. Working dilutions were made in DMEM medium and 
added to the corresponding well. For the experiments designed to set up RLS and sirtinol 
treatments, cells were exposed to increasing doses (ranging from 2.5 . tM to 15 µM) of the 
two drugs for 24 h. For the following experiments cells were exposed to sirtinol and/or 
RES at 2.5 µM and 7.5 µM, respectively. 
- 202 - 
RES protection against toxic challenges 
To investigate whether RES was able to protect cells from H202- or A3-induced cell death. 
SK-N-BE(2) cells were treated with two different experimental schedules: 
1) Cells were treated with RES 7.5 l. M, after 4h they were exposed to the toxic challenge 
and after further 24 h their viability was assessed. 
2) RES 7.5 µM was given twenty and 4h before the toxic challenge and alter further 24 h 
cell viability was assessed. 
To confirm SIRTI involvement in RES protection, sirtinol 2.5 pM was given 2h hetiorc 
each RES treatment. 
SIRT1 downregulation 
SK-N-BE(2) cells were seeded in multi-well plates (for the number of cells seeded cfr. \ý'l; 
and RT-PCR applications in table 6.1) and grown overnight. The next day, the medium 
was replaced with freshly prepared complete medium and a pre-designed double-strand 
small-interfering RNA (siRNA) against SIRT 1 mRNA sequence (sense: 5' - 
GCCUCACAUGCAAGCUCUAtt-3', antisense: 5'-UAGA000LJ(iCAII(itJGA(i(i('tc- 
3') (Ambion) was added in 50 pL serum-free Optimem (Invitrogen) (final concentration: 
300 nM) using SilentFect liposome formulation (siRNA lipid vehicle) (l3io-Rad 
Laboratories). The medium was not changed for 72 h from siRNA addition. To prove 
SIRTI specific down-regulation, a siRNA negative control (CT-) with no match to any 
known human transcribed sequence was used. 
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6.3. RESULTS 
6.3.1. H202 AND RES TREATMENT SET UP 
To construct a model of oxidative stress, SK-N-BE(2) cells were treated with 11202. 
Exposure for 24 h to increasing doses of H202, ranging from 25 to 100 µM, induced a 
dose-dependent decrease of cell viability in SK-N-BE(2) cells (figure 6.1). The dose of 75 
µM, that reduced cell viability by about 50%, was chosen for the subsequent experiments. 
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FIGURE 6.1. Dose response relationship between H202 concentration and SK-N- 
BE(2) viability. 
SK-N-BE(2) cells were exposed to increasing doses of H2O2 for 24 h, then cell viubilih' 
was assessed. Viability of control cells was set at 100%, and viability with respect to the 
control is presented. Bar graph indicates the mean f SEM (n =4). *: p< 0.05, **; p. 0.0/, 
***: p< 0.001; one-way ANOVA followed by Dunnett's post hoc test versus control 
(untreated cells). 
To evaluate the intrinsic toxicity of RES in SK-N-BE(2), cells were incubated with 
increasing doses of the molecule. Exposure for 24 h to RES, ranging from 2.5 to 10 µM, 
did not affect cell viability in SK-N-BE(2) cells. RES was slightly toxic starting from 10 
µM (figure 6.2). The following experiments were run using 7.5 pM RES. 
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FIGURE 6.2. Dose response relationship between RES concentration and SK-N- 
BE(2) viability. 
SK-N-BE(2) cells were exposed to increasing doses gfRES for 24 h, then cell viahilitti' was 
assessed. Viability of control cells was set at 100%, and viability with respect to they 
control is presented. Bar graph indicates the mean f SEM (n-4). *: p- 0.05, one-way 
ANOVA followed by Dunnetis 's post hoc test versus control (cells treated with vehicle 
0.05% DMSO). 
6.3.2. RES PRE-TREATMENT COUNTERACTS CELL DEATH INDUCED BY 
OXIDATIVE STRESS 
To investigate whether RES was able to protect cells from H202 exposure, SK-N-131: (2) 
were pre-treated with RES 7.5 µM 4h before H202 challenge. This treatment did not 
counteract cell death caused by 75 µM H202 (figure 6.3. ). Given this result, an overnight 
pre-treatment with RES was designed. To ensure a better bioavailability of RES, the drug 
was supplemented after an overnight incubation (15 h) with a further 7.5 µM of RES. 
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FIGURE 6.3. RES pre-treatment 4h before oxidative challenge is uneffective 
SK-N-BE(2) were pre-treated with RES 7.5 pM 4h before treatment with /I, O, 75 pM /or 
. 
further 24 h. Cells viability is expressed as percentage of the control (cells treated with 
vehicle = 0.05% DMSO). Bar graph indicates the mean ± SEM (n=4). 
To confirm RES uptake by SK-N-BE(2), and to estimate RES bioavailahility over time, 
cells were treated with RES as described above and the subsequent intracellular levels of 
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RES was measured at different time-points relevant for the following experiments (figure 
6.4). RES was taken-up by SK-N-BE(2) cells and its concentration decreased over time. 
However, after 44 h RES intracellular content was still appreciable and around 60% to that 
seen at the second time-point (16 h). 
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FIGURE 6.4. RES intracellular uptake in SK-N-BE(2) 
13 CT 
13 RES 
RES 7.5 pM was added at lime 0 and 16 h later. RES was quantified by mass . spectrometry 
at time point: 0,16,20 and 44 h. Each lime point was in triplicate and normalized to /06 
cells. *: p<0.05, one-way ANOVA followed by Tukey's test. 
The next experiment aimed to assess whether RES had a neuroprotective role in 
counteracting H202-induced cell death, SK-N-BE(2) cells were pre-treated with RES 7.5 
µM 20 and 4h before exposure to H202 for 24 h. Notably, a double-treatment protocol of 
RES did not affect cell viability. Conversely, this treatment significantly reduced the extent 
of cell death caused by H202 (cell viability was increased by about 30%) (figure 6.5). 
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FIGURE 6.5. RES prevents H202-induced toxicity in SK-N-ßW(2). 
SK-N-BE(2) were pre-treated with RES 7.5, uM 20 and 4h hefbre treatment with 11202 75 
pM for a further 24 h. Cells viability is expressed as percentage of the control (cells 
treated with vehicle = 0.1% DMSO). Bar graph indicates the mean + SEM (n 4). **p 
0.01 versus control: 4P< 0.01 H202 x RES. Two-way ANOVA. 
To exclude whether RES had a pro-apoptotic effect, apoptosis was checked in our model 
by Hoechst 33342 staining (figure 6.6. ). The double treatment with RES 7.5 µM did not 
increase the percentage of apoptotic nuclei, even in the presence of oxidative stress 
triggered by H202 75 µM. Following higher doses of RES (i. e. double treatment with 15 
µM) apoptotic nuclei were not detected. In contrast the introduction of 11202 75 µM in 
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addition to RES 15 µM significantly increased the number of fragmented nuclei in SK-N- 
BE(2) cells (24%, p<0.001, Tukey's Test). 
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FIGURE 6.6. Percentage of apoptotic nuclei stained with Hoechst 33342 in sly-N- 
BE(2) cells treated with RES and H2O2. 
Normal nuclei (N) and apoptotic nuclei (A) were counted and plotted as prrc entuýýc ul 
nuclei total count. Bar graph indicates the mean + . SEM (n 4 replicates, l0 field counted 
for each replicate), ***p < 0.001, RES 15 pM + H2O2 75 NM vs. REX 15 pM alone, 
Tukey's test. The insert below the histogram shows Hoechst 33342 stained nuclei under 
UV light. The arrows point to fragmented nuclei (magnification: 20X, scale har: /5 pin). 
To test whether RES-mediated neuroprotection against I-1202, was actually due to the 
activation of SIRTI by RES, SIRTI was inhibited by sirtinol. 
Sirtinol toxicity was first assessed in SK-N-BE(2) by exposing cells to increasing doses of 
the molecules for 24 h. Sirtinol was toxic starting from 5 µM (figure 6.7). The dose of 2.5 
µM sirtinol was chosen for the subsequent experiment. 
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FIGURE 6.7. Dose response effects of increasing doses of sirtinol on SK 
viability. 
SK-N-BE(2) cells were exposed to increasing doses of sirtinol 24 h, then cell viability was 
assessed. Viability of control cells was set at 100%, and viability with respect to the 
control is presented. Bar graph indicates the mean ± SEM (n - 4). * *: p- 0.0 1. ***: 
p<0.001; one-way ANOVA followed by Dunnetts's post hoc test versus control (cells 
treated with vehicle = 0.05% DMSO). 
To assess sirtinol ability to reverse RES protection, cells were pre-treated with sirtinol 2h 
before each RES treatment. Despite there being evidence of some sirtinol-mediated 
toxicity at micromolar concentrations, the double-treatment with the molecule at 2.5 pM 
did not significantly affect cell viability (column 3 figure 6.8). When SK-N-BF(2) cells 
that were exposed to H202 in the presence of RES having been pre-treated with sirtillol. tile 
protective RES-mediated effect was no longer detectable (column 7 figure 6.8). 
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FIGURE 6.8. Sirtinol conteracts RES-mediated protection against 11202-induced 
toxicity 
-N-BE(2) cells were pre-treated with sirtinol 2h before each RES ireatment. lnllowed by SK 
11202 challenge as summarized in the panel above the graph. Cells viability is expressed as 
a percentage of the control (cells treated with vehicle = 0.2% DMSO). Bar graph indicates 
the mean ± SEM (n=4). Statistical analysis was performed by 2-way AND VA (1l_0_ alone 
as reference group) **p < 0.01 RES effect: ns: sirlinol effect, $p0.01 sirtinol x RES at 
H202 75 uM. 
To confirm whether SIRTI was inolved in RES-mediated protection. SIR'I'1 expression 
was transiently downregulated in SK-N-BE(2) by adding 300 nM s1RNA liar 72 h. A 
reduction of SIRTI mRNA of about 70% was measured by RT-PCR, using (i-actin as 
-211 - 
internal standard (figure 6.9A). A corresponding reduction was verified by WB using a- 
tubulin as internal standard (figure 6.9B). To check for the specificity of the silencing 
strategy, SK-N-BE(2) cells were incubated with a siRNA negative control (CT-). Using the 
same time/concentration conditions as were used for the SIRTI silencing by siRNA, no 
reduction of SIRTI was found by mRNA/protein levels. 
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FIGURE 6.9. Effects of SIRT1 silencing in SK-N-13E(2) cells. 
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SK-N-BE(2)cells were transfected by liposome treatment with 300 nM siRNA against 
SIRTI or 300 nM siRNA negative control. 72 h after cell transfeclion, SIRTI mRNA 
expression levels [A] were analyzed using quantitative RT-P('R and were normalized to /1- 
actin expression as a standard. SIR Ti protein levels [B] were determined by WB and were 
normalized to a-tubulin. The relative densitometric values expressed as % of. the control 
group are shown below. Bar graph indicates the mean + SEM (n =3). ***: p,, 0.00 /. - one- 
way ANOVA followed by Dunnetts 's post hoc test versus control (cells treated with vehicle 
= 0.2 pL liposome). 
Under circumstances where SIRTI is silenced, RES-mediated protection against 11,02 was 
assessed. As expected, the group challenged by oxidative stress but pre-incubated with 
RES was protected from cell damage. Whereas, when cells were silenced for SIR'I'l and 
then exposed to H202 in the presence of RES, there was no difference to the cells which 
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were solely exposed to H202. In contrast, RES protection was not counteracted by the 
presence of a siRNA negative control (figure 6.10). Notably, SIRTI silencing alone was 
not toxic and did not increase H202 toxicity. 
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FIGURE 6.10. SIRTI silencing prevents RES-mediated protection of SK-N-BE(2) 
against oxidative challenge. 
SK-N-ßE(2) cells were transfected by liposome treatment with 300 Of siRNA against 
SIRTI or 300 nM siRNA negative control. Under conditions of ' S/RTI silencing, RI: 'S 
double treatment followed by H202 challenge was performed as summarized in the panel 
above the graph. Cells viability is expressed as the percentage of the control (cells treated 
with vehicle = 0.2 pL liposomes). Bar graph indicates the mean i SEM (n 4). Statistical 
analysis was performed by 2-way ANO VA (H202 alone as reference group) * *p - 0.01 
RES effect; ns: siRNA SIRTI, $p<0.01 siRNA SIRTI x RES at H. 0,75 pM. It n., s siRNA 
CT- x RES at H2O2 75 , M. 
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6.3.3. SIRTI INVOLVEMENT IN ROS PRODUCTION 
To attempt to elucidate the basis of SIRTI involvement in counteracting H202 toxicity, 
intracellular ROS were measured using DCFH-DA, a well-established compound to detect 
and quantify intracellular ROS (Rizzardini et al., 2003) (cfr. chapter 2.4.4). When cells 
were exposed to H202 for 24 h, ROS increased in comparison to untreated cells, while RES 
pre-treatment reduced ROS to basal levels (figure 6.11). Furthermore, when SIRT l was 
downregulated, RES pre-treatment was no longer able to restore ROS to basal level, even 
though there was a suggestion of a reduction of ROS level in comparison to 14202 alone 
(p= 0.08). 
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FIGURE 6.11. SIRT1 silencing prevents RES-mediated decrease of ROS in SK-N- 
BE(2) cells. 
, SK-N-BE(2) cells were treated as in figure 6.10.1 h before H, 07 challenge, cells were pre- 
loaded with DCFH-DA. At the end of the experiment fluorescence was recorded and 
expressed as arbitrary units (A. U. ). Bar graph indicates the mean {- SEM (n- 4), 
**p<0.01; one-way ANOVA. followed by Student's t-test; #p < 0.01 RES effect, ns: siRNA 
SIR Ti, and $p<0.01 siRNA SIRTI x RES at H202 75 pM, two-way ANOVA. 
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6.3.4. SIRT1 INVOLVEMENT IN AUTOPHAGY UNDER OXIDATIVE STRESS 
The potential role of SIRTI in autophagy was investigated under conditions of oxidative 
stress. SK-N-BE(2) cells were silenced for SIRTI and then challenged with H20-, for 24 h. 
as described above. At the end of the exposure to oxidative stress, the formation of 
autophagosomes was assessed using an antibody against the microtubule-associated 
protein 1 light chain 3 (LC3) by immunocytochemistry (IC) and WB. Newly synthesized 
LC3 is converted into the cytoplasmic form LC3-I. During autophagy, LC3 I is processed 
and recruited to the autophagosomes, where LC3 II is generated by site specific 
proteolysis. The amount of LC3-II is correlated with the extent of autophagosome 
formation (Kabeya et al., 2000). 
SK-N-BE(2) cells treated with H202 showed an increase in autophagosome formation in 
comparison to the control group, highlighted by the higher number of bright green spots 
observed by IC (figure 6.12A). Under conditions of oxidative challenge, SIR"I'l silencing 
by transfection with the siRNA against SIRTI partially prevented the increase of 
autophagosomes that remained unaffected when cells where transfected with a siRNA 
negative control (CT-) (figure 6.12A). Consistently, under H202 exposure, the ratio of 
LC3-II/LC3-I measured by WB analysis increased compared to untreated cells. Moreover, 
when SIRTI was downregulated by siRNA, LC3-II/LC3-I ratio decreased compared to 
cells exposed to H202 alone, while it remained unchanged in presence of a siRNA negative 
control (CT-). 
- 215 - 
ý 
fLl 
ki 
mi r-i i! 
aw 
la 
a 
m 
Lo 
siRNA siRNA 
SIRT1 CT- 
g 
N 
O 
ý 
In 
mL 
V 
-I \ 
a J 
CT H202 
!r =NNW Wr rý 
7 
6 
5 
4 
3 
2 
1 
0 
I 
+H202 + H202 
4ý 4ý 
. «. _.. & 
__ ............................... __ 
T 
** 
r, 
CT HzOz 
siRNA siRNA 
SIRT1 CT- 
+ H2o2 + H2o2 
ý LC3-I 19 KDa 
ý LC3-II 17 KDa 
FIGURE 6.12. SIRTI silencing attenuates autophagy after oxidative stress 
SK-N-BE(2) cells were transfected by liposome treatment with 300 nM siRNA against 
SIRTI or 300 nM siRNA negative control. 48 h after transfection, cells were exposed to 75 
pM H2O1 for further 24 h. At the end of the experiment, autophagosome formation was 
assessed with LC3 antibody. A] Immunocytochemistry. The arrows highlight LC3 bright 
spots reactivity (magnification: 40X, scale bar: 10, UM). B] WB. Cell lysates were loaded 
on 16% polyacrylamide gel. Immunostaining with the antibody against LC3 revealed two 
bands at 19 and 17 kDa corresponding to LC3-I and LC3-I1, respectively. The graph 
shows the densitomeiric quantification of LC3-11/LC3-I ratio. Bar graph indicates the 
mean + SEM (n=4), **p < 0.01 siRNA SIRTI X H202, two-way ANOVA. 
-216- 
In order to elucidate the involvement of autophagy in RES-mediated neuroprotection, 
autophagy was inhibited after treating SK-N-BE(2) cells with 3-Methyladenine [3-MA, 
specific inhibitor of autophagic/lysosomal protein degradation (Seglen and Gordon, 1982)] 
at a concentration of 10 mM. RES double treatment was performed as above and 3-MA 10 
mM was also added 1h before oxidative challenge that continued for a further 24 h. As 
shown in figure 6.13,3-MA treatment alone was toxic and increased H2O2 toxicity. Within 
this context, RES pre-treatment was able to counteract both H2O2 toxicity and H202 
toxicity in combination with 3-MA (with respect to the corresponding controls). 
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FIGURE 6.13. RES-mediated neuroprotection is not mediated by autophagy 
SK-N-BE(2) cells were pre-treated with RES as descibed above and Ih before H202 
challenge cells were exposed to 3-MA. Cells viability is expressed as a percentage of the 
control (cells treated with vehicle = 0.1 % DMSO). Bar graph indicates the mean ± SEM 
(n=4). Statistical analysis was performed by 2-way ANOVA (H202 alone as reference 
group) #P< 0.01 RES effect; &P<0.05 3-MA effect; * P<0.05 3-MA x RE. S x H2O2 vs 3-MA 
x H202 Tukey 's post hoc test. 
6.3.6. RES TREATMENT PREVENTS CELL DEATH TRIGGERED BY Aß42 
The potential preventative effect of RES was evaluated in SK-N-BE(2) cells challenged 
with Aß42. First SK-N-BE(2) cells were treated with increasing doses of Aß42 for 24 h. 
The dose of 10 pM Aß42 that reduced cell viability by about 50% was chosen for the 
following experiments. 
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FIGURE 6.14. Dose response effects of increasing doses of Aß42 on SK-N-BE(2) 
viability. 
SK-N-BE(2) cells were exposed to increasing doses of Aß42 
, 
for 24 h, then cell viability 
was assessed Viability of control cells was set at 100%, and viability with respect to the 
control is presented. Bar graph indicates the mean SEM (n=4). *: p<0.05, **; 1) - 0.01, 
***: p<0.001; one-way ANOVA. followed by Dunnetts's post hoc test versus control (cells 
treated with vehicle = 2% NaOH 0.01 M). 
Then, SK-N-BE(2) cells were pre-treated with RES 7.5 µM (20 and 4h before the toxic 
challange) and then exposed to Aß42 for a further 24 h. Cells pre-treated with RES were 
less susceptible to Aß toxicity (figure 6.15). Indeed, a reduction of about 30% in cell 
mortality was registered in this treatment group compared to Aß42 alone group. 
To assess if RES-mediated protection was elicited by SIRTI in this context the SIRT 
inhibitor sirtinol was used. Unexpectedly, when cells were exposed to sirtinol 2h before 
each RES addition, the protective effect was still present (though slightly less). 
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FIGURE 6.15. RES is associated with reduced cell toxicity arising from exposure of 
SK-N-BE(2) cells to aggregation-prone protein Aß42. 
SK-N-BE(2) cells were pre-treated with sirtinol 2h hefore each RES treatment. 1Lllowed by 
Aß42 challenge as summarized in the panel above the graph. Cell viability is expressed as 
a percentage of the control (cells treated with vehicle = 2% NaOH 0.01 M and 0.2% 
DMSO). Bar graph indicates the mean + SEM (n=4). Statistical analysis was performed by 
2-way ANOVA (Aß42 alone as reference group) #p < 0.01 RES effect; ns: sirtinol eflecl, $ 
n. s. sirtinol x RES at Aß42 10 NM. 
To better elucidate the RES-mediated protective mechanism against Aß42 exposure, 
intracellular levels of ROS were measured. Under conditions of Aß42 exposure, levels of 
ROS increased similarly to those observed following exposure to H202. Once again, 
increases in ROS were counteracted by RES pre-treatment. Notably, SIRTI inhibition by 
sirtinol treatment did not reverse increases in ROS. 
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FIGURE 6.16. RES treatment counteracts ROS generation following Aß42 in a 
SIRT 1-independent way. 
SK-N-ßE(2) cells were treated as in. figure 6.14.1 h before H? O, challenge, cells ºw ere pre- 
loaded with DCFH-DA. At the end of the experiment fluorescence was recorded and 
expressed as arbitrary units (A. U. ). The bar graph indicates the mean -}- SEM (n--4). 
**p<O. 01; one-way ANOVA followed by Student's t-test; #p < 0.11 RES effect, ns: sirlino/, 
and $ n. s. sirlinol x RES at Aß42 10 NM, two-way ANOVA. 
1,5 
I 
0,5 
0 
Given these results, it was postulated that the observed RES effects might be mediated 
independent of SIRTI. To this concern, a direct effect of RES on Aß42 fibrils was 
assessed. To achieve this, a fluorimetric binding assay was performed which took 
advantage of the intrinsic fluorescence of RES (excitation wavelength of 320 nm). With 
this technique RES was shown to bind Aß42. In fact, following the binding of RES to 
Aß42 its emission spectrum dramatically changed as highlighted in figure 6.17 by the red 
arrow (emission wavelength at which the highest peak was registered shifted from 400 nm 
to 380 nm). To evaluate the dissociating property of RES on Aß42 fibrils. RES was 
incubated with Aß42 fibrils for 24 h or 10 min and then measured at 320 nm excitation 
wavelength to assess the ratio between free RES (supernatant, emission at 400 nm) and 
RES bound to Aß42 (pellet, emission at 380 nm) separated by centrifugation. RES alone 
was found to be almost completely free in the supernatant, while after incubation with 
Aß42 fibrils a fluorescence signal was found in the insoluble pellet fraction. A weak 
dissociating effect of RES on Aß42 fibrils was found after 24 h (around 20% dissociation, 
p= 0.045) (figure 6.17). 
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FIGURE 6.17. RES binds and weakly dissociates Aß42 fibrils after 24 h. 
A. Fluorescence emission recording of RES, Aß42 and RES+Aß42 al excitation wavelength 
of 320 nm. B. Evaluation of RES dissociating property on Aß42 , 
fibrils perfbrmed by 
incubating RES + Aß42 fibrils for 24 h or 10 min and then measuring at 320 nm the ratio 
between free RES (supernatant, emission at 400 nm) and RES hound to A1142 (pellet, 
emission at 380 nm) separated by centrifugation. Each group was run in quadruplicate. 
Bar graph indicates the mean ± SEM (n=4). 
To test the ability of RES to counteract Aß42 aggregation, Aß42 oligomers and protofibrils 
formation was monitored over time by atomic force microscopy (AFM). By comparing 
Aß42 incubated with RES to Aß42 alone, it was shown that the presence of RFS delayed 
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the formation of Aß42 oligomers and protofibrils for up to 6h (figure 6.18), while at 24 h 
fibril dimension and density in absence or presence of RES were similar (not shown). 
FIGURE 6.18. RES can delay Aß42 fibril formation. 
Aß42 was incubated at 37 °C for increasing lime intervals (0.5,6 and 24 h) in absence or 
presence of RES (1: 1.5 ratio). One aliquot was then diluted to I uM with PBS 10 mM p11 
7.4 and incubated for 0.5 min on a freshly cleaved Muscovite mica disk. After the 
incubation time, the disk was washed with water and dried tinder gentle nitrogen stream 
and assessed with AFM. The graphs in the insert show an example of' the dimension 
distribution of Aß42 pre-fibrillar stage (Y-axis scale nm - left vs. pm --right). The arrows 
point to Aß42, filamentous aggregates. 
6.4. DISCUSSION 
The work summarized in this chapter first explored the question whether RFS was 
beneficial in counteracting oxidative stress that is triggered by H2O2, and whether this 
protective action was dependent on SIRTI. To this aim, an in vitro model of oxidative 
stress was developed in the human neuroblastoma cell line SK-N-BE(2) by exposing cells 
to H202. Cell exposure for 24 h to increasing doses of H2O? led to a dose-dependent 
reduction of cell viability. The final concentration of 75 tM H2O-,, that reduced cell 
viability of about 50%, was chosen for the experiments presented in this chapter. In this in 
vitro model set up, the induction of oxidative stress was confirmed by an increase in 
intracellular ROS registered with the DCFH-DA probe. Notably, this increase in ROS did 
not activate apoptosis in SK-N-BE(2) cells measured with nuclear fragmentation assessed 
by staining cells with Hoescht 33342. 
To investigate the role of SIRTI against oxidative stress, SIRTI activity was increased by 
RES and decreased by sirtinol in our cell-based model. RES and sirtinol concentration 
ranges were chosen according to those previously described in the literature (Chong and 
Maiese, 2008) and were finalised by pilot dose-response experiments. Moreover, since 
RES given 2h before H202 was not able to protect cells from H202-mediated toxicity. a 
longer pre-treatment scheme was adopted. RES was given as an overnight pre-treatment 
and refreshed the day after for an additional 4 h. Then cells were challenged with 11202 
treatment. Within this double pre-treatment schedule, RES uptake by SK-N-BE(2) cells 
and its stability over time were assessed by mass spectrometry. 
RES is a pleiotropic molecule reported to exert protective properties at low concentrations 
(few . tMs) and to induce apoptosis at higher concentrations (Mukherjee et at.. 2010). To 
this concern, the pro-apoptotic effect of RES was assessed in our in vitro model. RES did 
not induce apoptosis at the final concentration chosen (7.5 . tM) neither alone nor in 
combination with H2O2. Conversely, a higher concentration of RES (15 µM) although only 
in combination with H202, increased by 20% the percentage of apoptotic nuclei. 
Notably, double pre-treatment with RES 7.5 µM was able to increase cell viahiliy by about 
30% in SK-N-BE(2) cells challenge with H202 thus suggesting that RES at this 
concentration exerted neuroprotective effects. RES is a phytocompound that was reported 
to exert an antioxidant activity (Frankel et al., 1993). To assess this point the ability of 
RES to counteract H202-mediated increase in ROS species was evaluated. Interestingly, 
RES pre-treatment restored ROS basal levels under conditions of ll20- exposure. To 
evaluate whether the observed RES neuroprotective effect observed was due to its general 
antioxidant properties or to SIRTI activation by RES, SIRTI enzymatic activity was 
inhibited with sirtinol, and cell viability was assessed under oxidative stress. Interestingly, 
RES antioxidant property using cell viability as a surrogate marker was affected by sirtinol 
treatment thereby suggesting the involvement of SIRTI. 
To attempt to verify the actual involvement of SIRTI and exclude the potential 
activation\inhibition of other sirtuins by RES and sirtinol, SIRT1 gene expression was 
downregulated by transfecting cells with siRNA. This yielded consistent findings to those 
observed with sirtinol, where transient downregulation of SIRTI prevented RES-associated 
antioxidant properties as determined according by cell viability. 
Overall, these data suggest that the protection induced by RES was mediated through 
SIRT1 activation. Notably, the ability of RES to decrease ROS was significantly affected 
by SIRTI silencing thus suggesting that SIRTI could have a role in counteracting ROS. but 
since it was not completely reversed, it also possible that RES direct antioxidant action 
contributed to cell protection. 
Another interesting result was the effect of oxidative stress and SIR 77 silencing on 
autophagy. The relevance of the autophagic pathway under oxidative stress remains 
unclear. Indeed, basal levels of autophagic degradation of cell components (i. e.. organelles. 
cytosolic proteins) occur in nearly all cell types as a means to maintain cellular 
homeostasis. Additionally, autophagy rapidly increases during periods of cellular 
starvation as a means to generate the necessary nutrients to sustain cell survival. I lowever, 
excessive autophagy results in degradation of essential cell constituents, ultimately 
resulting in cell death. Determinants of whether autophagy promotes cell survival or cell 
death depend upon the severity and degree of stress in the cellular environment (Essick and 
Sam, 2010). SIRTI involvement in autophagy has already been reported under nutrient 
starvation (Lee et al., 2008) as well as autophagosome formation after oxidative stress 
challenge (Pyo et al., 2008). Here this study has shown for the first time that SIR II may 
have a role in autophagosome formation under oxidative stress. Indeed, SIRTI silencing 
partially counteracted H202-induced autophagy activation. However, the decrease in 
autophagy registered under H202 exposure in cells silenced for SIRTI did not affect cell 
viability. This result, which is in contrast to the toxic effect reported by Seo et al. following 
SIRT1 silencing in a neuroblastoma cell line (Seo et al., 2010) could be caused by the 
incomplete silencing of SIRT1 in current cell model used here. Furthermore, this could 
also partially explain the high sirtinol toxicity registered in SK-N-BE(2) cells, although 
there was no evidence that the observed RES protective effect was related to autophagy. 
Indeed, RES-mediated protection against H202 was insensitive to the inhibitor of 
authophagy 3-MA. 
Finally, the work presented in this chapter also evaluated the impact of RES as a 
neuroprotectent against A042. Exposure of cells to A042 triggered cell death and increased 
intracellular ROS in a similar manner as H202 treatment. This result is consistent with 
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previously published data showing that Aß protein causes H? O, and lipid peroxides to 
accumulate in cells (Behl et al., 1994). RES treatment was found to counteract cell 
death 
triggered by Aß42 treatment and rescued ROS to basal levels (Jang et al., 2007). However. 
sirtinol did not totally reverse . 
RES neuroprotective action. suggesting that other 
mechanisms independent of SIRT1 could also have been involved. For example, recently 
RES was shown to act as a ROS scavenger against the toxicity induced by A(1-metal 
complexes (Granzotto and Zatta, 2011). 
This study showed that RES could partly prevent Aß toxicity by direct interaction with A(3 
fibrils, as already reported (Ahn et al., 2007; Riviere et al., 2007). Moreover, a weak RES 
destabilization effect on Aß fibrils but also an anti fibrillogenic RES action that delayed 
A042 oligomers and fibrils formation was found. This double effect can partly explain how 
RES provided some protection against Aß42 toxicity. Indeed, it has been consistently 
reported recently that a subset of Aß conformers (soluble prelibrillar oligomers, fibrillar 
intermediates, and fibrils) elicit RES to dramatically remodel their structure, whereas non- 
toxic oligomers and monomers do not. Moreover, RES remodels soluble oligomers and 
both fibrillar conformers into aggregated species that possess biochemical properties not 
found in the original conformers (Ladiwala et al., 2010). 
Overall, in this cell model RES protected cells from Aß42 toxicity independently from 
SIRTI action but acting partly through the modifications of A P42 fibril formation and 
stability as well as by reducing intracellular Aß42-dependent ROS generation. Other 
protective mechanisms such as RES-mediated activation of proteasomes after Aß challenge 
could also be involved (Marambaud et al., 2005) or via alternate pathways not requiring 
SIRT I activation as suggested by Pfister et al. (Pfister et al., 2008). 
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CHAPTER 7: FINAL REMARKS AND 
FUTURE STUDIES 
A large body of evidence has underscored the potential relevance of members of the sirtuin 
family (SIRT1-SIRT7) in pathogenic mechanisms leading to AD. In particular, SIRTI was 
shown to counteract two important features of AD: APP metabolism and tauopathy. 
Indeed, several studies showed that SIRTI shifts APP metabolism towards the non- 
amyloidogenic pathway through a-secretase upregulation (Qin et al., 2006a, 2006b: 
Donmez et al., 2010) and more recently SIRTI was shown to deacetylate tau thus 
promoting its degradation and counteracting tauopathy (Min et al., 2010). Furthermore 
SIRTI was proposed to be involved in collateral pathways relevant for AD, for example in 
response to oxidative stress, apoptosis, axonopathy (Haigis and Sinclair, 2010). For the 
other six sirtuins (SIRT2-SIRT7) no direct evidence was available about their role in AD 
but there exists numerous data relating the involvement of sirtuins in cell survival and 
stress response in neurodegenerative contexts (Haigis and Sinclair, 2010). 
The importance of sirtuins in AD was first suggested in relation to calorie restriction (CR), 
a dietary regimen known to delay or even prevent age-related diseases such as AD (Baur, 
2010). Several studies had already shown that the beneficial effect of CR on longevity was 
mediated by sirtuins in simple organisms. As such, the existence of an evolutionary 
conserved pathway fired by CR and involving members of the sirtuin family was proposed 
(Baur, 2010). Notably, some members of the sirtuin family were also shown to he 
modulated under other beneficial environmental paradigms such as PA (Koltai et al., 2010; 
Ferrara et al., 2008; Suwa et al., 2008). However, a systematic analysis of' sirtuin 
modulation under these other paradigms was not yet performed especially in pathological 
contexts such as AD. 
Given these preliminary remarks, the experiments described in this thesis were aimed to 
investigate the involvement of all 7 known sirtuins in modulating AD susceptibility 
through a translational research design. This involved the use of human genetic association 
studies, the use of in vivo modeling to explore the involvement of this protein family in an 
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environmental enrichment (EE) paradigm, a non-pharmacological treatment proved to be 
beneficial in neurodegenerative contexts and explored possible mechanisms for SIRTI in 
AD through its pharmacological activation in in vitro models of AD. 
The genetic section of this thesis (chapter 3 and 4) was aimed to 1] conduct a analysis of 
sirtuin genes by denaturing high performance liquid chromatography (dHPLC) with a view 
to identify gene variants that might be associated with AD susceptibility and 2] to test the 
extent of the association between common sirtuin gene variants (previously known and 
newly identified) and AD risk. 
In achieving the first aim 29 SNPs were identified in a screening cohort of 48 AD patients 
and 48 controls. Eleven of these were novel SNPs which have not yet been reported while 
the remaining ones were already recorded in the NCBI SNP database. Despite being only a 
pilot study and using small numbers, it already suggested that some SNPs might be 
differently distributed between AD and CT. In particular, SIRTI and SIRT2 were 
characterized by several SNPs appearing to be different found in the two groups. In most 
cases these variants were intronic given the exception of SNP4 (rs2273773), a silent SNP 
lying on exon V of SIRTI. These SNPs, although lacking an obvious functional 
importance, could still serve as genetic markers for association with AD through their 
genetic association with other adjacent SNPs which may be more disease relevant. As 
such, these SNPs were included in a more formal case-control genetic association study 
aimed to collect more evidence of whether there might be a true genetic association 
between genetic variants laying on SIRT genes and AD susceptibility. 
In this second stage of the genetic study, beside previously identified SNPs, other intronic 
variants, laying in sirtuin portions not included in the dHPLC study, were selected so as to 
retain sirtuin variability in gene regions with high linkage disequilibrium (i. e. using a 
tagSNPs approach) (Stram, 2004). Thirty-four SNPs across all the 7 SIRT genes were 
assayed. This study replicated previous studies of SIRTI where no associations with AD 
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risk were found (Morgan et al., 2007; Helisalmi et al., 2008). There was marginally 
significant evidence of a new association between rs10410544 SNP in SIR T2 and AD from 
the initial case-control study (p= 0.05). Furthermore, although this was not confirmed in 
the separate replication analysis, there remained evidence of association after combining 
the two study samples. This combination increased the power of the analysis [power (n)> 
0.90] and was possible because the two sample sets were geographically related and the 
combined sample yielded an OR - 1.2 (95% Cl 1.02-1.5, p= 0.02). Overall, this is a small 
effect size, although it remains possible that allele T of the rs10410544 SNP might make a 
small contribution to SAD susceptibility. The small effect size is consistent with 
previously reported data suggesting that, apart from APOE c4, only associations of this 
magnitude are likely to be discovered in relation to AD. However, to confirm this 
association, further studies will be planned to validate it in larger sample sets. Furthermore, 
also given the interesting heterozygote distribution comparing AD and CT found in the 
dHPLC study of SNPs rs11879010 and rs45496398 in SIRT2 gene, a higher-density 
genotyping of SIRT2 might be worthwhile, particularly because as it transpired from this 
study, the tagging approach used was later found not to give good coverage to some 
regions with low LD. 
Finally, given the wide role of sirtuins in neurodegeneration/neuroprotection in general, 
and specifically the detrimental role of SIRT2 in Parkinson's disease, it may be worthwhile 
exploring the impact of this polymorphism as a susceptibility factor for other 
neurodegenerative diseases. 
The in vivo section of this thesis described the application of an EE protocol to APP23 
mice and addressed the question whether this paradigm could delay the onset and 
progression of AD-like pathology. In this context the modulation of sirtuins was also 
evaluated. 
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After 4 months of EE, TG mice revealed an improvement of performance in two different 
memory tasks: MWM and vORT. Overall, these tests showed that the normal levels of 
cognitive impairment expected in TG mice at 6-7 months of age, when compared to TG- 
SHs mice, was reversed by EE. Conversely, the EE paradigm did-not further improve 
learning and memory performance in WT mice. However, EE was shown to induce 
molecular changes in WT mice as shown by increased BDNF mRNA levels that were 
registered in 8-month-old mice were independent of genotype. This, highlighted the 
effectiveness of this EE protocol also in WT mice and prompts the need to further explore 
the effect of EE from the presence of the transgene. In particular, to evaluate the relevance 
of BDNF modulation in the pathogenic context of APP23 it would be worth to evaluate the 
outcome of the application of the EE protocol in transgenic APP23 mice crossbred with 
BDNF-/- mice. 
Moreover, given the improvement in performance in these tests measuring hippocampus- 
dependent memory and the increase in BDNF that is linked to long term potentiation 
(LTP), LTP could be assessed in TG mice housed in the two different housing conditions. 
Interestingly, despite the noted changes to pathology, EE did not appear to elicit any 
molecular changes relevant to the AD-phenotype in the APP23 TG mice such as APP 
overexpression and its metabolism, or in Aß oligomer production. However, given the now 
widely recognized acceptance of central role of oligomers in AD, considered to be the real 
toxic species, further studies would require a greater attention to these in the future. In 
particular, an ultrastructural analysis of intracellular Aß oligomers in synaptic 
compartments will be performed. Moreover, it will also be assessed whether EE could 
reverse the hippocampal postsynaptic alterations registered in APP23 such as in the 
trafficking of synaptic NMDA receptor subunits NR2A and NR2B shown by our 
laboratory in APP23 TG mice (Balducci et al., 2010). Eventual differences could explain 
the restored behavioural performance otherwise not fully elucidated by the data collected 
till now. Anyway, despite no difference was registered in APP metabolism in 8-month-old 
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mice, a marked decrease in plaque deposition in 18-month-old TG mice was observed in 
TG-EEs compared to TG-SHs. This evidence should be further elucidated for example by 
investigating the levels and activity of enzymes capable of degrading Aß such as neprilysin 
and insulin-degrading enzyme (Miners et al., 2008). Furthermore it could be worth of note 
to measure the accumulation of Aß within cerebral blood vessels since APP23 develop a 
marqued cerebral amyloid angiopathy (Sturchler-Pierrat et al., 1997). 
Finally sirtuin expression levels in 8-month-old mice were assessed. Both the presence of 
the transgene and/or housing conditions did not affect sirtuin levels. These findings would 
suggest that the EE paradigm provides benefits that are independent of or removed from 
the involvement of sirtuins. Although, it might be worth assessing whether EE modulates 
sirtuins in other peripheral tissues (e. g. skeletal muscle) which may identify changes 
already suggested in the literature in relation to sirtuins and physical stimulation. 
Overall, the present study showed that it is possible to attenuate the progression of 
cognitive decline and reduce some AD-like pathological hallmarks in the APP23 mouse 
model of AD by using EE. Moreover, preliminary indications suggest that, unlike other 
environmental paradigms, such as CR or physical activity, EE does not modulate sirtuin 
expression levels in the brain. 
In the last section of this thesis the role of SIRTI pharmacological activation by resveratrol 
(RES) was evaluated in in vitro models using SK-N-BE(2) recapitulating two different 
detrimental features of AD pathology, i. e. oxidative stress and exposure to A042. In the 
first part of the in vitro section, RES was shown to be neuroprotective against oxidative 
stress through the activation of SIRTI, since both pharmacological inhibition of SIRTI and 
its silencing affected RES neuroprotection. Moreover, RES counteracted resultant ROS 
increases under oxidative stress and this effect was significantly affected by SIRTI 
silencing suggesting that SIRTI could be involved. This is consistent with findings in a 
different model where SIRTI was protective against Aß-induced ROS production 
- 233 - 
(Savaskan et at., 2003). Another interesting finding was the novel observation that SIRTI 
may be involved in autophagosome formation under oxidative stress. However, the 
relevance of the autophagic pathway under oxidative stress still requires more work since 
this mechanism was insensitive to the inhibitor of authophagy 3-MA. All these findings 
highlighted a role for SIRTI in counteracting oxidative stress that could pass through 
different intracellular mechanisms, all giving their contribution. 
The potential neuroprotective effect of RES action against Aß42 was also shown, however, 
this appeared to be independent of SIRTI since sirtinol did not reverse RES-mediated 
neuroprotective actions nor did it affect the ability of RES to decrease ROS production 
following Aß42 challenge. All these results suggested that other mechanisms independent 
of SIRTI may be involved which could include direct molecular destabilizing interactions 
between RES and various species of Aß fibrils. It may still be worthwhile to investigate the 
neuroprotective role of SIRTI in relation to its activation with drugs not structurally 
related with RES. In particular, SRT 1720, a more potent activator of SIRTI now 
commercially available could be tested. Another interesting aspect to take into account 
concerns the neuroprotective role of SIRTI independently from its activation as suggested 
by Pfister. 
In conclusion, the present thesis identified that SIRT2 variation may confer some small risk 
or disease modifying effect for AD. It also confirmed the neuroprotective role of SIRTI 
activation by RES, proposing ROS clearance and autophagy as potential mechanisms that 
deserve further studies in relation to SIRTI. Finally this thesis has given further evidence 
that EE could be beneficial in an AD-like mouse model, but does not mediate its benefits 
through modifications of sirtuin expression levels in the brain. 
APPENDIX 
GENE/ 
PROTEIN 
CHR 
No 
CHROMOSOME, mRNA PROTEIN PROTEIN 
REFSEQ a REF SEQ REF SEQ LENGTH 
SIR T1/ 
SIRT1 
SIR T2/ 
SIRT2 
SIR T3/ 
SIRT3 
SIR T4/ 
SIRT4 
10 
19 
II 
12 
NC000010.10 
NC_000019.9 
NC00001 1.9 
NC 000012.11 
NM 012238.4* NP 036370.2* 
NM 00 11 42498.1 NP 001135970.1 
NM 012237.3* NP 036369.2* 
NM_030593.2 I NP 
_085096.1 
NM-001 193286.1 NP 001180215.1 
NM012239.5* 
INP_036371.1* 
NM_001017524.2 NP_001017524.1 
I 
NM 012240.2* NP 036372.1* 
N 
SIR T5/ 
SIRT5 6 
NC 000006.11 NM 031244.2 NP 112534.1 
NM 001193267.1 
SIR T6/ 
SIRT6 
SIRT7/ 
SIRT7 
NP 001180196.1 
NP 057623.2* 
NP 001180214.1 
NP 057622.1* 
TABLE A. I. NCBI Entrez reference sequences of human sirtuins. 
747 aa 
452 aa 
389 aa 
352 aa 
234 aa 
399 aa 
257 aa 
314 aa 
310 aa 
299 aa 
292 aa 
355 aa 
328 aa 
400 aa 
Abbreviations: CHR N°, chromosome number; REF SEQ, reference sequence; aa, amino 
acid. 
Chromosome reference sequences according to genome build 37.2 
* Full length transcripts and proteins. 
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19 
17 
NC 000019.9 
NC 000017.10 
NM 016539.2* 
NM 001193285.1 
NM 016538.2* 
GENE/ 
PROTEIN 
SIR T1/ 
SIRTI 
SIR T2/ 
SIRT2 
SIR T3/ 
SIRT3 
SIR T4/ 
SIRT4 
SIR TS/ 
SIRT5 
SIR T6/ 
SIRT6 
SIRT7/ 
SIRT7 
389 aa 
352 aa 
319 aa 
334 aa 
257 aa 
333 aa 
310 aa 
334 aa 
294 aa 
402 aa 
CHR 
No 
10 
7 
7 
5 
13 
10 
11 
CHROMOSOME 
REF SEQ # 
NC 000076.5 
NC 000073.5 
NC 000073.5 
NC 000071.5 
NC 000079.5 
NC 000076.5 
NC 000077.5 
mRNA PROTEIN PROTEIN 
LENGTH REF SEQ REF SEQ 
NM 019812.2* 
NM_001159589.1 
NM 001159590.1 
NP 062786.1 * 
NP 001153061.1 
NP 001153062.1 
737 aa 
698 aa 
576 aa 
NM 022432.4* 
NM_001122765.1 
NM 001122766.1 
NM 001177804.1* 
NM 001127351.1 
NM 001167691.1* 
NM 178848.3* 
NM 181586.3* 
NM 001163430.1 
NP 071877.3* 
NP_001116237.1 
NP 001116238.1 
NP 001171275.1* 
NP 00 11 20823.1 
NP 001161163.1* 
NP 849179.1 * 
NP 853617.1 * 
NP-001 156902.1 
------ i- ------------- 
NM 153056.2* NP 694696.2* 
TABLE A. 2. NCBI Entrez reference sequences of murine sirtuins. 
Abbreviations: CHR N°, chromosome number; REF SEQ, reference sequence: aa, amino 
acid 
Reference Assembly: MGSCv37-C57BL/6J 
* Full length transcripts and proteins. 
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I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
I 
II 
III 
IV 
V 
vi 
VII 
VIII 
VIII 
IX 
I 
II 
III 
IV 
V 
vi 
VII 
VIII 
IX 
X 
XI 
XII 
XIII 
XIV 
xv 
gccagagaggcagttgga I atctcctcctccctctcccc 
I aaccgttcatacattttaggtgc I ggtttgtttgttttgagacagagtt 
aaaaccctcacagaatgctaactc I cttatgccttttccaagtaggaa 
ttggcctgacttaaaaattcc I gtgaatgctgctactgtggc 
gcatccatctagatactttaaaatgc I ctgactgccatcgagaagtg 
cttaaaccctcttaacatttgtg I ggaagaaaatagttagcatttggg 
tgttgactatttctaacttgggc I gtcatgggttgtgggtctgt 
cccttgttggatttttgcat I tggaagaaaaaccacaggaag 
cccacacctcttcatgtttc I cggcaggttaatcgataggg 
agagctggaacccacacttc I gtatcttcaatcagctgttggtca 
ggacacagtggttggtgacg I cagccctcagaatcccactc 
cttaatcgttctccccactgtaac I agtgtgggatgtggaacaagtc 
cttttccccaaacctggtatc I tacatactttggatgtcactcctga 
ggccttgtgcctttagatgt I aaggtttcaataaatggttcaagtg 
gtcatatggtgcataagttcctctc I tataccatactaaccctcccaggac 
cctgggagggttagtatggtataga I tgaaatagctgatctcaaagatgg 
tgagatcagctatttcaaggtttgt I cacccatgtacttaatggctacata 
taaaacagtcacagtgcctagaaca I ctctgctgaggacaccatgc 
cctccatctctccctctagaaca I ctaagctggatgaaaggtgagg 
tcttactgccttctctttcttcc I acctctgtctctctgaacagtgc 
ccccatgtcactgtctctgtc I gtatgcagtcagtaagtggccc 
cagggaggtttgctgctg I cctcatcagcaagtaggttgg 
ctccctcatcagcaagtaggtt I cctctcacccttttcctcagag 
aagtcacagagctaggatacaaacc I agatgagaggagcaggcagg 
aaggcagatgagaggagcag I acagtgacctttgacttctgtgac 
501 
253 
404 
516 
379 
321 
317 
418 
421 
669 
216 
177 
249 
327 
183 
159 
299 
233 
155 
220 
110 
170 
218 
264 
243 
64,9- 
57,9 
57,1 
57,8 
59,8- 
52,8 
58,6 
56,0 
58,0 
54,4 
58,3 
59,1 
61,3 
60,2 
58,4 
56,5 
61,6 
63,1- 
56,1 
58,3 
60,2 
61,0 
64,3- 
57,3 
61,7 
59 
60,9 
61,1 
59,9 
Gene IAI Exon 
ý 
PC 
ý 
ý 
rd 
261 XVI 
Forward primer I Reverse primer 
(5'-+3') ý (3'-+5') 
tgacctttgacttctgtgacctt I ccagtgacagctgcatctcc 
Tmo,.;.... 
Size T "'F annealing 00 1n 
(bp) ('C) I DHPLC 
203 1 63,9- 
56,9 
66,7 
58,2 
55,5 
56,4 
57,0 
56,0 
57,6 
56,5 
57,0 
58,0 
56,5 
61,3 
61,0 
63,7 
59,6 
59,9 
62,5 
64,3 
60,6 
61,3 
62,1 
63,9 
63,5 
63,3 
63,7 
63,2 
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27 I tccggaggactccttggact aaatacctcgaaaagaagaaactgg 3.16 63,4- 
56,4 
67,5 
28 II ctatctgtttcctttgctgctgt gactgtgggcagtacctgaagt 245 64,2- 
57,2 
59,0 
29 III gcccagtttattccacttcc aggaagaagcataagcgataggt 451 57,9 61,4 
30 IV aagttgtgctcttggccttg cttttccagatcaccccaac 232 57,2 63,0 
31 V tccttttacagggtgttgcag ccatgagatgactcctgtaccc 291 63,8- 
56,8 
62,3 
32 VI ctgtggcatgaaacatcctg aggtggaccataccctagagc 348 63,4- 
56,4 
61,5 
33 VII ctgtttgaacagagatctgct gaggtcttgtcagaattggga 167 56,7 58,2 
34 1 aaccaccccagtttctcaca caacacacgggmgcgttc 580 58,3 60,9 
35 II cgtctctgacagctttgtgc tctctccaggactcccaatc 419 59,3 60,8 
36 III ggagagacaccctgtttgg caagtgaaagtccctgttgg 277 58,1 58,1 
37 I gcctcaagcattagaactacagaca gaaagtcctacacttcgagaggaat 221 60,8 59,7 
38 II aaatgtccaaactgtacactggatt agtttccagaacattaaaagcctct 215 57,5 57,1 
39 III ctcactcctgcctcctctcc attcagggaaccagctttaaaac 299 62,7- 
55,7 
63,0 
40 IV tggagaaggttgctcttgattatac aaatgtgaggaaattgaacattcat 229 60,7- 
53,7 
55,3 
41 V gccaggcaaatatacaaactgag gtgttccaggttaccaaaacaaa 194 57,6 54,0 
42 VI cttaaggatcccattcttccag tttatgtctagtggtgggtcatg 156 58,3 60,9 
43 VII atctccgtgtacttgccttgtag agattcaggtactgggataccct 154 60,2 61,9 
44 VIII cttgctgaagtagggcattcatt cttatgggtggtgagctgagtac 236 64,3- 
57,3 
58,2 
45 1 agtcgaggatgtcggtgaatta ctcccattgtctagcctcagtg 189 64,0- 
57,0 
69,2 
46 II acttgggggaactgttttgac ctgcacaatcacagacctgaagt 192 59,0 63,9 
47 III gtctctttttctgttcccctctc atagaaccaggaaaaggggactc 331 60,2 66,2 
48 IV atcaagcctcttcctgctcttc agagacccagagggtatggg 176 60,6 62,5 
49 V ctagaaacagtgcgagagtcacc actctcctcagcttcctcattg 244 61,0 66,1 
50 VI actctcctcagcttcctcattg gacgacagcagaaacacagc 170 59,6 66,7 
51 VII cacagatggcctaggtgtgaac ctcagacacctacgtgcttggt 231 61,8 66,7 
52 VIII accaagcacgtaggtgtctgag gtgagaccacgagagaaaaagaa 487 64,2- 
57,2 
65,3 
ý ý 
ý 
r-I 
53 1 gaagcggaagagcaggtctc ctgcagctccgttaccaggtc 287 62,4 69,0 
54 II cggacctggtaacggagctg gcctgtgtagacgaccaagtatt 268 65,8- 
58,8 
70,4 
55 III gtgaccaccctggcgtctt tggagctcatactccgtcct 176 60,2 66,0 
56 IV ccttttgacttggcttacctttt caaggtgaggagagctggag 186 63,0- 
56.0 
63,7 
57 V agtgtggacactgcttcagaaag gctcttaccagcttctgctcat 215 60,1 65,5 
58 VI ggtactgacctccccaccac gcaggactgctcacttcaatgta 177 65,8- 
58,8 
64,2 
59 VII ttgcctctaggtctgtacctcct ctcggttcactcattgtgtcat 279 64,1- 
57,1 
65,2 
60 VIII tacagacttgtcccttgtgtgtg taagacccagatctaaggacgtg 175 60,2 63,0 
61 IX gctgttactctcactcggcttt ctcacgagagaagacagacaagg 214 61,0 66,3 
62 X ctttccctttttggcaggtg aaaatgtcatccccaaagagttc 327 57,0 63,5 
TABLE A. 3. List of the primers and analysis settings for dHPLC study 
Abbreviations: Amplicon (A) 
List of primer sequences, size of the amplified products, annealing temperature in PCR 
and dHPLC melting temperature. 
Gene NCBI ref seq (NM) TagMan® Assay ID_ 
mSIRTI All Mm00490758 
mSIRT2 
NM 022432.4* 
- 
NM_001122765.1 
Mm00452114 
mSIRT3 All Mm00452129 
mSIRT4 All Mm01201915 
mSIRT5 All Mm00663721 
mSIRT6 NM 181586.3 Mm00725029 
mSIRT7 All Mm00461895 
mß-ACTIN NM007393.1 4352933E 
mBDNF All Mm04230607 
hSIRT1 All HsO 1009006 
hß-ACTIN NM 001101.2 4333762T 
TABLE A. 4. RT-PCR TagMan® gene expression assays 
Abbreviations: m, murine; h, human. NCBI reference sequences are listed in table A. 2. 
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